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Abstract 
The kidney plays a key role in the systemic clearance of new molecular entities 
(NMEs). Approximately 32% of drugs exhibit significant renal elimination. It is 
estimated that nephrotoxicity accounts for 8 % of pre-clinical and 9% of clincal 
safety failures in drug development. Current pre-clinical models used to screen 
NMEs are poor predictors of human nephrotoxicity. The focus of my project is thus 
to develop predictive in-vitro rat and human primary proximal tubule cell models as 
a platform drug transporter and drug-drug interaction (DDI) studies. 
Primary human and rat proximal tubule cells (PTCs) were isolated from renal cortex 
using a combination of enzymatic digestion and density centrifugation. The isolation 
procedure was optimised to maximise cell yield and viability. Human and rat PTCs 
cultured on Transwell® inserts formed confluent monolayers with low paracellular 
permeability. Quantitative PCR showed mRNA expression of key renal transporters, 
OAT1, OAT3, OATP4C1, OCT2, BCRP, MATE1, MATE2-K, MDR1, MRP2, URAT1, 
NaPi-IIa, NaPi-IIc and PiT2, in human PTC monolayers. Orthologs of these 
transporters were also detected in rat PTC monolayers. 
The utility of human and rat PTC monolayers as predictive in-vitro models of 
proximal tubular drug handling were demonstrated using radiolabeled [3H]-tenofovir 
(TFV). Human and rat PTC monolayers exhibited a cell-to-media ratio greater than 
1, which indicated uptake and accumulation of TFV across the basolateral 
membrane. We also observed a predominant absorptive pathway of TFV. The 
transporters mediating the transport of TFV were identified using a cocktail of 
transporter inhibitors. The basolateral uptake of TFV was mediated by OATP4C1 
and OAT1. TFV had low affinities for the apical efflux transporters MRP2, MRP4, 
MDR1 and BCRP. The novel identification of OATP4C1 as a TFV transporter has 
led Gilead to develop assays for investigating OATP4C1-mediated DDIs, and the 
FDA to recognise OATP4C1 as a key renal transporter.  
The handling of radiolabelled inorganic [32P]-phosphate (Pi) by human and rat PTC 
monolayers was also investigated. Pi flux measurement revealed a net absorptive 
pathway of Pi across human and rat PTC monolayers. Uptake of Pi across the 
apical membrane was sodium dependent, saturable, and inhibited by parathyroid 
hormone, fibroblast growth-factor 23 and -klotho. Apical uptake of Pi was also 
inhibited by TFV in a saturable manner. This suggests that the mechanisim of TFV-
induced hypophosphatemia is not via TFV-induced nephrotoxicity, but TFV 
inhibition of Pi reabsorption. The outcomes of this work have initiated a patient 
clinical trial. This finding could have a large translational impact, as over 14.9 
million HIV-patients are pescribed TFV and TFV-related hypophosphatemia affects 
30 % of patients.  
The data highlight the importance of developing holistic cell based models of the 
proximal tubule. The outcomes of this work demonstrate the power of translational 
science to have an impact on how the pharmaceutical industry operates. 
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1. Introduction and literature review 
1.1. Improving research and development productivity  
Without a dramatic increase in research and development productivity, today’s 
pharmaceutical industry is not sustainable. For every dollar lost in declining 
product revenues due to patent expirations in 2012, large pharmaceutical 
companies were only able to replace on average 26 cents with new product 
revenues (Goodman, 2008). A key aspect of this problem is the decreasing 
number of NMEs approved by the regulatory bodies such as the European 
Medicines Agency (EMA) and United States Food and Drug Administration 
(FDA). With an estimated $50 billion in collective annual research and 
development spending by the large pharmaceutical companies, the average 
cost for these companies to bring an NME to market in 2013 was approximately 
$2.87 billion (Tufts Center for the Study of Drug Development, 2014).  
It is estimated that the probability of successful transition from pre-clinical to 
Phase I, Phase I to Phase II, Phase II to Phase III and Phase III to launch is 
59.52%, 35.52%, 61.95% and 90.35%, respectively with an overall success of 
11.83% between Phase I and regulatory approval (Tufts Center for the Study of 
Drug Development, 2014). Miscalculation of drug distribution is a key factor in 
attrition in drug development; it can result in a lack of efficacy or adverse drug 
reactions. This is highlighted in Figure 1.1, where the primary causes of NME 
failure from 2005 to 2010 at AstraZeneca are shown (Cook et al., 2014).  
Intracellular drug concentrations are important in the prediction of drug efficacy, 
toxicity and drug interactions, yet difficult to quantify in humans. Based upon the 
free drug hypothesis i.e. the free drug concentration is the same on both sides 
of any biomembrane (Smith et al., 2010) the plasma drug concentrations are 
typically used as a surrogate measure under the assumption that unbound drug 
concentrations in the systemic circulation mirror intracellular unbound drug 
concentrations (Chu et al., 2013). However this assumption is not valid for many 
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drug molecules which have poor membrane permeability (charged or polar 
compounds) or are extensively metabolised in-vivo (Muller and Milton, 2012). 
 
 
Figure 1.1: The primary reasons for project closures from 2005 to 2010 at 
AstraZeneca.  
Project closures were classified as failing due to safety (toxicology or 
clinical safety), efficacy (failure to achieve sufficient efficacy), 
pharmacokinetics/ pharmacodynamics (PK/PD, Bioavailability, 
formulation, target occupancy) or the strategy (molecular diverse 
back-up candidate molecules). The pre-clinical phase was defined as 
the phase from the first good laboratory practice toxicology dose of a 
candidate drug through to an investigational new drug application or 
first clinical trial application before first-in-human testing. Phase I was 
defined as the phase that included the first-in-human trials within a 
small trial population (<50 patients) and included safety, tolerability 
and dose-ranging studies. These studies were often conducted in 
healthy volunteers. Phase II trials were defined as trials that were 
aimed at evaluating the candidate drug's efficacy in a patient 
population, leading up to clinical proof of concept. Phase II was 
subdivided into Phase IIa and Phase IIb. Phase IIa studies were 
generally smaller (<200 patients) and designed to mainly address 
early evidence of drug activity, whereas Phase IIb studies included 
larger numbers of patients (<400 patients) and were designed to 
demonstrate clinical proof of concept and an understanding of dose 
response. Information taken from Cook et al., (2004). 
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Species and inter-individual differences in the pharmacokinetic and toxicokinetic 
profiles between pre-clinical animals and man result from differential expression 
of transport proteins and metabolic enzymes (Bleasby et al., 2006; Hilgendorf et 
al., 2007). Transport proteins in the cellular membrane assist in the passage of 
specific molecules across the phospholipid bilayer and can thus determine drug 
disposition. Substances may pass through transport proteins by diffusion or 
active transport. Metabolic enzymes are responsible for the conversion of 
lipophilic chemical compounds into more readily excreted hydrophillic products. 
The rate of drug metabolism therefore determines the duration and intensity of a 
drug’s pharmacological action. Predicting metabolic drug clearance from in-vitro 
studies using physiologically based pharmacokinetic models is well validated, 
however prediction of transporter mediated drug disposition has been 
hampered by a lack of critical information on the tissue localisation and 
expression of transporters in human and animal tissue. Unlike metabolic 
enzymes, selective inhibitors or antibodies for most drug transporters have not 
been identified.  
With the realisation that screening of drug molecules through animals is poorly 
predictive of the outcome in man, both the FDA and EMA have endeavoured to 
promote the development of alternative screening technologies to reduce and 
replace animal testing in pre-clinical assessments of drug safety and efficacy 
(Giacomini et al., 2010). One strategy to achieve this would be the development 
of in-vitro cell based screening assays, in which species differences in 
pharmacokinetics and toxicokinetics are identified before animal studies 
commence. In terms of the 3Rs (reduction, replacement, refinement), this would 
effectively reduce the total number of animals entering the mandatory pre-
clinical drug safety testing regime by identifying the 54% of compounds with the 
potential to generate human toxicity at the in-vitro screening stage. 
Realistic cell based models of drug transport in the liver have been established. 
The development of human and rat primary sandwich-cultured hepatocytes has 
given an insight into species differences and the prediction of in-vitro to in-vivo 
handling of drug molecules (Xu et al., 2008; Swift et al., 2010). In contrast, the 
development of similar predictive in-vitro methodology to understand the renal 
handling and metabolism of drug molecules has lagged behind, due to the lack 
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of a suitable in-vitro human or rat proximal tubule experimental model to 
investigate renal drug transport. In this project, we aim to characterise and 
validate primary renal proximal tubule models from human and rat kidney as in-
vitro platform for drug safety studies. 
1.2. Renal clearance of xenobiotic compounds 
The renal clearance of xenobiotic compounds is a mechanism essential to 
protecting the body from toxicity. Foreign chemical substances that undergo 
renal excretion include drug molecules; toxic contaminants found in food; toxins 
produced by micro-organisms; agrichemicals and heavy metals. The process of 
renal clearance can be broken down into three key mechanisms, glomerular 
filtration, tubular secretion and tubular reabsorption.  
Each human kidney is composed of approximately 1.2 million functional units 
called nephrons (Nyengaard and Bendtsen, 1992). Comparatively, each rat 
kidney contains roughly 30 000 nephrons (Haley and Bulger, 1983). Blood 
enters each nephron through afferent arterioles, passes through glomerular 
capillaries then leaves via efferent arterioles. In the glomerular capillaries water, 
urea, glucose, amino acids and other small molecules pass across the 
basement membrane of the Bowman’s capsule into the nephron due to Starling 
forces, in a process named ultrafiltration, leaving red blood cells, proteins and 
other large molecules too large to pass through the capillaries behind. This is a 
highly efficient process; on average the human kidneys collectively receive 20% 
of cardiac output (1000 mL of blood per minute) then form around 120 mL of 
protein free ultrafiltrate per minute (Levey et al., 2006; McArdle et al., 2010). 
The ultrafiltrate within the nephron then passes through the proximal tubule, the 
loop of Henle, the distal convoluted tubule and a series of collecting ducts to 
form urine. During the passage through renal tubules and ducts, solutes and 
water can be reabsorbed from the ultrafiltrate into the blood of peritubular 
capillaries. This two-step process is known as tubular reabsorption. Within the 
first step, solutes are taken up from the tubular lumen into an epithelial cell, by 
transport proteins, driven predominately by an inwardly directed sodium 
gradient. Solutes then exit out of the epithelial cells into peritubular capillaries 
via passive diffusion or transporter-mediated mechanisms.  
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More importantly, in the context of this project, molecules can also be 
transported from peritubular capillaries to the renal tubular lumen through 
proximal tubule epithelial cells in a process named tubular secretion. This two-
step process consists of uptake of molecules across the basolateral membrane 
followed by exit across the apical membrane.  
In terms of renal drug clearance, many drug molecules and their metabolites 
are excreted in urine solely as a consequence of glomerular filtration. If a 
xenobiotic is freely filtered from the renal glomerular capillaries into the 
Bowman’s capsule and is neither reabsorbed nor secreted, then its clearance 
rate will equal the glomerular filtration rate. Several techniques can be used to 
estimate an individual’s glomerular filtration rate, the most common method is to 
collect urine over a timed period to determine the amount of endogenous 
creatinine removed from the blood over a given time interval.  
In addition to clearance by glomerular filtration, some drug molecules 
(particularly small hydrophilic compounds) also undergo tubular secretion. The 
rate of renal clearance of these drug metabolites exceeds the rate of filtration by 
several-fold. For several drug molecules, a combination of glomerular filtration 
and tubular secretion can result in the total removal of the drug molecule from 
plasma in a single pass (compared to a glomerular filtration fractional clearance 
of 20 % in a single pass). Tubular secretion is primarily mediated in the proximal 
tubule of the nephron, to fulfil this role epithelial cells lining the proximal tubule 
express a number of drug transport proteins asymmetrically distributed to either 
the basolateral or apical membrane. 
1.3. Drug transporter expression in the proximal tubule  
Renal proximal tubular cells carry out specialised directional transport of various 
endogenous and exogenous molecules. Whilst all transporters expressed in the 
proximal tubule cells are vital in homeostasis, in the context of drug transport, 
several families of transporters are paramount. In 2010, the international 
transporter consortium (ITC) published a review titled; “Membrane transporters 
in drug development” in which transporters considered to be clinically relevant 
and should be investigated in drug development were highlighted (Giacomini et 
al., 2010). In 2012 and 2014 the EMA and Japanese pharmaceuticals and 
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medical devices agency (PMDA) published similar guidance (European 
Medicines Agency, 2012; Japanese Ministry of Health Labour and Welfare, 
2014). If renal secretion of the NME separately accounts for more than 25 % of 
drug elimination, renal transporters are considered to be clinically relevant. The 
renal transporters that should be studied in this instance according to the 
reviews are summarised in Table 1.1 and discussed in detail in this subchapter. 
Furthermore, a summary of transporters deemed clinically relevant in drug 
development by the regulatory authorities at the human and rat renal 
pharmacological barrier are compared in Figure 1.2. 
 
Table 1.1: Renal transporters that the FDA, EMA and PMDA consider to be 
clinically relevant in drug development.  
These transporters play key roles in determining the bioavailability, 
therapeutic efficacy, and pharmacokinetics of a variety of drug 
molecules. Information gathered from Giacomini et al., 2010; EMA, 
2012; and Japanese Ministry of Health Labour and Welfare, 2014. 
 
The uptake of molecules from circulation across the basolateral membrane of 
proximal tubular cells is generally mediated by the solute carrier (SLC) 
transporter superfamily. Many drugs are known substrates of the SLC 
Transporter ITC/FDA EMA PMDA 
OCT1 - consider - 
OCT2 + + + 
OAT1 + + + 
OAT3 + + + 
MATEs consider consider + 
MDR1 + + + 
BCRP + + + 
MRPs consider - - 
OATP4C1 consider - - 
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superfamily therefore they significantly contribute to the pharmacokinetics and 
toxicity of drugs. SLC transporters can be grouped into three categories by their 
transport mechanisms: (i) facilitated diffusion via a concentration gradient (ii) 
sodium utilisation or hydrogen co-transport, and (iii) substrate exchange 
(Kusuhara and Sugiyama, 2009). All SLC transporters act independently of 
adenosine triphosphate (ATP) hydrolysis. The main renal xenobiotic 
transporters include members of the organic organic anion transport (OAT), 
organic organic anion transporting polypeptide (OATP), and organic cation 
transport (OCT) families. 
The efflux of molecules across the apical membrane of proximal tubule cells 
into ultrafiltrate is typically mediated by the ATP-binding cassette (ABC) and 
SLC transporter superfamilies. The physiological function of ATP binding 
cassette transporters (ABC transporters) is to protect cells against toxic 
compounds and metabolites. ABC transporters utilise energy from ATP 
hydrolysis to efflux substrates by active transport. The main renal efflux 
transporter families include the multidrug resistance-associated protein (MRP) 
and multidrug and toxin extrusion (MATE) familes, in addition to multidrug 
resistance protein 1 (MDR1) and breast cancer resistance protein (BCRP). 
 
 
 
A 
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Figure 1.2: Species differences in the expression of transport proteins 
clinically relevant in drug development.  
A wide range of transporters are expressed in human (A) and rat (B) 
proximal tubule cells to regulate the excretion and reabsorption of 
endogenous and exogenous organic anions, cations, peptides and 
nucleosides, thereby influencing the plasma levels of these 
substances. Renal transporters that the FDA, EMA and PMDA 
consider to be clinically relevant in drug development include the 
OATs, OATPs, OCTs, MATEs, MDR1, BCRP and MRPs. Species 
differences in renal transporter expression are listed. OAT2/Oat2 is 
present at both the apical and basolateral membrane of human 
proximal tubule cells, but only the apical membrane in rodents. Apical 
OAT4 has only been identified in humans and primates. Only one 
OATP isoform has been characterised at the apical membrane of 
human proximal tubule cells, OATP1A2. In contrast, rodents are 
thought to express multiple isoforms including Oatp1a1, Oatp1a2, 
Oatp1a3_v1 and Oatp1a3_v2. Oct1 has been identified at the 
basolateral membrane of rodent proximal tubule cells but comparative 
studies in humans have failed to detect OCT1 in human kidney. 
MATE2-K appears to be exclusively expressed in the apical 
membrane of human proximal tubule cells. In humans apical MDR1 is 
encoded by one gene, whereas rats possess two isoforms Mdr1a and 
Mdr1b. BCRP is expressed at low levels at the apical membrane of 
human proximal tubular cells, whilst Bcrp is expressed abundantly in 
rat kidney. Additionally, Mrp5 is expressed at the basolateral 
membrane of rat proximal tubular cells but absent from human kidney. 
B 
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1.3.1. OAT family 
The OAT isoforms OAT1/Oat1 (SLC22A6), OAT2/Oat2 (SLC22A7), OAT3/Oat3 
(SLC22A8) and URAT1/Urat1 (SLC22A12) are found in both humans and rat 
proximal tubule cells. OAT4 (SLC22A11) has only been found in humans and 
primates thus far (VanWert et al., 2010). In both species OAT1/Oat1 and 
OAT3/Oat3 are localised to the basolateral membrane and mediate the 
transport of organic anions and anionic drugs (OA-) from blood into the tubule. 
OAT2 is present in the basolateral and apical membrane of human proximal 
tubule cells, but only the apical membrane in rodents (Burckhardt and 
Burckhardt, 2011; Shen et al., 2015). OAT4 and URAT1/Urat1 are located at 
the apical membrane.  
Oat1 was the first OAT to be cloned within rat kidney in 1997 (Sekine et al., 
1997; Sweet et al., 1997). The gene is located on chromosome 11q12.3, and is 
co-localised with the gene for OAT3 (Eraly et al., 2003). Oat3 was first cloned 
from rat brain in 1999 (Kusuhara et al., 1999). OATs are 542 to 556 amino acids 
long with 12 predicted transmembrane spanning domains (Koepsell and Endou, 
2004). They function as antiporters; the uptake of extracellular OA- across the 
basolateral membrane is driven by the efflux of intracellular α-ketoglutarate 
(Berkhin and Humphreys, 2001). Thus, OAT1/Oat1 and OAT3/Oat3 are 
functionally coupled to sodium driven mono- and di-carboxylate transporters 
that establish and maintain the intracellular extracellular gradients of lactate, 
nicotinate and α-ketoglutarate. 
OAT1/Oat1 and OAT3/Oat3 substrates, listed in Table 1.2, are generally 
monovalent or divalent anions that are less than 500 Daltons (Giacomini et al., 
2010); although OAT3 can also transport some positively charged drugs such 
as cimetidine (Wright, 2005). Studies of OAT1/Oat1 and OAT3/Oat3 in 
expression systems such as Xenopus Laevis oocytes and transfected cell lines 
have shown that they have wide overlapping substrate specificities (Rizwan and 
Burckhardt, 2007). OAT1/Oat1 is primarily known for its high affinity transport of 
para-aminohippurate (PAH) from renal proximal tubule cells (Hosoyamada et al., 
1999). OAT3 can also transport PAH but with slightly lower affinity (Cha et al., 
2001). Studies using Oat1 and Oat3 knock out mice have led to identification of 
endogenous OAT substrates and initial assessments of the influence of each 
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transporter on the renal handling of selected compounds (Eraly et al., 2006; 
Vallon et al., 2008). Genetic variants in the OATs have not been associated with 
clinically significant DDIs or changes in the amino acids transcribed (Shin et al., 
2010). 
OAT1/Oat1 and OAT3/Oat3 can be the site of DDIs during competition of two or 
more drugs for the same transporter, particularly for drugs with a narrow 
therapeutic index. For example, several case studies have reported an increase 
in serum urate levels during antihypertensive therapy with low-dose diuretics 
(toasemide and hydrochlorothiazide). The diuretics are substrates of OATs and, 
by counter exchange, cause increased urate absorption resulting in 
hyperuricemia. Furthermore, OAT1 and OAT3 can also mediate cell damage by 
transporting cytotoxic compounds. Probenecid can be used to reduce the 
nephrotoxic liability of therapeutics by inhibiting transport of potentially 
nephrotoxic drugs into proximal tubular cells. Cidofovir is toxic in the proximal 
tubular cells, co-administration with probenecid results in a reduced 
accumulation of cidofovir in the proximal tubule cells and thus reduced 
nephrotoxicity (Cundy et al., 1996).  
Oat2 expression was first identified in rat liver (Simonson et al., 1994; Sekine et 
al., 1998). Oat2 was later found to be highly expressed at the mRNA level in rat 
kidney (Buist et al., 2002; Kobayashi et al., 2005). Evidence for similar renal 
expression of OAT2 in human kidney was not published until recently (Cheng et 
al., 2012). OAT2 interacts with a wide range of nucleobases, nucleosides and 
nucleotides. Three splice variants of OAT2, which result in amino acid changes, 
have been identified (Emami Riedmaier et al., 2012). The clinical consequences 
of these are yet to be investigated. OAT2 has been implicated in the renal 
handling of creatinine; previous evidence suggested that the basolateral organic 
cation transporter OCT2 served as the primary means of uptake into proximal 
tubular cells. This theory was challenged when knock out of Oct1/Oct2 
expression in mice had no effect creatinine clearance, but the presence of 
cimetidine and PAH significantly reduced creatinine secretion (Eisner et al., 
2010). At physiologically relevant creatinine concentrations, the affinity of 
creatinine for OAT2 has been shown to be greater than the affinity for OCT2, 
OCT3, MATE1 and MATE-2K (Lepist et al., 2014; Shen et al., 2015). OAT2 
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mRNA expression is reported to be 3-fold higher than expression of OCT2 
(Cheng et al., 2012). Collectively this suggests that OAT2 plays a major role in 
the tubular secretion of creatinine. 
OAT4 has been linked with drug exit into the ultrafiltrate and the uptake of 
estrone-3-sulphate (E3S) and urate from ultrafiltrate into the cell. It effluxes OA- 
accumulated within the cell by OAT1/Oat1 and OAT3/Oat3 in exchange with 
extracellular chloride ions. Additionally, urate and E3S are reabsorbed by OAT4 
from ultrafiltrate in exchange for dicarboxylate/hydroxyl ions. The gene for 
OAT4 is located on chromosome 11q13.1 and is co-localised with the gene 
encoding URAT1 (Eraly et al., 2003). URAT1/urat1 is the major urate 
reabsorbing transporter in proximal tubular cells and the target of uricosuric 
drugs. Many genetic variants in SLC22A12 (URAT1) have been associated with 
hypouricemia (Enomoto et al., 2002; Anzai et al., 2007; Roth et al., 2012). 
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 Table 1.2: Substrates of OAT1/Oat1 and OAT3/Oat3 transporters. 
 
1.3.2. OATP family 
In human renal proximal tubule cells only two OATP family isoforms have been 
characterised, basolateral OATP4C1 (SLCO4C1) and apical OATP1A2 
(SLCO1A2). In contrast, rodents are thought to express multiple OATP isoforms 
including basolateral Oatp4c1, and apical Oatp1a1 (SLCO1A1), Oatp1a2, 
Oatp1a3_v1 (SLCO1A3, previously known as Oat-K1), and Oatp1a3_v2 
(SLCO1A3, previously known as Oat-K2) (Hagenbuch B, 2004).  
OATPs are located in numerous epithelia throughout the body. They mediate 
the sodium-independent transport of a diverse range of amphiphilic organic 
compounds with a molecular weight greater than 350 Daltons (Hagenbuch and 
Meier, 2003; Roth et al., 2012). The general predicted structure consists of 12 
Substrates of OAT1/Oat1 and OAT3/Oat3 
Endogenous compounds α-Ketoglutarate 
 Prostaglandin E2/F2α 
 Cyclic nucleotides 
 Folate 
 Urate 
 Estone-3-Sulphate 
 Conjugated hormones 
Drugs  
Antibiotic Benzylpenicillin, Cephaloridine, Tetracycline 
ACE inhibitor Captopril 
Antiviral Acyclovir, Adefovir 
Histamine receptor 2 antagonist Cimetidine, Ranitidine 
Anti-inflammatory Ibuprofen, Diclofenac 
Diuretic Torasemide, Chlorothiazide 
Statin Pravastatin, Fluvastatin 
Cytostatic Methotrexate, Chlorambucil 
Uricosuric Probenecid, Benzbromarone, Losartan 
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transmembrane spanning domains (Hagenbuch and Gui, 2008). The majority of 
substrates are OA-, although some OATPs have been reported to also transport 
neutral and cationic compounds (Bossuyt et al., 1996). They function as 
antiporters, the uptake of organic compounds is coupled with the efflux of 
bicarbonate, glutathione, or glutathione-s-conjugates in an electroneutral 
exchange (Takeuchi A, 2001; Badagnani I, 2006). The overall direction of 
transport is dependent upon the local substrate gradients. Examples of 
OATP4C1 and OATP1A2 substrate are listed in Table 1.3 and Table 1.4. 
Oatp4c1 was first cloned from rat kidney in 2004, based upon northern blot 
analysis it was thought to be kidney-specific (Mikkaichi T, 2004). More recently 
however, microarrays have suggested that it is also expressed within the liver, 
however, this has not yet been verified with PCR or protein analysis (Bleasby et 
al., 2006). The human gene is located on chromosome 5q21 (Hagenbuch B, 
2004; Mikkaichi et al., 2004). From rat Oatp4c1 localisation studies it is 
assumed that human OATP4C1 is also located on the basolateral membrane of 
proximal tubule cells. Oatp4c1 is reported to possess multiple substrate 
recognition sites. So far, two distinct recognition sites for E3S and digoxin (DX) 
have been characterised (Mikkaichi et al., 2004). 
Oatp1a2 (SLCO1A2) first cloned within rat liver, is located on human 
chromosome 12p12 (Kullak-Ublick GA, 1995; Hagenbuch B, 2004). In human 
and rat proximal tubular cells OATP1A2/Oatp1a2 is expressed at the apical 
membrane (Lee et al., 2005), where it is thought to be responsible for either the 
reabsorption from or the secretion of xenobiotics into ultrafiltrate. In the kidney 
OATP1/Oatp1 expression is stimulated by testosterone and inhibited by 
oestrogen. As a consequence, kidney Oatp1 is less abundantly expressed in 
female compared to male rats (Lu et al., 1996; Gotoh et al., 2002). Functional 
downregulation of OATP1/Oatp1 can occur via serine phosphorylation by 
extracellular ATP (Glavy et al., 2000). Furthermore, protein kinase C activation 
in Oatp1a expressing Xenopus Laevis oocytes leads to decreased transport of 
E3S (Guo and Klaassen, 2001). Altered expression levels and polymorphisms 
of OATP1A2 are associated with disease states and altered drug disposition e.g. 
imatinib (Yamakawa et al., 2011), and methotrexate (Badagnani et al., 2006). 
Six nonsynonymous single nucleotide polymorphisms (SNPs) have been 
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identified (T38C (I13T), A516C (E172D), G559A (A187T), A382T (N128Y), 
A404T (N135I), and C2003G (T668S)), the allelic frequencies of which appear 
to be ethnicity-dependent (Lee et al., 2005). A516C and A404T variants have a 
reduced capacity for mediating the cellular uptake of OATP1A2 substrates such 
as E3S, whereas G559A and C2003G variants appear to have substrate-
dependent changes in transport activity.  
 
Table 1.3: Substrates of OATP4C1/Oatp4c1 transporters. 
   
Substrates of OATP4C1 
Endogenous compounds Cyclic nucleotides 
 Estrone-3-sulphate 
 Thyroid hormones 
Drugs  
Cytostatic Methotrexate 
Cardiac glycoside Ouabain, Digoxin 
Antidiabetic Sitagliptin 
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Table 1.4: Substrates of OATP1A2/Oatp1a2 transporters. 
 
1.3.3. OCT family 
The OCT isoforms OCT2/Oct2 (SLC22A2), and OCT3/Oct3 (SLC22A3) are 
found in both humans and rat proximal tubule cells. Oct1 (SLC22A1) has been 
identified at the basolateral membrane of rodent proximal tubular cells by 
northern analysis and RNA in-situ hybridisation (Gründemann D, 1994; Karbach 
et al., 2000). However in-situ hybridization studies have failed to detect OCT1 in 
human kidney. It is reported to be primarily expressed in the liver, indicating a 
species difference in renal transporter expression (Gorboulev V, 1997; Zhang et 
al., 1997). 
Oct1 was the first OCT isoform to be cloned in 1994 from rat kidney 
(Gründemann D, 1994). A human orthologue was later cloned in 1997 
(Gorboulev et al., 1997). By homology screening, a second member Oct2 was 
identified in rat kidney (Okuda et al., 1996) and later cloned in human 
(Gorboulev et al., 1997). OCT3/Oct3 was independently cloned and identified 
Substrates of OATP1A2 
Endogenous compounds Anionic cyclic and linear peptides 
 Estrone-3-sulphate 
 Thyroid hormones 
 Bile acids 
 Steroid hormones and conjugates 
Drugs  
Antibiotic Erythromycin, Rifampicin 
Antiviral Ritonavir, Lopinavir 
Antihypertensive Enalapril, Verapamil 
Statin Pravastatin, Rosuvastatin 
Anti-inflammatory Dexamethosone 
Narcotic Naloxone 
Antihistamine Fexofenadine 
Cytostatic Imatinib, Methotrexate 
β-blocker Acebutolol, Atenolol 
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as the extraneuronal monoamine transporter in 1998 (Grundemann et al., 1998; 
Kekuda et al., 1998; Wu et al., 1998). OCTs encode proteins that are 542 to 
556 amino acids long with 12 predicted transmembrane spanning domains 
(Koepsell and Endou, 2004). Oct1, OCT2/Oct2, and OCT3/Oct3 located at the 
basolateral membrane of proximal tubule cells mediate the passive facilitated 
diffusion of a broad range of structurally diverse organic cations (OC+s) down 
their electrochemical gradients (Urakami et al., 1998; Karbach et al., 2000). 
Therefore transport can occur in either direction and is driven not only by the 
difference in substrate concentration but also by membrane potential. Due to 
the negative resting membrane potential of the cell maintained by Na+/K+ 
ATPase, transport is favoured at normal membrane potential (Wright SH and 
Dantzler WH, 2004). The functional characteristics of these transporters have 
been studied in expression systems such as Xenopus Laevis oocytes and 
transfected cell lines. They have extensively overlapping substrate specificities. 
The OC+s range in size from 60 to 350 Daltons, with at least one positively 
charged moiety at physiological pH (Jonker and Schinkel, 2004), examples are 
shown in Table 1.5.  
OCT regulation can occur at the transcriptional or protein level. The OCT2/Oct2 
promoter region has androgen receptor elements. Activation via steroid 
hormones increases both OCT2/Oct2 mRNA levels and activity (Shu et al., 
2001). Additionally phosphorylation of Oct1 and OCT2/Oct2 by tyrosine kinase 
and protein kinase A, C and G can alter activity (Roth et al., 2012). Whilst 
OCT3/Oct3 activity can be altered by both the mitogen activated protein kinase 
pathway and calcium-calmodulin pathway. Oct1, Oct2, Oct3 knock out mice 
have been generated with no obvious phenotype (Jonker et al., 2001; Zwart et 
al., 2001; Jonker et al., 2003). Similarly no polymorphisms in OCTs are 
associated with pathologies. OCT1 has 18 SNPs that alter amino acids – 6 
have reduced transport activity and 1 has increased activity (Kerb et al., 2002). 
OCT2 has 10 variants with the exception of a premature stop codon, all are 
functionally active, though substrate selectivity and the ability to transport may 
be slightly altered (Koepsell et al., 2007). 5 non-synonymous polymorphisms 
have been identified in OCT3, 3 of which show reduced transport activity 
(Sakata et al., 2010). In Chinese and Korean populations the OCT2 variant 
A270S has been associated with a significant reduction in renal clearance of 
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metformin (Song et al., 2008; Wang et al., 2008). Tubular secretion of 
creatainine can be inhibited by OCT2 substrates. Therefore, alternative 
methods should be used to assess golmerular filtration rate in NMEs capable of 
OCT2 inhibition.  
 
Table 1.5: Substrates of OCT2/Oct2 and OCT3/Oct3 transporters. 
 
1.3.4. MATE family 
Within mammals there are two MATE proteins, MATE1/Mate1 (SLC47A1) and 
MATE2 (SLC47A2). MATE1/Mate1 is expressed in both human and rat kidney. 
Substrates of OCT2/Oct2 and OCT3/Oct3 transporters 
Endogenous compounds Creatinine 
 Bile acids 
 Choline 
 Hormones 
 Neurotransmitters 
 L-Carnitine 
 Guanidine 
Drugs  
Antidiabetic Metformin 
Antihypertensive Debrisoquine, Verapamil 
Antiviral Amantadine 
Histamine H2 receptor antagonist Cimetidine, Ranitidine 
Antiparkinsonian Amantadine, Memantine 
Antiarrhythmic Procainamide 
-blocker Propranolol 
Diuretic Amiloride 
Cytostatic Cisplatin, Oxaliplatin 
Nicotinic receptor partial agonist Varenicline 
Antidepressant Citalopram, Desipramine 
Antimalarial Quinine 
 18 
 
Currently the MATE2 splice variant, MATE2-K, is the only member of the 
subfamily in which functional transport activity has been demonstrated. MATE2-
K appears to be exclusively expressed in the apical membrane of human renal 
proximal tubular cells, whilst MATE2 is expressed in intracellular vesicles 
(Komatsu et al., 2011).  
MATE1, first cloned within humans is highly expressed on the apical membrane 
of both rat and human proximal tubular cells (Otsuka et al., 2005; Terada et al., 
2006). A paralog of MATE1, MATE-2K was first cloned from human kidney in 
2006 (Masuda et al., 2006). The predicted structure is 12 transmembrane 
domains (He et al., 2010). Both MATEs expressed at the apical membrane of 
proximal tubular cells appear to function in conjunction with basolateral OCT2 to 
mediate the excretion of OC+s from blood into ultrafiltrate (Dresser et al., 2001; 
Otsuka et al., 2005). Initial characterisation of the transporter when it was first 
identified within Vibrio Parahaemolyticus described MATE1 as a secondary 
active antiporter (Morita et al., 2000). It couples the movement of toxic OC+ out 
of the cell, against the concentration gradient using the energetically favourable 
inward movement of hydrogen and sodium ions along their electrochemical 
gradient. Similar to OCTs, substrates of these transporters include structurally 
diverse low molecular weight OC+s. In addition select OA-s such as E3S, 
acyclovir and gancyclovir are reported to be substrates for MATE1 (Tanihara et 
al., 2007). Functional characterisation in-vitro studies in membrane vesicles and 
transfected cell lines have revealed an extensive overlapping substrate 
specificity but different binding affinities. The functional characteristics of these 
transporters have been studied in expression systems such as Xenopus Laevis 
oocytes and transfected cell lines. They have extensively overlapping substrate 
specificities (Masuda et al., 2006; Tanihara et al., 2007). Examples of 
endogenous and exogenous substrates are shown in Table 1.6. 
The ubiquitously expressed transcription factors specificity protein 1 (SP1) and 
activator protein 1 (AP1) are reported to affect MATE1/Mate1 transcription in 
both human and rat proximal tubule cells (Kajiwara et al., 2007; Ha Choi et al., 
2009; Baumann et al., 2010). In MATE1 and MATE2-K 11 and 2 
nonsynonymous SNPs have been identified (Chen et al., 2009; Kajiwara et al., 
2009; Yonezawa and Inui, 2011). The mutations G64D and V480M in MATE1 
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and G211V in MATE2-K cause a complete loss of membrane expression. Thus 
these variants can affect the pharmacokinetics of substrates. The allelic 
frequency of dysfunctional mutations is less than 5% and homozygous carriers 
have not been found. Polymorphisms in both the SP1 and AP1 transcription 
factor binding regions have also been identified (rs72466470, rs2252281), 
which result in a decreased binding and a reduced transcriptional activity. The 
frequency of these polymorphisms is 3.7 and 23.1 to 44.5 %, respectively. The 
MATE genes are also located in the commonly deleted region in Smith-Magenis 
syndrome, a genomic disorder of chromosome 17p11.2 (Bi et al., 2002; Slager 
et al., 2003). The disease is a developmental disorder, with major features 
including mild to moderate intellectual disability, distinctive facial features, sleep 
disturbances and behavioural problems. The relevance of MATE1 and MATE2-
K to the progression of this disorder is under investigation. Experiments in 
Mate1 knock out mice have identified the role of MATE1 in the 
pharmacokinetics of many drug molecules. For instance in Mate1 knock out 
mice, plasma and renal concentrating of metformin increased and urinary 
excretion decreased, indicating Mate1 plays a role in the tubular secretion of 
metformin (Tsuda et al., 2009). In heterozygous Mate1 knock out mice the 
pharmacokinetics of metformin were not significantly different from wild type, 
suggesting Mate1 is not the rate limiting step in the tubular secretion of 
metformin (Toyama et al., 2010). 
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Table 1.6: Substrates of MATE1/Mate1 and MATE2-K transporters. 
 
1.3.5. MDR1  
MDR1/Mdr1 (ABCB1) first cloned from human carcinoma cells (Ueda et al., 
1987), is highly expressed on the apical membrane of human and rat proximal 
tubule cells. In humans MDR1 is encoded by one gene, whereas rats possess 
two isoforms Mdr1a and Mdr1b (Bush JA, 2002). 
The function of apically expressed MDR1/Mdr1 is the movement of substrates 
out of the cell for renal clearance. ATP hydrolysis provides the energy for active 
transport, enabling the transporter to function against steep concentration 
gradients. Endogenous and exogenous substrates of human and rat 
MDR1/Mdr1 have been identified through functional studies in membrane 
vesicles and transfected cell lines. They transport a broad range of therapeutics, 
as shown in Table 1.7. Substrates preferentially are neutral or hydrophobic OC+ 
molecules ranging in size from less than 200 to 1900 Daltons. The transporter 
Substrates of MATE1/Mate1 and MATE2-K transporters 
Endogenous compounds Peptides 
 Nucleosides 
 Creatinine 
 Thiamine 
 Guanidine 
 Estrone-3-sulphate 
Drugs  
Antidiabetic Metformin 
Antibiotic Cephalexin, Cephradine 
Antiviral Acyclovir, Gancyclovir 
Antihistamine Fexofenadine 
Cytostatic Oxaliplatin, Topotecan 
Histamine H2 receptor antagonist Cimetidine 
Antiarrhythmic Quinidine, Verapamil, Procainamide 
Antimalarial Pyrimethamine 
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consist of 1276 to 1280 amino acids in a tandem duplicated structure, with 12 
hydrophobic transmembrane domains (Aller et al., 2009). Containing at least 
three distinct substrate binding sites within the ligand binding domain and two 
ATP binding motifs (Shapiro et al., 1999). A high resolution structure of mouse 
Mdr1 has been described (Aller et al., 2009). Cholesterol stimulates basal 
ATPase activity (Rothnie et al., 2001; Gayet et al., 2005). It is an endogenous 
substrate of MDR1 (Garrigues et al., 2002). Furthermore, it has been shown 
that cholesterol effects the affinity of low molecular weight molecules (350 to 
500 Daltons) for MDR1 (Kimura et al., 2007). As a result it has been 
hypothesised that cholesterol may directly bind or allosterically affect the 
substrate binding site to help the recognition of smaller substrates. Many 
inhibitors of MRD1/Mdr1 contain aromatic ring structures, a tertiary or 
secondary amino group, and have high lipophilicity (Wang et al., 2003). They 
can be categorised into either high-affinity substrates that bind non-
competitively, or efficient inhibitors of ATP hydrolysis. 
Protein kinases, chaperones (HSP90), ubiquitin-related enzymes, and 
transcription factors regulate the expression and function of MDR1. A variety of 
mitogen-activated protein kinase signalling inhibitors have been shown to 
reduce expression of MDR1/Mdr1. Some have suggested phosphorylation of 
serine residues in the linker region of MDR1/Mdr1 is essential for the 
translocation and function. Several groups have reported conflicting results on 
the role of the transcription factor, AP1. Some have demonstrated that AP1 
downregulates expression (Liu et al., 2008; Bark and Choi, 2010), whereas 
other have reported that AP1 activates expression (Guo et al., 2008; Chen et al., 
2014). Suggesting that dual regulation must occur at the site of the AP1 site of 
the MDR1 promoter (Katayama et al., 2014). Oestrogen mediates down-
regulation of MDR1/Mdr1 expression (Mutoh et al., 2006). A number of 
microRNAs (miR-27a, miR-451) have been reported to modulate expression of 
MDR1/Mdr1 (Katayama et al., 2014). 
MDR1/Mdr1 is highly polymorphic, over 50 SNPs have been identified in both 
the coding and noncoding regions of the gene, with significant linkage 
disequilibrium (Marzolini et al., 2004; Coller et al., 2006). SNPs in exons 26 
(C3435T), 21 (G2677T/A), and 12 (C1236T) have been characterised in a 
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number of ethnic populations. The frequencies of the variant alleles differ in 
various populations (Marzolini et al., 2004). Expression of G2677T and C3435T 
are reported to protect Chinese but not Caucasian men from late-onset 
Parkinson’s disease (Lee et al., 2004; Tan et al., 2004; Tan et al., 2005). In 
addition, G2677T/A is linked with lower plasma concentrations of fexofenadine, 
a higher risk of cyclosporine A failure in steroid resistant ulcerative colitis, and 
tacrolimus toxicity (Yamauchi et al., 2002; Yi et al., 2004; Daniel et al., 2007). 
C3435T is associated with an increased efflux of rhodamine 123, reduced efflux 
of nelfinavir, and no effect on fexofenadine efflux (Hitzl et al., 2001; Drescher et 
al., 2002; Fellay et al., 2002). C1236T genotype has been linked to an 
increased exposure to irinotecan and increased response to temozolomide, 
cyclosporine A (Zhou et al., 2005; Zhang et al., 2008; Schaich et al., 2009). 
Direct clinical evidence of the contribution of MDR1/Mdr1 inhibition or induction 
to DDIs is limited due to cross specificity of MDR1/Mdr1 substrates with the 
drug metabolising enzymes CYP3A4. DX is a MDR1/Mdr1 substrate that is not 
metabolised by cytochrome P450 enzymes (Hinderling and Hartmann, 1991; 
Lacarelle et al., 1991). Therefore it is commonly used as a model substrate to 
determine MDR1/Mdr1 transporter activity in-vivo (Endres et al., 2006). Co-
administration of DX with other MDR1/Mdr1 substrates or inhibitors (such as 
verapamil, quinidine, itraconazole and ritonavir) can significantly affect the 
bioavailability and/or systemic clearance (Woodland et al., 1998; Hunt, 2005). 
DX has a narrow therapeutic window thus increases in plasma concentration 
can cause digitalis toxicity. 
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Substrates of MDR1/Mdr1 transporters 
Endogenous compounds Steroids 
 Lipids 
 Bilirubin 
 Bile Acids 
 Guanidine 
 Estrone-3-sulphate 
 Opioid peptides 
Drugs  
Analgesic Asimadoline 
Anticancer Vinblastine, Paclitaxel, Etoposide 
HIV protease inhibitor Saquinavir, Ritonavir 
-blocker Talinolol 
Histamine H2 receptor antagonist Cimetidine, Ranitidine 
Antigout agent Colchicine 
Antidiarrheal agent Loperamide 
Antiemetic Domperidone, Ondansetron 
Antifungal Ketoconazole, Itraconazole 
Antihistamine Fexofenadine, Cetirizine 
Calcium channel blocker Verapamil, Diltiazem 
Cardiac glycoside Digoxin 
Antiarrhythmic agent Quinidine, Losartan 
Statin Atorvastatin 
Immunosuppressant agent Cyclosporine A, Tacrolimus 
Corticosteroid Dexamethasone, Hydrocortisone 
Antibiotic Erythromycin, Gramicidin D 
 
Table 1.7: Substrates of MDR1/Mdr1 transporters. 
 
1.3.6. BCRP 
BCRP/Bcrp (ABCG2) was first identified within MCF-7/AdrVp breast cancer 
cells (Doyle LA, 1998). It is primarily expressed in the small intestine, blood 
brain barrier, liver and placenta. The transporter is also expressed within human 
proximal tubular cells (Huls et al., 2008); however its expression level is very 
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low in comparison to the small intestine and liver. Alternatively the transporter is 
abundantly expressed in rat kidney. 
BCRP/Bcrp has a major role in drug disposition and distribution, similar to 
MDR1. BCRP/Bcrp is an apical efflux transporter that mediates the movement 
of substrates out of the cell for renal clearance. ATP hydrolysis provides the 
energy for active transport, enabling the transporter to function against steep 
concentration gradients. Unlike the other multi-substrate transporters 
BCRP/Bcrp consists of 655 amino acids and six transmembrane domains (Ni et 
al., 2010). This implies that the transporter need to dimerise to be functional 
(Nicolle et al., 2009). A homotetramer structure has been reported in humans 
(Xu et al., 2004; McDevitt et al., 2006). The transporter possess a very broad 
substrate specificity that overlaps with MDR1/Mdr1 which increases the barrier 
function of the efflux transporters. 
Table 1.8 lists examples of BCRP/Bcrp endogenous and exogenous substrates. 
High-speed screening and quantitative structure activity relationship analysis 
methods suggest that one amine bonded to one carbon of a heterocyclic ring is 
an important component for drug interaction with BCRP/Bcrp (Saito et al., 2006; 
Nicolle et al., 2009; Giacomini et al., 2010). Many inhibitors of MRD1/Mdr1 are 
also inhibitors of BCRP/Bcrp with varying affinity. They can be categorised into 
either high-affinity substrates that bind non-competitively, or efficient inhibitors 
of ATP hydrolysis. 
BCRP expression can be regulated at the transcriptional and protein level. In 
humans the predominant promoter is E1B/C that contains multiple SP1 sites, 
followed by E1A (Bailey-Dell et al., 2001). Transcription factors that bind to cis 
elements upstream of the BCRP E1B/C promoter with subsequent activation or 
repression of the promoter include hypoxia-inducible factor 1α, estradiol, 
progesterone, interleukin-6, aryl hydrocarbon receptor agonists, peroxisome 
proliferators-activated receptor gamma, zinc finger protein - GLI1, nuclear factor 
2, and transforming growth factor-β (Natarajan et al., 2012). Epigenetic 
regulation of the ABCG2 gene has been reported in renal cancer cell lines. 
Elevated BCRP levels have been associated with hypomethylation and 
unmethylation of CpG islands, and histone hyperacetylation of the promoter 
region (To et al., 2006). BCRP expression can be downregulated by microRNAs 
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(miR-519c, miR520h, miR328) (Mao and Unadkat, 2015). Serine/threonine-
protein kinase 1 phosphorylates BCRP/Bcrp which promotes its dimerisation 
and trafficking to the plasma membrane (Xie et al., 2008).  
More than 80 SNPs of the ABCG2 gene have been identified although few 
modify transport activity (Mao and Unadkat, 2015). Of these, the V12M and 
Q141K alleles are found at high frequency in East Asians (30 to 60%) with a low 
frequency in Caucasian and African-American populations (5 to 10%). The 
Q141K variant results in a reduced protein expression of BCRP/Bcrp 
(Vethanayagam et al., 2005). Clinically this allele has been linked with higher 
plasma levels of BCRP substrate drugs such as topotecan, rosuvastatin, 
sulfasalazine, gefitinib, atorvastatin and methotrexate (Sparreboom et al., 2005; 
Cusatis et al., 2006; Urquhart et al., 2008; Warren et al., 2008; Keskitalo et al., 
2009) but not of irinotecan, pitavastatin and lamivudine (de Jong et al., 2004; 
Ieiri et al., 2007; Kim et al., 2007). 2 SNPs result in a premature stop codon 
(Q126stop, E334stop). 
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Substrates of BCRP/Bcrp transporters 
Endogenous compounds Flavonoids 
 Porphyrins 
 Estrone-3-sulphate 
Drugs  
Antibiotic Anthracycline, Daunorubicin 
Anticancer agent Topotecan, Methotrexate 
Nucleoside analogue Azidothymidine, Lamivudine 
Antianxiety Prazosin 
Proton pump inhibitor Pantoprazole 
Statin Rosuvastatin 
Antiarthritis Sulfasalazine 
Histamine H2 receptor antagonist Cimetidine 
Antidiabetic Glibenclamide 
 
Table 1.8: Substrates of BCRP/ Bcrp transporters. 
1.3.7. MRP family 
The isoforms MRP1/Mrp1 (ABCC1), MRP2/Mrp2 (ABCC2), MRP3/Mrp3 
(ABCC3), MRP4/Mrp4 (ABCC4) and MRP6/Mrp6 (ABCC6) are expressed in 
both human and rat proximal tubular cells. Additionally rat proximal tubular cells 
also express Mrp5 (ABCC5). MRPs are unidirectional efflux transporters. 
MRP2/Mrp2 and MRP4/Mrp4 are located at the apical membrane (Schaub et al., 
1997; van Aubel et al., 2002). MRP1/Mrp1, MRP3/Mrp3, Mrp5 and MRP6/Mrp6 
are located at the basolateral membrane. Of all the MRPs MRP2/Mrp2 is 
deemed the most clinically relevant. 
MRP1 was the first isoform to be characterised; it was originally identified in a 
human multi-drug resistant lung carcinoma cell line (Cole et al., 1992). By 
searching the human genome with an expressed sequence tag of ABCC1 the 
other isoforms of MRP were identified (Allikmets et al., 1996; Kool et al., 1997). 
Each of the MRPs contain two ATP-binding cassettes and two core membrane 
spanning domains each consisting of 6 transmembrane regions (MSD1 and 
MSD2). MRP1/Mrp1, MRP2/Mrp2, MRP3/Mrp3 and MRP6/Mrp6 also contain an 
additional membrane-spanning domain (MSD0) containing a further 5 
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transmembrane regions (Toyoda et al., 2008). It has been shown that this 
additional transmembrane domain within MRP1 is not required for function of 
MRP1/Mrp1 nor for localisation to the basolateral plasma membrane (Bakos et 
al., 1998). However, mutation of Cysteine (7) residue within MSD0 changes 
the amino-terminal conformation of MRP1, thereby reducing the maximal 
transport rate (Vmax) of leukotriene C4 5 to 7-fold (Yang et al., 2002). 
Suggesting that MSD0 may have some function. The energy of ATP hydrolysis 
is used to actively efflux substrates across either the apical of basolateral. The 
MRPs again have a broad substrate specificity they act as a defence 
mechanism effluxing potentially cytotoxic endogenous and exogenous 
molecules from cells. They are able to transport hydrophobic anionic molecules, 
and conjugates of glucoronate, sulphate and glutathione. Lipophilic glutathione-
s-conjugates are transported predominantly by MRP2/Mrp2 (Konig et al., 1999; 
König J, 1999), while cyclic nucleotides, uric acid, anticancer agents and 
antiviral drugs are transported by MRP4/Mrp4 (van Aubel et al., 2002). 
Examples of MRP substrates are listed in Table 1.9. The development of knock 
out animal models has led to a better understanding of the role of MRP1 and 
MRP2 in drug disposition (Endres et al., 2006). The remaining isoforms have 
not been sufficiently characterised to date. 
MRP expression is regulated at the transcriptional and protein level in response 
to substrate concentrations, oxidative stress, and disease states. 
Characterisation of the human and rat promoter region of the ABCC2 identified 
numerous transcription factor binding sites, such as SP1 and AP1. A hormone 
response element in rat ABCC2 promoter has also been recognised. Many 
lipophilic compounds are ligands for nuclear receptor hormones (such as 
farnesoid X receptor, pregnane X receptor, or constitutive androstane receptor). 
The binding of heterodimers of the retinoid X receptor-α with the ligand-
activated nuclear receptor hormones at the hormone response element induces 
transcription of ABCC2 (Nies and Keppler, 2007). Oxidative stress leads to 
activation of nuclear factor 2. Once activated this transcription factor binds the 
antioxidant response element to up-regulate transcription of ABCC1 and 
ABCC2 (Toyoda et al., 2008). In an in-vivo rat model of cholestasis it has been 
shown that ABCC2 expression in the liver is down regulated whilst expression 
in the kidney is upregulated (Lee et al., 2001). This adaptation in transporter 
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expression is thought to limit liver injury and facilitate extrahepatic excretion of 
bile salts. 
More than 200 naturally occurring sequence variants have been identified in the 
human ABCC2 gene (Nies and Keppler, 2007). Many of these sequence 
variants are SNPs that do not result in amino acid changes and are thus without 
functional consequence. Impairment of MRP2 function by polymorphisms (i.e. 
splice site, premature stop codons, deletion and frame insertion mutations) or 
chemical inhibitors results in Dubin-Johnson syndrome. An autosomal recessive 
disorder that causes an increase of conjugated bilirubin in the serum without 
elevation of liver enzymes (Nies and Keppler, 2007). 
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Table 1.9: Substrates of MRP/ Mrp transporters. 
   
Substrates of MRP/Mrp transporters 
Endogenous compounds Bilirubin 
 Leukotrienes 
 Bile salts 
 S-glutationyl- estradiol 
 Cholecystokinin peptide 
 E3S 
 Conjugates of 17β-estradiol 
 Leukotriene 
 Cyclic nucleotide 
 Urate 
 Prostaglandins 
 PAH 
 Taurocholic acid 
 Folic Acid 
Drugs  
 Glutathione and glucuronide conjugates 
Anticancer Methotrexate, Etoposide 
HIV protease inhibitor Saquinavir, Ritonavir 
Angiotensin II receptor antagonist Valsartan, Olmesartan 
Anitviral Acyclovir 
Diuretic Frusemide 
Antibiotic Ciprofloxacin, Cefazolin 
Antihistamine Fexofenadine 
Analgesic Paracetamol 
Statin Rosuvastatin, Atorvastatin 
Stimulant Para-methoxy-N-ethylamphetamine 
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1.4. Current proximal tubule cell models 
Models of the renal proximal tubule commonly used to measure transport 
activity in drug development pre-clinical in-vitro screening assays include; 
expression systems, transfected cells, immortalised animal and human renal 
cell lines, membrane vesicles, cortical renal slices, and primary cells. The 
advantages and disadvantages of these models are discussed herein. These 
models are commonly used for mechanistic studies, to determine the rate 
limiting step in transepithelial transport, and identify transporter based DDIs. In 
academia radiolabelled or fluorescent substrates are commonly used to 
measure transporter expression in these expression systems. Alternatively 
pharmaceutical companies utilise expensive, high-throughput, sensitive liquid 
chromatography – mass spectrometry techniques. 
1.4.1. Expression systems 
One of the earliest techniques to determine the function of a transport protein is 
microinjection of the transport protein cRNA into an expression system such as 
a Xenopus Laevis oocyte (Gurdon et al., 1971). This provides a platform for the 
study of only the transporter of interest, without the influence of others. The 
structure, substrates and inhibitors of OCTs and OATs have been elucidated 
using this technique (Gründemann D, 1994; Okuda et al., 1996; Sekine et al., 
1997). A drawback of this model is its lack of physiological relevance due to the 
absence of other transporters that may influence a molecules distribution. 
Another disadvantage is that oocytes only provide transient expression of 
transport proteins. As a result marked variation in expression levels and thus 
kinetic parameters (such as maximum rate of transport and transporter affinity 
values) between batches of oocytes have been reported (Walker, 2008). 
Furthermore, kinetic values derived from oocytes differ from those from 
mammalian expression systems due to differences in the plasma lipid 
membrane (Goldin, 1992).  
1.4.2. Transfected cell lines 
Transporters of interest have also been transfected in to immortalised animal 
and human cell lines. This is achieved by inserting a vector such as a plasmid 
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containing the cDNA of the desired transporter. Recombinant transporter that 
are stably of transiently expressed in various cell lines can be used to 
characterise drug transporter interactions. Cultured renal cell lines commonly 
used to study drug transporter interactions include MDCK, LLC-PK1 and 
HEK293 cells. MDCK have been transfected with OATPs and MDR1 (Takeuchi 
et al., 2001; Kuteykin-Teplyakov et al., 2010). Cells can be stably transfected to 
express multiple transporters. A quintuple multi-transporter renal model of 
creatinine clearance containing OAT2, OCT2, OCT3, MATE1 and MATE2-K is 
commercially produced by Optivia biotechnology. Transfection of cells with 
recombinant uptake and efflux transporters endogenously missing enables the 
study of transcellular transport (Cui et al., 2001; Sasaki et al., 2002). However, 
transporter expression in these cell lines does not reflect the transporters’ 
physiological expression levels as they are driven by the vector promoters and 
the cells’ translation transcription machinery. 
1.4.3. Immortalised animal and human renal cell lines 
Immortalised mammalian renal epithelial cell lines commonly used include LLC-
PK1 (porcine), MDCK (canine), and OK (opossum) cells. Immortalised human 
renal cell lines include HK-2, RPTEC, HEPTEC and ciPTEC cells. Immortalised 
renal epithelial cells inherently express some transport proteins. However, 
overall expression of renal transporters is low in comparison to primary tissue. 
For example the LLC-PK1 and HK-2 renal epithelial cell lines express functional 
MDR1 and have been used to investigate the efflux of prototypic substrates 
(Ryan et al., 1994; Ohtomo et al., 1996; Tramonti et al., 2001). Advantages of 
such cells are that they are easy to cultivate in large quantities and have an 
infinite lifespan. Some, but not all of these cell lines can be grown on 
Transwell® inserts to form polarised monolayers. This enables measurement of 
the molecules tubular secretion and reabsorption.  
A further limitation is that the cells lose differentiation over time with repeated 
passages. Often they lack expression of key transporters and fail to maintain 
brush-border microvilli. The LLC-PKI cells lack expression of the enzyme 
fructose- 1,6-bisphosphatase, rendering them incapable of gluconeogenesis, 
which is a key metabolic pathway in proximal nephron cells (Gstraunthaler et al., 
1985). In addition, LLC-PKI cells are not responsive to parathyroid hormone and 
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lack a probenecid-sensitive organic anion transporter (Gstraunthaler et al., 1985; 
Pfaller and Gstraunthaler, 1998). MDCK cells, on the other hand, do not 
express type 2 sodium/phosphate transporters, Sodium/glucose cotransporter 1 
and 2, or amino acid transporters. HK-2 cells lack expression of OAT1, OAT3 
and OCT2 (Jenkinson et al., 2012). ciPTEC cells lack expression of OATs 
(Jansen et al., 2014). SLC transporter expression is yet to be characterised 
within RPTEC cells (Aschauer et al., 2013). Additionally, slight variations in 
culture conditions (i.e. culture medium, passage frequency, passage protocol) 
between laboratories has been shown to effect transporter expression.  
1.4.4. Membrane Vesicles 
Basolateral and apical brush border plasma membrane vesicles can be used to 
study transporter activity. The technique was commonly used in transport 
studies in the 1970s and 80s but has been effectively superseded by cell 
transfection. Membrane vesicles have previously been prepared from intact 
renal tissue and primary, immortalised or transfected cell lines. The approach 
has provided a wealth of information on the quantitative structure activity 
relationship and interaction of many substrates and inhibitors with various 
transporters and provided much of the background to our current understanding 
of epithelial membrane transporters. Advantages of the methodology are that 
substrates and inhibitors of a known concentration are directly applied to the 
cytoplasmic compartment, and gradients can be easily optimised to drive 
transporter activity. But the procedure provides no molecular knowledge about 
transporter identity, and is unsuitable for hydrophobic compounds due to the 
molecule binding to the vesicle membrane or cellular systems. More data is 
available for apical membrane transporters than basolateral transporters as 
preparation of basolateral membrane vesicles is technically difficult and has 
mixed yields of membranes orientated in the outside-out and inside-out 
configuration, which makes experimental design and data interpretation difficult. 
1.4.5. Cortical renal slices 
An alternative to immortalised cells which dedifferentiate over time is the use of 
fresh primary tissue. Isolated cortical renal slices represent the truest 
anatomical in-vitro model of the kidney. 80% of each renal slice is composed of 
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proximal tubule cells, therefore they have potential to provide good information 
on renal drug handling (Lohr et al., 1998). Cisplatin was shown to competitively 
inhibit tetraethylammonium uptake in renal slices in 1984, indicating that it was 
an OCT2 substrate (Nelson et al., 1984). Cross sections are available from 
human and animal kidneys which allow direct comparison between species. 
However, the lumen of the tubules within the slices collapse, which means they 
provide information only on basolateral uptake, not apical membrane transport 
nor net direction of movement (Atterwill, 1987). Other drawbacks are they 
contain a heterogeneous population of cells and discriminating between which 
cell type can be difficult. They have a short finite lifespan, and a skilled 
experienced worker for kidney dissection. 
1.4.6. Primary proximal tubular cells 
The need for a robust in-vitro model of drug transport that expresses a full 
complement of transporters has been highlighted. Primary cells are derived 
from intact tissue, which, at the time of isolation express the full complement of 
drug transporters present in the tissue of interest. Proximal tubular cells can be 
isolated by a wide range of techniques that include enzymatic tissue digestion, 
differential sieving, gradient density centrifugation and fluorescence-activated 
cell sorting. Isolated proximal tubular cells in suspension are physiologically 
relevant intact cell models containing all the relevant transporters (Lohr et al., 
1998). However they are only viable for 2-3 hrs, after this functional integrity 
declines rapidly (Jones et al., 1979). Furthermore during the course of an 
experiment polarity of the cells is lost, which results in a marked down 
regulation of transporter expression. 
In recent years, proximal tubule cells isolated from intact tissue by collagenase 
digestion and isopynic centrifugation have been successfully cultured from 
human and rat kidneys. Cultures are structurally polarised, with numerous 
microvilli and tight junctions at the apical side, and preserved characteristic 
features of proximal tubule cells e.g. alkaline phosphatase and γ-glutamyl 
transferase enzyme activity (Racusen et al., 1997; Kim et al., 2001). Human 
primary proximal tubule cells also express the OA- and OC+ transporters absent 
from many immortalised proximal tubule cell lines in addition to ABC 
transporters MDR1 and MRP2 (Lash et al., 2006; Brown et al., 2008). The cells 
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have shown prototypic transport of endogenous OA- and OC+ such as PAH and 
creatinine and xenobiotics such as rosuvastatin (Lash et al., 2006; Brown et al., 
2008; Verhulst et al., 2008). Similarly cultured rat proximal tubule cells have 
shown sodium dependent uptake of α-methyl-D-glucopyranosine, ergothionine 
and carnitine suggesting expression of sodium-glucose (SGLT) and 
OC+/carnitine (OCTN) transport proteins (Nakanishi et al., 2011). Furthermore, 
Dr Lawrence H Lash (Wayne State University) has published several studies 
confirming the suitability of rat and human primary proximal tubular cells 
cultures as an in-vitro models to study nephrotoxicity (Cummings and Lash, 
2000; Cummings et al., 2000; Lash et al., 2001; Lash et al., 2003; Lash et al., 
2005; Lash et al., 2006). A disadvantage of primary culture is the finite lifespan 
of cells (approximately 14 days). A further limitation is human tissue availability 
and the expense of transport from hospitals. 
As discussed, a key deficiency in the drug development process is the 
availability of applicable pre-clinical in-vitro models that can be used to predict 
toxicological and efficacious outcomes in the clinical setting. Many widely used 
pre-clinical in-vitro models of transport in the kidney are based on transfected 
human or animal cells. These models express a limited number of human renal 
transporters, and so do not accurately reflect the situation in-vivo. Wherein the 
complex interplay between multiple transporters is key to transepithelial 
transport. In contrast, cultured primary renal proximal tubule cell monolayers 
appear to maintain a full complement of key renal transporters, resulting in a 
more physiologically relevant, and thus predictive model of drug handling in the 
clinical setting. 
1.5. Development of human and rat in-vitro models of 
drug transport. 
As previously mentioned a major challenge in drug development is the 
extrapolation of drug safety information from animals to humans. Approximately 
40.42 % of compound fail at Phase I (Tufts Center for the Study of Drug 
Development, 2014). Meaning that large numbers of animals are being 
sacrificed in pre-clinical trials with little to no benefit. For each drug lost at this 
stage $740 million is lost in developmental costs and 6.5 years in lead time to 
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clinic (Paul et al., 2010). Overall this results in a delay in getting molecules to 
clinic and an increased cost of successful drug molecules.  
Rat is the initial test species in drug development and safety determination 
(Bass et al., 2009). Due to the unpredictable differences in renal drug handling 
between species (Rasmussen, 1983) the development of a parallel rat primary 
proximal tubule cell model in addition to a human is encouraged. It enables 
clear unambiguous transport data on the handling drug molecules in either 
species to be ascertained. It allows direct comparison of the renal handling of a 
molecule between human and rat kidney, which would flag up any differences in 
handling that might impact upon the progress of the candidate drug molecule 
into a pre-clinical study. Furthermore, the data could be crucial in validating the 
cell-based assay as an acceptable surrogate for renal clearance experiments in 
rats.  
1.6. Project Aims 
The aims of this project are 3-fold. Firstly; to optimise the human and rat 
primary proximal tubule cell isolation technique. Secondly; to characterise 
expression of key renal transporters in human and rat primary proximal tubular 
cells. Thirdly; to validate their use as a screening tool to identify drug transporter 
interactions and transporter mediated DDIs. In the hope that further 
characterisation and validation of human and rat primary proximal tubular cell 
model will encourage their use of as an in-vitro proximal tubule cell model in 
industry and academia.  
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2. Materials and Methods 
2.1. Materials 
2.1.1. Cell Culture 
Cell culture reagents used in this project included high-glucose Dulbecco’s 
modified eagles medium (HG-DMEM), Ham’s F-12 nutrient mixture, Roswell 
Park Memorial Institute (RPMI)-1640 medium, foetal calf serum (FCS), penicillin, 
streptomycin, L-glutamine, trypsin with 0.02% ethylenediaminetetraacetic acid 
(EDTA), collagen, Dulbecco’s phosphate-buffered saline (PBS) and mouse 
epidermal growth factor (EGF) purchased from Sigma-Aldrich (UK). Percoll® 
was bought from GE Healthcare Life Sciences (UK), type 2 collagenase from 
Worthington Biochemicals (USA), and 10X Hanks’ balanced salt solution (HBSS) 
from Invitrogen (USA). Renal epithelial cell growth medium (REGM) SingleQuot 
kit supplements and growth factors (containing insulin, hydrocortisone, 
gentamycin amphotericin-B (GA) - 1000, adrenaline, tri-iodothyronine (T3), 
transferrin, FCS and human EGF) were procured from Lonza (Switzerland). 
The renal proximal tubular epithelial cell line, RPTEC, was licensed from 
Evercyte (Austria), along with ProxUp-2 ready-to-use medium (consisting of 
HG-DMEM/Hams-F12 (1:1), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES) buffer, glutamax, human epidermal growth factor, tri-iodothyronine, 
ascorbic acid, holo-transferrin, prostaglandin E2, hydrocortisone, sodium 
selenite, insulin and geneticin (G418)). 
Cells were grown on various cell culture vessels bought from Corning (UK). 
These included 24-well Transwell® permeable insert cell culture plates (with a 
surface area of 0.33 cm2 per insert and polycarbonate filter pore size of 0.4 µm), 
plastic 96-well plates (0.33 cm2 surface area), plastic 12-well plates (3.8 cm2 
surface area), T25 flasks (surface area 25 cm2) and T75 flasks (surface area 75 
cm2).  
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2.1.2. Quantitative polymerase chain reaction 
SV Total RNA isolation System, purchased from Promega (UK), was used to 
isolate total cell RNA. Moloney murine leukaemia virus (M-MLV) reverse 
transcriptase, M-MLV 5x reaction buffer, RNasin, Magnesium Chloride, 
deoxyribonucleotide triphosphate (dNTP) mix, 5x Green GoTaq® reaction buffer, 
GoTaq polymerase, and pGem-T-easy cloning vector kit (consisting of T4 DNA 
ligase, pGem®-T vector, 2x ligation buffers) were also procured from Promega 
(UK). Random hexamers were obtained from GE Healthcare Life Sciences, and 
MiniElute PCR purification kit from Qiagen. Agarose, EDTA, sodium hydroxide 
pellets, boric acid, ethidium bromide, bacto-tryptone, bacto-yeast extract, 
isopropyl β-D-1-thiogalactopyranoside, 5-bromo-3-indolyl β-D-
galactopyranoside, dimethylformamide, ampicillin, GenElute Plasmid Miniprep 
were gifts from Dr Judith Hall, and sourced from Sigma-Aldrich. Competent 
E.coli strain, DH5, was bought from New England Biolabs (UK). The 125U 
ThermoStart Taq DNA polymerase and 1x ThermoStart buffer were acquired 
from ABgene. Bespoke primers were ordered from IDT DNA (Belgium). Human 
and Rat Drug Transporter RT2 Profiler PCR array plates from SABiosciences 
(UK). 
2.1.3. Uptake and Flux Assays 
Radiolabelled [1-14C]-mannitol D, [32P]-monosodium phosphate ([32P]-Pi), and 
Optiphase Hisafe 2 scintillation solvent were purchased from PerkinElmer 
(USA). Bisbenzimide Hoechst 33342 (H33342), 5-(3-(2-(7-Chloroquinolin-2-
yl)ethenyl)phenyl)-8-dimethylcarbamyl-4,6-dithiaoctanoic acid (MK-571), 
mannitol, sodium chloride, potassium chloride, monosodium dihydrogen 
orthophosphate, magnesium sulphate, monopotassium phosphate, calcium 
chloride, HEPES, glucose, tris base, ethanol, chenodeoxycholic acid (CDC), T3, 
rosuvastatin (RSV), cimetidine (CIM), PAH, DX, E3S, GF120918, Ko143 
hydrate, heparin sodium, molecular-grade water, bovine serum albumin (BSA) 
and chloroform were purchased from Sigma-Aldrich. 5-chloromethylfluorescein-
diacetate (CMFDA) was purchased from Invitrogen (USA), and coomassie blue 
dye reagent from ThermoFisher Scientific (UK). Scintillation vials were 
purchased from Meridian Biotechnologies Ltd (UK). TFV and radiolabelled 
[adenine-2,8-3H]-TFV ([3H]-TFV) were gifts from Gilead (USA), and sourced 
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from Bio-techne and Hartmann Analytic GmbH respectively. Recombinant 
human Klotho- (amino acid residues 32-981) was purchased from Bio-techne 
(USA), recombinant fibroblast growth factor 23 (FGF-23) from BioVision (USA), 
and recombinant human parathyroid hormone (amino acid residues 1-84, PTH) 
from Cambridge Biosciences (UK). Trisodium phosphonoformate (PFA) was 
bought from Santa Cruz Biotechnology (USA).  
2.1.4. Nephrotoxicity 
CellTiter 96® AQueous one solution cell proliferation assay was purchased from 
Promega.  
2.2. Methods and Protocols 
2.2.1. Primary human proximal tubular epithelial cell isolation 
Primary human proximal and distal tubular and collecting duct epithelial cells 
(human PTCs) were isolated from healthy human kidneys unsuitable for 
transplant supplied by the human tissue bank Scievita Ltd. The donations came 
from a variety of anonymous UK hospitals. The demographics of the donors 
such as age, gender and ethnicity were unknown to protect patient anonymity. 
Ethical approval and consent for medical research were granted to Scievita 
prior to tissue procurement. The work carried out at Newcastle University was 
approved by the Scientific Review Board at Scievita in line with the ethical 
approval for medical and commercial usage granted to Scievita acting as a 
human tissue bank. 
Once excised from the donor, the kidney was stored with saline solution in 
sealed surgical bags placed in a polystyrene box filled with ice and transported 
to Newcastle University Medical School within 18 hours (hrs). All cell culture 
conducted at Newcastle University was performed in a class II vertical laminar 
flow hood to ensure sterility. The isolation procedure, summarised in Figure 2.1 
has been previously published (Van der Biest et al., 1994; Helbert et al., 1997; 
Helbert et al., 1999; Helbert et al., 2001; Brown et al., 2008). 
Under sterile conditions, the kidneys were decapsulated and macroscopically 
normal cortex slices were dissected, cut into pieces of about 1 mm3 and 
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enzymatically digested using type 2 collagenase in isolation medium. In order to 
optimise the enzymatic digestion phase of the isolation procedure renal cortex 
was incubated with different concentrations of collagenase over two different 
incubation periods. The cell suspension was shaken vigorously either (i) 
overnight at 4 °C followed by 37 °C for 1 hr (an overnight incubation) or (ii) for 2 
hrs at 37 °C (an acute incubation). 
Following enzymatic digestion of the renal cortex, the resulting cell suspension 
was passed through a 40 µm nylon mesh cell strainer to remove undigested 
cortex and glomerular endothelial cells. The collagenase was then removed by 
centrifuging the cell suspension at 1200 revolutions per minute (rpm) for 7 
minutes (min) in a 4 x 200 mL swing-out rotor at 4 °C. To remove any residual 
collagenase the cell pellet was resuspended in fresh isolation medium and 
recentrifuged at 1200 rpm for 7 min, this wash process was repeated twice. 
After the second wash, the heterogeneous cell population was separated by 
gradient density centrifugation. The cell suspension was loaded on top of a 
discontinuous Percoll® gradient then centrifuged at 3000 rpm for 25 min 
(minutes) at 4 ˚C. The densities of the gradient were 1.04 g / mL and 1.07 g / 
mL. Proximal and distal tubular epithelial cells from the intersection of the 1.04 g 
/ mL and 1.07 g / mL densities were carefully aspirated, washed and cultured as 
a mixed population of approximately 80 % proximal and 20 % distal tubule cells 
in 37 °C human REGM. The yield of cells collected from the isolation was 
quantified using a haemocytometer (Hawksley, UK). The compositions of the 
isolation medium and human REGM are shown in Table 2.1 and Table 2.2, 
respectively. 
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Figure 2.1: A schematic flow diagram of the proximal tubule cell isolation 
procedure.  
The enzymatic digestion of renal cortex was optimised in both species 
to generate the highest yield of viable cells. 
 
 
Table 2.1:The composition of isolation medium used in both human and 
rat PTC isolation. 
   
Cortex excised
Cortical slices 
taken from rat or 
human kidneys 
and minced.
Enzymatic 
digestion 
Minced cortex 
incubated with 
type 2 collagenase. 
Efficacy of an 
overnight and 
acute exposure 
compared.
Density 
centrifugation
PTCs separated 
from 
heterogeneous cell 
populations using 
Percoll® gradients 
of 1.04 g/mL and 
1.07 g/mL. 
Cell culture
Isolated PTCs 
culutred on 
Transwell® inserts 
and plastic cell 
cultureware at 
37˚C with 5% 
CO2/95% air in a 
humidified 
incubator.
Supplements Amount Final concentration 
Basal Medium   
RPMI-1640 Medium 500 mL - 
Supplements   
FCS 25 mL 5 % 
Penicillin/Streptomycin 2.5 mL 200 units/mL, 200 µg/mL respectively. 
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Ingredient Amount 
Basal Medium  
DMEM/Ham’s F-12 (1:1) 500 mL 
Supplements  
L-Glutamine 2.5 mL 
Human EGF 0.5 mL 
Insulin 0.5mL 
Hydrocortisone 0.5 mL 
GA 0.5 mL 
FCS 2.5 mL 
Adrenaline 0.5 mL 
T3 0.5 mL 
Transferrin 0.5 mL 
Penicillin/Streptomycin 2.5 mL 
 
Table 2.2:The composition of human REGM. 
The REGM SingleQuot Kit (CC-4127) was purchased from Lonza 
(Switzerland). The concentrations of the supplements and growth 
factors are withheld from consumers.  
 
2.2.2. Primary rat proximal tubular epithelial cell isolation 
Primary rat proximal and distal tubular epithelial cells (rat PTCs) were isolated 
from healthy 8 to 12 week old male Sprague-Dawley rats (weighing 250 - 300 g) 
purchased from Charles River (UK). The rats were euthanised by trained 
university staff in accordance with Schedule 1 of the Animals (Scientific 
Procedures) Act 1986. The kidneys were excised using sterile tweezers and 
scissors, and stored in ice-cold sterile isolation medium. The isolation procedure, 
which commenced within 30 min of the kidneys retrieval, was identical to the 
human isolation protocol described in subchapter 2.2.1. Isolated rat PTCs were 
cultured in rat REGM. The composition of rat REGM can be found in Table 2.3. 
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Ingredient Amount 
Basal Medium  
DMEM/Ham’s F-12 (1:1) 500 mL 
Supplements  
L-Glutamine 2.5 mL 
Mouse EGF 0.5 mL 
Insulin 0.5 mL 
Hydrocortisone 0.5 mL 
GA 0.5 mL 
FCS 2.5 mL 
Adrenaline 0.5 mL 
T3 0.5 mL 
Transferrin 0.5 mL 
Penicillin/Streptomycin 2.5 mL 
 
Table 2.3: The composition of rat REGM.  
The REGM SingleQuot Kit (CC-4127) was purchased from Lonza 
(Switzerland). The concentrations of the supplements and growth 
factors are withheld from consumers. 
 
2.2.3. RPTEC cell line cell culture 
The RPTEC cell line was also used in this project. It was developed by 
overexpressing the catalytic subunit of human telomerase (hTERT) in primary 
renal proximal tubular epithelial cells isolated from human kidney. The cells 
were cultured in ProxUp-2 ready-to-use medium, whose composition can be 
found in Table 2.4. Upon confluency, the cells were detached from the plastic 
flasks by incubating the cells with 5 mL trypsin/0.02 % EDTA for 5 min. After 
detachment of the cells, 5 mL of fresh culture medium was added to neutralised 
the trypsin before the cells were pelleted by centrifuging the suspension at 1500 
rpm for 5 min. The cell pellet was resuspended in fresh culture medium and cell 
yield determined using a haemocytometer. The cells were then seeded out onto 
cultureware as described below. The cells were cultured up to passage 20.  
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Ingredient Final concentration 
DMEM/Ham’s F-12 (1:1) _ 
HEPES Buffer 10 mM 
Glutamax 2 mM 
Human EGF 10 ng / mL 
T3 5 pmol 
Ascorbic Acid 3.5 g / mL 
Holo Transferrin 5 g / mL 
Prostaglandin E2 25 ng / mL 
Hydrocortisone 25 ng / mL 
Sodium Selenite 8.65 ng / mL 
Insulin 5 µg / mL 
G418 100 g / mL 
 
Table 2.4: The composition of ProxUp-2 Medium purchased from Evercyte. 
 
2.2.4. Cell Culture 
The human PTC, rat PTC and RPTEC cells were grown on a variety of cell 
culture flasks and plates. They included plastic 12-well plates at a density of 
200 000 cells per well with 1 mL of culture medium, plastic 96-well plates at a 
density of 20 000 cells per well with 200 L of culture medium, and 24-well 
Transwell® inserts at a density of 75 000 cells per insert with 200 L of culture 
medium in the apical chamber and a further 1000 L in the basolateral well. All 
cells were also seeded on plastic T75 culture flasks at a density of 3 million 
cells with 25 mL of culture medium. The type of cultureware used for each 
experiment is defined in the relevant methods subchapter. Once seeded, cells 
were incubated at 37 ˚C with 5 % carbon dioxide and 95 % air in a humidified 
incubator. 
The cells were grown until confluent to allow tight junction formation and cell 
polarisation. Cell confluency within 12-well, 96-well plates and T75 flasks was 
monitored regularly using a phase contrast microscope. Due to the opacity of 
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the Transwell® polycarbonate filter the confluency of cells on 24-well 
Transwell® inserts could not be observed using the microscope. Alternatively, 
the trans-epithelial electrical resistance (TEER) was measured at regular 
intervals to determine tight junction integrity using an epithelial voltohmmeter 
(EVOM, World Precision Instruments, UK). The silver metal and silver chloride 
chopstick electrodes were stored in 70 % ethanol to maintain sterility. The 
following calculation was used to determine TEER values (Ω.cm2). 
TEER = (RM – RF) x A 
RM = Cell TEER measurement (Ω) 
RF = Resistance of the filter (80 Ω) 
A = Area of the filter membrane (24-well filter surface area is 0.33 cm2) 
Experiments were performed when monolayers had a TEER value of 80 Ω.cm2 
or greater. 
2.2.5. Cell Growth Assays 
In order to optimise the enzymatic digestion phase of the isolation procedure, 
samples of renal cortex were incubated with different concentrations of 
collagenase for an overnight and acute incubation period and the resulting yield 
of cells and their growth over 8 days was compared. The collagenase 
concentrations used to enzymatically digest human and rat renal cortex were 10, 
20, 25, or 30 mg collagenase / gram of renal cortex (activity of around 300 units 
/ mg). The yields of isolated proximal tubular cells per gram of renal cortex for 
each concentration of collagenase were estimated 3 times using a 
haemocytometer (Hawksley, UK) and the average yield was recorded (n = 3). 
Following isolation the cells were seeded onto six plastic 12-well plates. In total 
8 wells were seeded from cells isolated from each of the above mentioned 
conditions. The growth of these cells was then determined by quantifying the 
number of cells in the well at 24 hrs (Day 1), 48 hrs (Day 2), 72 hrs (Day 3), 96 
hrs (Day 4), 120 hrs (Day 5), 144 hrs (Day 6) 168 hrs (Day 7) and 192 hrs (Day 
8) after seeding. At the designated time point, the wells were washed with PBS 
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solution twice, trypsinised with 500 L of trypsin / 0.02 % EDTA for 5 min at 37 
C, neutralised with 500 L of human or rat REGM, and the number of cells in 
each well quantified using a haemocytometer. The number of cells in each well 
were counted 3 times and the average recorded (n = 3). The cell yield and 
growth measurements were performed in triplicate using samples derived from 
3 individual kidneys (N = 3). 
2.2.6. Total cell RNA isolation and quality assessment 
In order to understand how cell culture conditions may affect cellular expression 
of transport proteins, total cell RNA was isolated from: 
 Freshly isolated human PTCs and rat PTCs, 
 Human PTCs, rat PTCs and RPTEC cells cultured on 24-well Transwell® 
inserts, and 
 Human PTCs, rat PTCs and RPTEC cells cultured in plastic T25 flasks. 
This was achieved using the SV Total RNA Isolation System according to the 
manufacturer’s protocol. The yield and purity of the isolated RNA samples were 
determined using a NanoDrop ND-1000 UV-Vis Spectrophotometer 
(ThermoFisher Scientific, USA). The yield was calculated from the absorbance 
at 280 nm on the basis that an optical density reading of 1 is equivalent to 40 μg 
/ mL single stranded RNA. The purity of each sample was estimated from the 
relative absorbance at 260 nm and 280 nm (A260 / 280) to assess protein 
contamination, then at 260 nm and 230 nm (A260 / 230) to determine guanidine 
contamination. Values of 1.8 to 2.2 for both ratios indicated the samples were of 
sufficient purity for downstream applications. Isolation was performed in 
triplicate using samples derived from 3 individual kidneys or 3 different passage 
numbers (N = 3). 
2.2.7. Reverse transcription of total cell RNA and endpoint PCR 
Total cell RNA was reverse transcribed into cDNA using MMLV-RT. Initally, 1 
µg of total cell RNA was mixed with 1 µL of 0.5 mg / mL random hexamers for 5 
min at 65 ˚C then immediately cooled on ice. Once cooled 0.5 µL MMLT-RT 
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(activity: 200 units / µL), 4 µL of 5x MMLT-RT buffer, 5 µL of 2 mM dNTPs and 
0.25 µL of RNasin (a ribonuclease A inhibitor, activity: 40 units / µL) was added 
to create a final reaction volume of 20 µL. The reaction was performed in a Px2 
Thermo Cycler (ThermoScientific, UK), where the reaction mixture was 
incubated at 42 ˚C for 2 hrs, then 70 ˚C for 10 min. Once the reaction was 
completed, the resulting cDNA was diluted using molecular grade water (1 
cDNA: 3 water). 
Primers for transport protein genes of interest were designed using Primer-
BLAST from the National Center for Biotechnology Information website (NCBI, 
http://www.ncbi.nlm.nih.gov/tools/primer-blast/), unless otherwise stated. When 
designing the forward and reverse primer pairs, the following criteria were set:  
 A product size of around 100 base pairs should be amplified by the 
primer pair,  
 Each individual primer should be 18-22 base pairs in length,  
 The total guanine and cytosine (GC) content of each primer should be 
40-60 %, 
 The melting temperature of each primer should be between 58 and 64 ˚C, 
 Within each pair the difference in the melting temperature between the 
forward and reverse primer should be no more than than 2 ˚C, and  
 One of the primers in the pair must cross an exon-exon boundary.  
The retrieved primers by Primer-BLAST were analysed for hetero-dimer, homo-
dimer, as well as hairpin formation, using the NetPrimer software 
(http://www.premierbiosoft.com/netprimer/). The specificity of a primer pair to 
the intended gene was analysed by running the basic local alignment search 
tool on their sequences. High performance liquid chromatography purified 
primers with customised sequences were then ordered from IDT DNA (Belgium). 
The genes of interest and their relative primer pair sequences are listed in Table 
2.5 and Table 2.6.  
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In order to confirm the specificity of the primers, endpoint PCR followed by gel 
electrophoresis was carried out for each gene of interest. The endpoint PCR 
reaction mixture included 0.25 µL GoTaq DNA polymerase (activity: 5 units / µL), 
2 µL of 2 mM dNTPs, 0.5 µM of each primer for the gene of interest (forward 
and reverse), 4 µL of 5x Green GoTaq buffer, 1.5 µL of cDNA template and 
enough molecular grade water to make the total reaction volume to 20 µL. 
Using a Px2 Thermo Cycler, the reaction mixture was incubated at 95 ˚C for 2 
min to activate GoTaq DNA polymerase (initialising step), then amplified for 35 
cycles by incubating the reaction mixture at 95 ˚C for 30 seconds (denaturation 
step), Ta ˚C for 30 seconds (primer annealing step) and 72 ˚C degree for 30 
seconds (elongation step). This was followed by 72 ˚C for 10 min (final 
elongation step). Ta denotes the annealing temperature of the primer pair. The 
Ta was calculated by subtracting 5 ˚C from the melting temperature of the least 
stable primer. In order to check if the PCR had generated the anticipated DNA 
fragment, the PCR products were separated by agarose gel electrophoresis and 
visualised with ethidium-bromide staining (0.01 % volume for volume). PCR 
products were separated on 1.5 % agarose gels. The sizes of PCR products 
were determined by comparing them with DNA ladders containing fragments of 
known size that were run on the gels alongside the PCR products. 
  
 48 
 
 
Table 2.5: Sequence of human primers used in endpoint and qPCR for the 
amplification of drug transporters.  
The number in brackets underneath the gene name is the NCBI 
reference number, from which the mRNA sequence of the gene was 
Gene 
(NCBI Reference) Primer Sequence 
Ta 
(C) 
Product 
Size (base 
pairs) 
MATE1 
(NM_018242.2) 
F 1353ATC GGG ATC GCG CTG ATG TT1372 
58 149 
R 1501TGT ACC TGA GCC TGC TGA CA1482 
MATE2-K 
(NM_152908.3) 
F 614 TCC AGG TTG ACC CAG GAC TA633 
58 106 
R 719CCT TCA GCC ATC CCT GAT TTT699 
MDR1a/b 
(NM_000927.4) 
F 1683TTC ACT TCA GTT ACC CAT CTC1703 
56 76 
R 1758GTC TGC CCA CTC TGC ACC TTC1738 
MRP1 
(NM_004996.3) 
F 2161TGG CAT CAC CTT CTC CAT CC2180 
58 81 
R 2241GAG AGC AGG GAC GAC TTT CCG2221 
MRP2 
(NM_000392.4) 
F 4735CAC CAT CAT GGA CAG TGA CAA GG4757 
60 60 
R 4794CCG CAC TCT ATA ATC TTC CCG4774 
MRP3 
(NM_003786.3 ) 
F 3140TCT GCA AGG GTT CTT GGT GAT G3161 
60 120 
R 3259AAG AAG GAC TGT GGC GAG CG3240 
MRP4 
(NM_001105515.2) 
F 195CGT GTT CTT CTG GTG GCT CAA T216 
60 70 
R 264CAT ATC ATC TTC CTC TAA TCT CCG241 
BCRP 
(NM_001257386.1) 
F 593CAG GTG GAG GCA AAT CTT CG612 
58 54 
R 646TTG GAT CTT TCC TTG CAG CTA626 
URAT1 
(NM_001276326.1) 
F 241AAA CTT AGG CCT CCC CAA GA260 
58 158 
R 398TGA CCG GTG ACA CTT ATG GA379 
OAT1 
(NM_004790.4) 
F 1586ACCAGTCCATTGTCCGAACC1605 
56 116 
R 1701TGTCTGCCGGATCATTGTGG1682 
OAT3 
(NM_001184732.1) 
F 15AGAGCTGAGCTGCCCTACTA34 
58 117 
R 131AGAAGGTCATGGCACTGGTGG111 
OAT4 
(NM_018484.2) 
F 879AGG AAG CCG ATG CTG AGC TG898 
59 162 
R 1040GGT CCA CTC CAC CAT CAG TG1021 
OATP4C1 Purchased from Qiagen 60 
OCT2 
(NM_003058.3) 
F 1446ACC TGG TGA TCT ACA ATG GCT1466 
58 145 
R 1590TGA GGA ACA GAT GTG GAC GC1571 
NPT1 
(NM_005074.3) 
F 737TTG TGG CTG TGC CGT ATG TC756 
57 126 
R 862CTT GAA CTG ACC TGC TGG AC843 
NPT4 
(NM_001098486.1) 
F 530GCG AGT GGT TGG CAT TTC T548 
51 127 
R 656TAT TGA GGA CTG GCT TAG G638 
NPT5 
(NM_001286121.1) 
F 1382TCA GAT CCA GCC ACA GCA TG1402 
57 118 
R 1499AAG CCA GTG TAC CGA GGA GC1479 
NaPi-2A 
(NM_003052.4) 
F 351GAG CAG AAG CCA GAG TCC AG370 
50 170 
R 520TCC TTG AAG ATG TCA CCA GC501 
NaPi-2C 
(NM_001177316.1) 
F 811TCT TCA ACT GGC TCA CAG TGC831 
57 174 
R 984AGT CAG CAG CTT AGC AGC CA965 
PiT2 
(NM_006749.4) 
F 2173GAC GTG AGT AAT GCC ATC GG2182 
57 80 
R 2252GTA GCT GCT TCT TGC GTT ACC2231 
GAPDH Purchased from Primer Design 60 
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obtained. F and R denoted forward and reverse primer sequence, 
respectively. The superscript numbers are the position of the bases in 
the mRNA sequence. Ta denotes the annealing temperature of the 
primer pair. 
 
Table 2.6: Sequence of rodent primers used in endpoint and qPCR for the 
amplification of drug transporters.  
The number in brackets underneath the gene name is the NCBI 
reference number, from which the mRNA sequence of the gene was 
obtained. F and R denoted forward and reverse primer sequence, 
respectively. The superscript numbers are the position of the bases in 
the mRNA sequence. Ta denotes the annealing temperature of the 
primer pair.  
 
Gene 
(NCBI Reference) Primer Sequence 
Ta 
(C) 
Product Size 
(base pairs) 
Mate1 
(NM_001014118) 
F 442CCA GAT GTA TCC AGG CTC ACC462 
59 123 
R 564AAC CTG AGG CAG AAC GAT GC545 
Mdr1a 
(NM_133401.1) 
F 5CAG AGC CGC TGC TTC TTC C23 
57 195 
R 199CAT TGT GAG CAC ACT GAC CGC179 
Mdr1b 
(NM_012623.2) 
F 129GTT GGC ATA TTC GGG ATG TTT CGC152 
57 184 
R 312CAC TTT GA TAG TAA CGC TCG GC290 
Mdr1a/b 
(M81855.1) 
F 1609GTC AAG GAA GCC AAT GCC1626 
59 147 
R 1755AAG GAT CTT GGG GTT GCG GAC1735 
Mrp1 
(NM_022281.2) 
F 1870AGC GTG TCC CTC AAG CGT CTC1890 
60 170 
R 2039AAG GTG ATG CCA TTC AGT GTG2019 
Mrp2 
(NM_012833.2) 
F 1063GTT CTC GTC CTG GAA GAA GC1082 
57 170 
R 1232TTC AGC AGC TGA GGA TTC AG1213 
Mrp3 
(NM_080581.1) 
F 2439TGT GCT GGC AGG CAA GAC TC2458 
59 158 
R 2596TTC GGA GGA AGT TGG CAA AGG2576 
Mrp4 
(NM_133411.1) 
F 2800CAT TCA GAG GCT TGG TTC TTG2820 
57 185 
R 2984CAC TGG AAC ATC CCC ATG AG2965 
Bcrp 
(NM_181381.2) 
F 836TTG ACA GCC TCA CCT TAC TGG856 
59 95 
R 930ACA GTG GTA ACC TGC TGA TGC910 
Urat1 
(NM_001034943.
1) 
F 906ACA GCC AGC CTC TTG ATG G924 
55 109 
R 1051ACA GCC AAC TGC AGC ATC C1033 
Oat1 
(NM_017224.2) 
F 1075ATG CTG TGG TTT GCC ACT AGC1095 
59 119 
R 1193AAC TTG GCA GGC AGG TCC AC1174 
Oat3 
(NM_031332.1) 
F 82TCCAGCTCCAACCACCAGT100 
54 65 
R 146TCCAGAATCTCGGAGAAGG128 
Oct2 
(NM_031584.2) 
F 1358ATC CCT GAT GAT CTA CAG TGG1378 
57 127 
R 1484CAA GAT TCC TGA TGT ATG TGG1464 
Oatp4c1 
(NM_001002024) 
F 330AGC CCT AAC GCA AGG TAT TGT350 
57 101 
R 430ATA TCA GGC CGG TCA GGG AA411 
Gapdh Purchased from Primer Design 60 
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2.2.8. Quantitative real-time polymerase chain reaction 
Following on from the validation of the specificity of the in-house designed 
primers, quantitative real-time polymercase chainr eaction (qPCR) was 
performed on the cDNA of:  
 Freshly isolated human PTCs and rat PTCs, 
 Human PTCs, rat PTCs and RPTEC cells cultured on 24-well Transwell® 
inserts,  
 Human PTCs, rat PTCs and RPTEC cells cultured in plastic T25 flasks. 
A typical qPCR reaction mixture consisted of 2.5 L cDNA, 5 L 2x SYBR®-
green Master Mix, 0.5 µL of 10 µM mix of forward and reverse primers (1:1) and 
2 µL water, contained in wells of a white 96-well format qPCR plate. In a Roche 
LightCycler 480 (Roche, UK), the reaction mixture was heated to 95 ˚C for 10 
min to denature the initial template and activate the enzyme. The amplification 
of the target gene was carried out for 40 cycles by heating the sample to 95 ˚C 
for 10 seconds (denaturation step), Ta ˚C for 20 seconds (primer annealing step) 
and 72 ˚C for 10 seconds (elongation step). A melt curve was also performed 
(cooling to 65 ˚C followed by heating to 97 ˚C) before a final cooling step to 4 ˚C 
complete the reaction. The cycle number during gene amplication and its 
corresponding fluorescence from each sample were logged by the software 
LightCycler 480 (version 1.5, Roche, UK). The software calculated the 
fluorescence baseline during the first 15 cycles of the amplication stage to 
create a common starting fluorescence intensity for all the samples. A threshold 
level of fluorescence intensity was also defined by an algorithm showing it was 
significantly above the background fluorescence but still within the linear phase 
of amplification. The cycle at which a sample produces fluorescence intensity 
that crosses the threshold is termed the threshold cycle (Ct), and is correlated 
to the starting amount of the cDNA template; the greater the amount of starting 
cDNA, the earlier the Ct. As such, for the purpose of analysis, samples that 
produced Ct of 35 and above were disregarded. PCR analysis of gene 
expression was repeated 3 time using cDNA derived from 3 separate kidney 
preaparations. 
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Serially diluted endpoint PCR product of the gene of interest was also used as 
the DNA template and loaded on the same plate as the samples to produce a 
standard curve for quantification. Efficiency of the PCR was determined from 
this standard curve. Data generated from the qPCR were normalised to their 
respective species reference gene, which were human GAPDH and rat Gapdh.  
2.2.9. Drug transporter RT2 profiler array plates 
Human and rat drug transporter RT2 profiler array plates were used to 
charaterise drug transporter gene expression. Each PCR array plate contains 
84 transporter genes and 5 house keeping genes. cDNA from freshly isolated 
human and rat PTCs and human and rat PTCs cultured for 7 days on plastic 
was combined with SYBR green quantitative PCR Master Mix according to the 
manufacturer’s protocol. The mixture was then aliquopted onto the array plates, 
25 µL per well. Real-time PCR detection was then performed using the Roche 
Lightcycler 480 two-step cycling programme of; 1 cycle of 10 min at 95 °C to 
activate the HotStart DNA polymerase, then 45 cycles of 15 seconds at 95 °C 
(denaturation step) and 1 min at 60 °C (annealing and elongation step) at a 
ramp rate of 1 °C per second. The data was analysed with Lightcycler 480 
software. Second derivative maximum analysis was used to indentify the 
crossing point (Cp value). The manufacturer’s web-based software application 
was used to calculate Ct values from this information. 2-∆Ct values were then 
calculated using the following equation. The human data were normalised to 
GAPDH expression and the rat data to ß-actin expression. 
2ିሼ஼௧	ீ௘௡௘	௢௙	௜௡௧௘௥௘௦௧ି஼௧	௥௘௙௘௥௘௡௖௘	௚௘௡௘ሽ 
2.2.10. Cellular H33342 accumulation assays 
H33342 is a cyan/blue fluorescent dye that binds to the minor groove of double 
stranded DNA without intercalation - preferably at adenine thymine-rich regions. 
H33342 is both cell membrane permeable and a substrate of MDR1 and BCRP. 
The functional activities of MDR1 and BCRP within human PTCs and rat PTCs 
can therefore be determined by measuring the level of intracellular retention of 
H33342 in the presence and absence of transporter specific inhibitors. 
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Cells were seeded into plastic 96-well plates at a density of 20 000 cells per 
well in 200 L of medium. The cells were cultured for 6 to 8 days, with medium 
being replaced every 2 days, until they had formed a confluent monolayer. Cell 
confluency was assessed visually using a phase contrast microscope. The 
medium was aspirated from the wells and the cells washed twice with 200 L of 
37 C modified Krebs buffer. The composition of the modified Krebs buffer is 
shown in Table 2.7. The cells were then incubated with a transporter specific 
inhibitor dissolved in 200 L modified Krebs buffer for 40 min at 37 C. 
GF120918 was used to inhibit the efflux of H33342 by MDR1. Ko143 hydrate 
(Ko143) was used to inhibit the efflux of H33342 by BCRP. Inhibitor-only buffer 
was then removed and replaced with 200 µL of modified Krebs buffer containing 
the inhibitor and H33342. The cells were incubated for a further 30 min at 37 C. 
Following this, the cells were washed twice with 200 L of ice-cold modified 
Krebs buffer. Cellular fluorescence levels were then determined using a 
FLUOstar Omega Microplate Reader (BMG Labtech, Germany). DNA 
complexed H33342 fluorescence was measured at 355 nm excitation and 465 
nm emission, as per the manufacturer’s recommendation. The number of 
technical replicates for each experimental condition was 6 (n = 6). Each 
experiment was performed 3 separate times in cells derived from 3 separate 
kidney preparations or passage numbers (N = 3). The concentrations of 
H33342, GF120918 and Ko143 used are detailed in the results chapter. 
Bradford assay was performed at the end of the fluorescence readings to 
ascertain relative amount of protein in each well. Modified Krebs buffer was 
replaced with 100 µL of coomassie blue reagent and incubated at room 
temperature for 5 min. Thereafter, absorbance readings were taken at 595 nm 
using the microplate reader. A protein standard curve was also created using 
known amounts of BSA in the same 96-well plate as the unknown samples. The 
relative amount of protein in each well was thus determined by referring to the 
protein standard curve.  
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Ingredient Concentration (mM) 
Sodium Chloride (NaCl) 140 
Potassium Chloride (KCl) 5.4 
Magnesium Sulphate (MgSO4) 1.2 
Monosodium dihydrogen orthophosphate 
(NaH2PO4) 0.3 
Monopotassium phosphate (KH2PO4) 0.3 
D-Glucose (C6H12O6) 5 
HEPES (C8H18N2O4S) 10 
Calcium Chloride (CaCl2) 2 
TRIS Base (NH2C(CH2OH)3 Ad hoc to pH 7.4 
 
Table 2.7: Composition of modified Krebs buffer. 
 
2.2.11. Cellular glutathione methylfluorescein accumulation 
assays 
CMFDA is a cell membrane permeable molecule that is transformed into an 
impermeant fluorescent product glutathione methylfluorescein (GSMF), within 
living cells (as shown in Figure 2.2). Cell-impermeant GSMF can be effluxed 
from cells through MRP (ABCC) transport proteins. Therefore, using the same 
protocol as stated in 2.7.1., the functional activity of the MRP family within 
human PTCs and rat PTCs cells was determined by measuring the level of 
intracellular retention of GSMF. MK-571 was used to inhibit the efflux of GSMF 
by the MRP family. Cellular GSMF fluorescence was measured at 492 nm 
excitation and 517 nm emission using a FLUOstar Omega Microplate Reader, 
as suggested in the manufacturers’ product information sheet. 
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Figure 2.2: Intracellular reactions of CMFDA.  
Within cells CMFDA is esterified by intracellular esterase enzymes, 
the chloromethyl group of this product then reacts with thiols in a 
glutathione mediated reaction to create a green fluorescent dye-
thioether adduct, glutathione methylfluorescein (GSMF). The amount 
of GSMF dye can be quantified by measuring the fluorescence at 492 
nm excitation and 517 nm emission. Figure created using ChemDraw. 
 
2.2.12. Cellular radiolabelled-substrate accumulation assays 
in freshly isolated PTCs 
In order to identify the proximal tubule cell transporters that mediate the uptake 
of radiolabelled substrates cells and their relative contributions, freshly isolated 
PTCs were incubated with the substrate of interest in the presence and 
absence of a combination of transporter inhibitors. 
Freshly isolated human PTCs and rat PTCs were suspended at 4 million cells 
per mL in modified Krebs buffer. 400 000 PTCs (100 L of the PTC mixture) 
were incubated with 100 L of modified Krebs buffer in the presence and 
absence of a transporter inhibitor for 30 min. Uptake was initiated by adding the 
radiolabelled substrate (1 Ci / mL); the cells were incubated at 37 C for 30 
min with the radiolabelled substrate and inhibitor in modified Krebs buffer. The 
entire reaction mixtures were then overlaid onto previously prepared 
microcentrifuge tubes containing 100 L of 2N sodium hydroxide (bottom layer) 
and 100 L of filtration oil (middle layer, 74.5:25.5 silicon oil : mineral oil mix). 
Samples were centrifuged immediately at 13 000 rpm for 1 min to transfer the 
cells containing radiolabelled substrate through the filtration oil layer, into the 
sodium hydroxide layer, which lysed the cells. The samples were then frozen for 
at least 1 hr at -80 C. Using a sterile razor blade the microcentrifuge tubes 
were cut through in the middle layer and 50 L of the bottom aqueous layer was 
Esterases Glutathione‐SH 
CMFDA GSMF 
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collected and placed in a scintillation vial. 2 mL of Optiphase Hisafe 2 
scintillation solvent was added to each vial and mixed by vortexing. The 
radioactivity of each vial in disintegrations per min (DPM, nuclear decays per 
min) was determined by liquid scintillation counting using a Beckman LS5000 
liquid scintillation counter, (Beckman-Coulter Ltd, UK). The scintillation counter 
was normalised using a vial containing only 2 mL of scintillation fluid prior to 
each experiment. 
The number of technical replicates for each experimental condition was 3 (n = 
3). Each experiment was performed 3 separate times in cells derived from 3 
separate kidney preparations (N = 3). A negative control where cells were 
exposed to no inhibitor and no radiolabelled substrate was included to measure 
machine background DPM. In addition to a positive control where cells were 
exposed only to the radiolabelled substrate. The following formula was used to 
determine the relative contributions of transporters (%). 
ܫ݄ܾ݊݅ݐ݅݋݊	݋݂	ݎܽ݀݅݋݈ܾ݈݈ܽ݁݁݀	ݏݑܾݏݐݎܽݐ݁	ݑ݌ݐܽ݇݁	ሺ%ሻ ൌ ቀܦܲܯௌ௉௅	 ܦܲܯା஼்௅ൗ ቁ	ൈ 	100 
DPMSPL = The DPM reading from the sample (DPM) 
DPM+CTL = The average DPM reading from the positive control (DPM).  
 
2.2.13. Cellular radiolabelled-substrate accumulation assays 
in PTCs cultured on 24-well Transwell® inserts 
In addition to freshly isolated human PTCs and rat PTCs. Human PTCs and rat 
PTCs grown on 24-well Transwell® inserts were also used in the investigations 
of transporter functionality. Experiments were performed when monolayers had 
a TEER value 80 Ω.cm2 or greater. Culture medium was first aspirated from the 
inserts and wells. The cell monolayers were washed 3 times in 37 C modified 
Krebs buffer and placed in sterile 24-well plates. Monolayers were matched 
according to their TEER values. 500 L of modified Krebs buffer was added to 
the basolateral well and 100 L to the apical chamber, and the monolayers left 
to equilibrate for at least an hr. Thereafter, the buffer in either one or both 
compartments of the monolayer was replaced with Krebs buffer containing the 
appropriate inhibitor and incubated for a further hr.  
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Uptake of radiolabelled substrates was initiated by introducing the radiolabelled 
substrate (1 Ci / mL) and [14C]-mannitol-D (0.1 Ci / mL) at an equal 
concentration, to the appropriate compartment of the monolayer for a defined 
period of time. These solutions are referred to as the standard solutions. To 
measure uptake across the basolateral membrane the substrate of interest was 
added to the basolateral well, and vice versa. The activity of the radiolabelled 
substrates used were 1 Ci / mL. Following the incubation with the radiolabelled 
substrate of interest the monolayer was then washed in ice-cold modified Krebs 
buffer 3 times to halt all reactions and to remove extracellular isotope. 
In order to measure the cellular uptake of radiolabelled substrate and the level 
of extracellular label left behind after washing, (i.e. the amount of [14C]-mannitol-
D bound to the filter), the filters and hence the adhered cell monolayers, were 
excised from the inserts and transferred to scintillation vials. 2 mL of Optiphase 
Hisafe 2 scintillation solvent was added to each vial and mixed by vortexing. 
The substrate and [14C]-mannitol-D radioactivity of each sample was 
determined by liquid scintillation counting using a Beckman LS5000 liquid 
scintillation counter. 100 L of the standard solutions were also transferred to 
scintillation vials, whose counts were used in converting the radioactivity, 
measured in DPM, to amount of substrate. The number of technical replicates 
for each experimental condition was 3 minimum (n ൒ 3). Each experiment was 
performed 3 separate times in cells derived from 3 separate kidney preparations 
(N = 3). A negative control where cells were exposed to no inhibitor and no 
radiolabelled substrate was included to measure the machine background DPM. 
The following calculation was used to determine cellular uptake of radiolabelled 
substrate (pmol / cm2 / min or hr) and the amount of extracellular label ([14C]-
mannitol-D) bound to the filter.  
ܥ݈݈݁ݑ݈ܽݎ	ܷ݌ݐܽ݇݁ ൌ
ቂቀ ࢡௌ்஽ܦܲܯௌ்஽ቁ ൈ	ܦܲܯௌ௉௅ቃ ݔ	ܣ
ܶ  
ASTD = The amount of the radiolabelled substrate in 100 L of the standard 
solution (pmol) 
DPMSTD = The average DPM reading from 100 L of the standard solution 
(DPM) 
DPMSPL = The DPM reading from the sample (DPM) 
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A = Area of the filter membrane (24-well filter surface area is 0.33 cm2) 
T = Exposure time to the radiolabelled substrate (min or hr) 
2.2.14. Unidirectional transepithelial flux of radiolabelled 
substrates 
In order to determine the net movement of a radiolabelled substrate across the 
proximal tubule epithelia, unidirectional flux of the substrate in the secretory 
(basolateral to apical, JB-A) and absorptive (apical to basolateral, JA-B) direction 
across PTC monolayers was compared as dpecited in Figure 2.3. Human PTCs 
and rat PTCs cultured on 24-well Transwells® were used in these experiments. 
Experiments were performed when monolayers had a TEER value 80 Ω.cm2 or 
greater. The monolayers were washed as before (subchapter 2.2.13) and 
paired according to TEER values. After the initial incubation, the buffer in either 
one or both compartments of the monolayer was replaced with Krebs buffer 
containing the appropriate transporter inhibitor and incubated for a further hr.  
Flux was initiated by introducing the radiolabelled substrate (1 Ci / mL) and 
[14C]-mannitol-D (0.1 Ci / mL) at an equal concentration, to the appropriate 
monolayer compartments. These solutions are referred to as the standard 
solutions. Sampling of the opposite compartment was done at defined times to 
measure the appearance of the radiolabelled substrate by aspirating 50 µL from 
the apical or 250 µL from the basolateral compartment, and replacing it with 
equal amount of appropriate buffer. The samples and 100 L of the standard 
solutions were then placed in scintillation vials and the radioactivity was 
measured as described in subchapter 2.2.13. In order to decipher between the 
transcellular and paracellular movement of the radiolabelled substrate the 
movement of [14C]-mannitol-D was also measured as a marker of paracellular 
flux. 
The number of technical replicates for each experimental condition was 3 
minimum (n ൒ 3). Each experiment was performed 3 separate times in cells 
derived from 3 separate kidney preparations (N = 3). A negative control where 
cells were exposed to no inhibitor and no radiolabelled substrate was included 
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to measure machine background DPM. The following equation was used to 
calculate the flux of the radiolabelled substrate and [14C]-mannitol-D: 
ܨ݈ݑݔ ൌ
ቂቀ ࢡௌ்஽ܦܲܯௌ்஽ቁ ൈ	ሺܦܲܯௌ௉௅ ൈ	ܦௌ௉௅ሻቃ ݔ	ܣ
ܶ 	 
ASTD = The amount of the radiolabelled substrate in 100 L of the standard 
solution (pmol) 
DPMSTD = The average DPM reading from 100 L of the standard solution 
(DPM) 
DPMSPL = The DPM reading from the flux sample (DPM) 
DSPL = The dilution factor of the flux sample 
A = Area of the filter membrane (24-well filter surface area is 0.33 cm2) 
T = Exposure time to the radiolabelled substrate (min or hr) 
 
 
 
 
Figure 2.3: A simplified diagram of how to study unidirectional 
transepithelial flux.  
In order to determine the net movement of a radiolabelled substrate 
across the proximal tubule epithelia the secretory (JB-A) and 
absorptive (JA-B) flux of radiolabelled substrate was measured in 
paired resistance matched monolayers. Monolayers were paired 
according to TEER values. 
 
2.2.15. CellTiter 96® AQueous one solution cell proliferation 
assay 
The CellTiter Aqueous one solution cell proliferation assay is a colorimetric 
method for assessing cell metabolic activity. The reagent contains [3-(4,5-
dimethyl-2-yl) – 5 – (3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium 
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salt (MTS) and an electron coupling reagent (phenazine ethosulfate (PES). In 
metabolically active cells the MTS is reduced by NAD(P)H-dependent cellular 
oxidoreductase enzymes into an insoluble coloured formazan product, as 
shown in Figure 2.4. The formazan dye produced can be quantified by 
measuring the absorbance at 490 nm. The ability of various chemicals to affect 
the metabolic activity of proximal tubule epithelial cells was assessed using this 
reagent. 
Cells seeded onto 96-well plates were used for this assay. When confluent, the 
cells were incubated with a range of concentrations of the compound of interest 
for 48 hrs. Following treatment, the medium was aspirated and the cells washed 
twice with 200 L modified Krebs buffer. The cells were then incubated in 100 
L of modified Krebs buffer with 20 L of CellTiter AQueous one solution regent 
added and for 120 min and maintained at 37 C. The amount of formazan 
product was then quantified by measuring the absorbance at 490 nm using a 
FLUOstar Omega Microplate Reader. In each experiment a positive control 
(cells incubated with only growth medium and modified Krebs buffer, 100 % 
metabolic functionality), and negative control (cells incubated with 10 % Triton-X, 
0 % metabolic activity) was included. The relative viabilities of the treated cells 
were thus calculated with reference to the positive and negative controls. The 
number of technical replicates for each experimental condition was 6 (n = 6). 
Each experiment was performed 3 separate times in cells derived from 3 
separate kidney preparations or passage numbers (N = 3). 
Bradford assay was performed after the absorbance readings to ascertain 
relative amount of protein in each well. Modified Krebs buffer containing 
CellTiter AQueous one solution was replaced with 100 µL of coomassie blue 
reagent and incubated at room temperature for 5 min. Thereafter, absorbance 
readings were taken at 595 nm using the microplate reader. A protein standard 
curve was also created using known amounts of BSA in the same 96-well plate 
as the unknown samples. The relative amount of protein in each well was thus 
determined by referring to the protein standard curve.  
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Figure 2.4: Intracellular reactions of MTS.  
In metabolically active cells, the MTS is reduced by NAD(P)H-
dependent cellular oxidoreductase enzymes into an insoluble coloured 
formazan product. The formazan dye produced can be quantified by 
measuring the absorbance at 490 nm with a plate reader. Figure 
created using ChemDraw. 
 
2.3. Statistics 
Data are expressed as mean ± standard error of mean (SEM) of the specified 
number of replicates, where “n” denotes technical replicates, and “N” denotes 
biological replicates. To test hypotheses normal distribution of the data and 
equal variance was assumed. Statistical comparison of mean values was made 
using a Student’s t test. A one-way analysis of variance test (one-way ANOVA, 
otherwise known as the Kruskal-Wallis test) was used for multiple comparisons 
of 3 or more experimental conditions and significance was assigned using a 
Dunnett post-test. Differences in mean values were considered to be significant 
when p ൑ 0.05. Non-linear regression analysis of the data and other statistical 
analyses were carried out using GraphPad Prism 4.0 software (GraphPad 
software Inc. USA). 
   
MTS  Formazan 
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3. Isolation and characterisation of PTCs 
3.1. Background 
Understanding renal drug handling in man has been hampered by the lack of a 
good model of the human proximal tubule. The current in-vitro screening tools 
rely on immortalised renal epithelial cell lines that are poorly predictive of in-vivo 
drug handling. Immortalised animal and human renal epithelial cell lines 
commonly used in pre-clinical screening include, LLC-PK1 (porcine), MDCK 
(canine), OK (opossum), HK-2 (human), HEK293 (human), and ciPTEC (human) 
cells. Several characterisation studies have reported these cells lack expression 
of key drug transporter and metabolic enzymes, fail to maintain brush-border 
microvilli, or are unable to form confluent monolayers with good tight junction 
integrity. The cells can be stably transfected to express missing transporters. 
However, transporter expression in these cell lines does not reflect the 
transporters’ physiological expression levels as they are driven by the vector 
promoters and the cells’ translation transcription machinery. Primary cells 
derived from intact tissue are a better model as they retain the characteristic 
biochemical and physiological properties. (See subchapters 1.4.3 and 1.4.6 for 
further details.) 
Research has identified that time ex-vivo, isolation protocol and growth medium 
are key in maintaining primary cell differentiation (Taub et al., 1989; Courjault-
Gautier et al., 1995). It is recommended that renal primary cell isolation begins 
less than 18 hrs ex-vivo. The human renal cortex contains at least 18 different 
resident cell types, 10 of which line the tubular basement membrane (Helbert et 
al., 1999). Many renal primary cell culture techniques have been developed. 
Published techniques include a mixture of the following: density centrifugation, 
flow cytometry, free flow electrophoresis, enzymatic digestion, and differential 
sieving (Van der Biest et al., 1994; Helbert et al., 1997; Helbert et al., 1999; 
Helbert et al., 2001; Verhulst et al., 2003; Verhulst et al., 2004; Verhulst et al., 
2008). The most widely used protocol for isolating pure proximal tubular cell 
cultures involves enzymatic dispersion of tubular cells, followed by differential 
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sieving, (Percoll) gradient centrifugation, cell labelling with a fluorescent 
surface marker antibody, and then fluorescence activated cell sorting (FACS) 
(Van der Biest et al., 1994; Helbert et al., 1997; Helbert et al., 1999; Helbert et 
al., 2001; Brown et al., 2008). Following isolation, cells are further selected 
using cultured growth medium that promotes the growth of cells of interest over 
other cell types. 
Proximal tubular cells can be distinguished from distal tubule, interstitium 
glomeruli and collecting duct cells through incubation with anti-human leucine 
aminopeptidase (LAP) monoclonal antibody (Helbert et al., 1997). When 
compared with other fluorescent surface markers, LAP labeling of cell samples 
gave the clearest distinction between positive (proximal) and negative (non-
proximal) cell subpopulations (93  4% purity) (Helbert et al., 1997). Other 
surface markers for proximal tubular cells include neutral endopeptidase, 
dipeptidyl peptidase IV, -glutamyl transferase, alanine aminopeptidase, TN20 
antigen and intestinal type alkaline phosphatase (Helbert et al., 1997). When 
selecting for the most appropriate surface marker antibody, it is important to 
consider that some characteristics may disappear from a cell type during cell 
culture due to dedifferentiation (Eguchi and Kodama, 1993; Hay, 1993), as has 
been shown for -glutamyl transferase and alkaline phosphatase expression on 
human proximal tubular cells (Trifillis et al., 1985). Alternatively, certain 
characteristics may appear, as has been shown for dipeptidyl peptidase IV 
expression on distal tubular cells (Baer et al., 1999). 
In previous years, our research group has identified that seeding proximal 
tubule cultures with a proportion of distal cortical cells gave a more robust 
model than a pure primary proximal tubular cell culture segregated by free flow 
electrophoresis. mRNA expression of key transporters in native human kidney 
cortex and 10-day old purified proximal and distal tubule/collecting duct cell 
monolayers were compared using qPCR. mRNA expression of NaPi-IIa, SGLT2, 
OCT2, OCTN2, NBC, OAT1, OAT3, BCRP and MDR1 were restricted to native 
kidney and proximal tubule cells (Brown et al., 2008). SGLT1, OAT4 and MRP2 
on the other hand were detected in native tissue, proximal and distal 
tubular/collecting duct cell monolayers (Brown et al., 2008). Protein expression 
of key transporters OAT1, OAT3 and NaPi-IIa were investigated using 
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immunohistochemistry and confocal microscopy. In accordance with the qPCR 
data, the results demonstrated the expression of OAT1, OAT3 and NaPi-IIa 
were restricted to human proximal tubular cells (Brown et al., 2008). 
Correspondingly, functional characteristic studies in distal tubule / collecting 
duct cell monolayers showed no transcellular transport of PAH, sodium-
dependent glucose uptake or endocytotic uptake of albumin (Brown et al., 2008). 
A limitation of pure proximal tubule monolayers was the low tight junction 
integrity. The mean TEER value of a pure proximal tubular cell monolayer 
cultured on a Transwell insert was 26  0.8  cm2, compared with 205  3.8  
cm2 for purified distal tubular / collecting duct cell monolayers and 78.3  1.7  
cm2 for a co-culture of proximal and distal tubular cells (Brown et al., 2008). 
When the monolayer tight junction integrity is low studies of secretion and 
absorption is not feasible because of the large paracellular movement of the 
substrate of interest. As a result of the low tight junction integrity of pure 
proximal tubule monolayers and low expression of key transport proteins in 
distal tubular / collecting duct cells, it was concluded that co-cultures of proximal 
and distal tubular cells (PTCs) were a better in-vitro model. Two practical 
advantages of human PTC and rat PTC monolayers are the cell yield generated 
from a single kidney is much greater and with a high TEER value transporter-
mediated absorption and secretion of compounds can be studied. Analysis of 
the human PTC co-cultures produced with the isolation procedure detailed in 
subchapter 2.2.1 deduced that the co-cultures are 80% proximal tubule cells 
and 20% distal tubular / collecting duct cells (Brown et al., 2008).  
A challenge in the use of primary cells is the acquisition of tissues from which 
the cells are derived. The supply of fresh human kidneys is undoubtedly limited, 
not least because of the short fall in organ donation and the long transplant 
waiting list. However, in the occasions of the availability of kidneys that are 
unsuitable for transplants but still viable, it is paramount that an efficient 
isolation protocol is performed maximise the yield of cells. Rat kidneys, on the 
other hand, are more accessible. Nonetheless, the principles of the 3Rs of 
animal use should be practice. Optimisation of the isolation procedure is thus 
essential, and forms the basis of this chapter. 
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3.2. Aims 
The aim of this chapter was to develop and optimise the methodology required 
to isolate human and rat PTCs. 
In order to achieve this the enzymatic digestion phase of the isolation procedure 
was optimised. The yield and growth of cells isolated with a range of 
collagenase concentrations were studied up to day 8 of cell culture. Human 
PTC, rat PTC and RPTEC cell monolayer formation was assessed using TEER. 
The correlation between TEER and paracellular permeability of cell monolayers 
was studied using radiolabelled [1-14C]-mannitol D. Then finally the mRNA 
expression of key renal drug transport proteins was evaluated in human PTCs, 
rat PTCs and RPTEC cells grown on different cultureware. 
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3.3. Results 
3.3.1. Collagenase concentration and cell yield 
In order to optimise the enzymatic digestion of renal cortex in terms of the yield 
of isolated PTCs, human or rat renal cortex was incubated with a range of 
concentrations of collagenase using 2 different incubation conditions. The 
concentrations of collagenase investigated were 10, 20, 25, and 30 mg 
collagenase per g of renal cortex. The activity of collagenase was approximately 
300 units per mg. The tissues were exposed to the collagenase overnight (4 C 
for more than 12 hrs followed by 1 hr at 37 C) or acutely (2 hrs at 37 C). The 
number of isolated PTCs per g of renal cortex were estimated using a 
haemocytometer. 
Focusing on the human data, Figure 3.1 shows a positive correlation between 
collagenase concentration and human PTC yield; the higher the concentration 
of collagenase used, the higher the yield, which suggests enzyme concentration 
is the rate-limiting factor (n = 9, N = 3). In order to determine the effect of the 
incubation period on the yield of isolated human PTCs, the number of isolated 
human PTCs per g of renal cortex following an overnight incubation was 
compared to an acute incubation for each collagenase concentration. Except at 
10 mg collagenase per g of tissue, which gave 1.58  0.09 million cells with an 
overnight incubation and 2.13  0.04 million cells with an acute incubation (** P 
< 0.01), the incubation period did not affect cell yield. For instance, overnight 
and acute incubation of human renal cortex with 30 mg collagenase per g of 
tissue yielded 3.07  0.09 million and 3.07  0.03 million cells, respectively. 
Similarly, 25 mg collagenase per g of tissue gave 2.80  0.01 million and 2.62  
0.16 million cells with overnight and acute incubation, respectively. 20 mg 
collagenase per g of tissue gave 2.56  0.04 million and 2.40  0.13 million cells 
with overnight and acute incubation, respectively. 
Enzymatic digestion of rat renal cortex produced similar findings, shown in 
Figure 3.2 (n = 9, N = 3). The number of isolated rat PTCs following an 
overnight or acute incubation at each collagenase concentration was compared 
and no significant difference in the cell yield was found. For instance, an 
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overnight and acute incubation of rat renal cortex with 30 mg collagenase per g 
of tissue yielded 13.75  0.05 million and 13.76  0.73 million cells, respectively. 
25 mg collagenase per g of tissue yielded 11.19  0.36 million and 11.11  0.42 
million cells from an overnight and acute digest, respectively. 20 mg 
collagenase per g of tissue yielded 4.60  0.10 million and 4.51  0.37 million 
cells from an overnight and acute digest, respectively. The lowest concentration 
of collagenase (10 mg collagenase per g of renal cortex) yielded 3.36  0.04 
million and 3.31  0.17 million cells from overnight and acute digests, 
respectively. The significance of the difference in cell yield using an overnight 
and acute incubation was determined using a Student’s t-test. 
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Figure 3.1: The yield of isolated human PTCs following an overnight and 
acute incubation with different concentrations of collagenase.  
Samples of human renal cortex were incubated with 10, 20, 25 or 30 
mg collagenase per g of renal cortex. Cell numbers were estimated 
using a haemocytometer. There were no differences in the number of 
isolated human PTCs per g of tissue in an overnight incubation 
compared to an acute incubation when using 20, 25 and 30 mg 
collagenase per g of tissue. Cell isolation with 30 mg collagenase per 
g of renal cortex gave the highest cell yield, at 3.07  0.09 million 
cells per g of tissue from an overnight digest, and 3.07  0.03 million 
cells per g of tissue from an acute digest. 25 mg collagenase per g of 
tissue yielded 2.80  0.01 million cells from an overnight digest and 
2.62  0.16 million cells from an acute digest. 20 mg collagenase per 
g of renal cortex yielded 2.56  0.04 million cells from an overnight 
digest and 2.40  0.13 million cells from an acute digest. However, 10 
mg collagenase per g of tissue yielded a significantly lower number of 
cells in an overnight digest with 1.58  0.09 million cells per g of 
tissue compared to an acute digest with 2.13  0.04 million cells per g 
of tissue (** P < 0.01). The results are expressed as the mean  SEM 
from 3 samples of renal cortex derived from 3 individual kidneys. The 
significance of the difference in cell yield using an overnight and 
acute incubation was determined using a Student’s t-test.  
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Figure 3.2: The yield of isolated rat PTCs following an overnight and acute 
incubation with different concentrations of collagenase.  
Samples of rat renal cortex were incubated with 10, 20, 25, or 30 mg 
collagenase per g of tissue. The number of cells was estimated using 
a haemocytometer. The mean number of isolated rat PTCs following 
an overnight and acute incubation at each concentration of 
collagenase was compared and no significant difference was found. 
Using 30 mg of collagenase per g of tissue gave the highest yield of 
rat PTCs; 13.75  0.05 million cells per g of tissue was isolated from 
an overnight digest, and 13.76  0.73 million cells per g of tissue from 
an acute digest. 25 mg collagenase per g of tissue yielded 11.19  
0.36 million cells in an overnight digest and 11.11  0.42 million cells 
from an acute digest. 20 mg collagenase per g of renal cortex yielded 
4.60  0.10 million cells in an overnight digest and 4.51  0.37 million 
cells from an acute digest. 10 mg collagenase per g of tissue yielded 
3.36  0.04 million cells in an overnight digest and 3.31  0.17 million 
cells in an acute digest. The results are expressed as the mean  
SEM from 3 samples of renal cortex derived from 3 individual kidneys. 
The significance of the difference in cell yield using an overnight and 
acute digest was determined using a Student’s t-test. 
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3.3.2. Collagenase concentration and cell viability. 
The collagenase used in the isolation process contained a mixture of protease 
enzymes. It has been reported that prolonged exposure to high concentrations 
of protease enzymes can affect cell viability (Boogaard et al., 1990; Cummings 
et al., 2000). In order to determine the effect of collagenase concentration and 
incubation condition upon cell health, growth assays were performed. Isolated 
cells were seeded into plastic 12-well plates at a density of 200 000 cells per 
well. The number of cells in a well per cm2 at 1, 2, 3, 4, 5, 6, 7, and 8 days of 
cell culture were quantified using a haemocytometer. 
Figure 3.3 shows the number of human PTCs per cm2 over 8 days following an 
(a) overnight and (b) acute incubation with different concentrations of 
collagenase (n = 9, N = 3). For both incubation periods, the cells isolated using 
25 mg collagenase per g of tissue displayed the highest rate of cell propagation. 
At day 8 of cell culture, following an overnight incubation, the number of human 
PTCs per cm2 was significantly greater for cells isolated using 25 mg 
collagenase per g of tissue (220 000  3 824) compared to 10 (127 000  3 163, 
**** P < 0.0001), 20 (195 000  3 039, ** P < 0.01) and 30 (197 000  4 558, * P 
< 0.05) mg collagenase per g of tissue. Similarly, at day 8 of cell culture 
following an acute incubation, the number of human PTCs per cm2 was 
significantly greater for cells isolated using 25 mg collagenase per g of tissue 
(221 000  3 039) compared to 10 (87 000  1 519, **** P < 0.0001), 20 (188 
000  4 642, ** P < 0.01) and 30 (182 000  2 321, *** P < 0.001) mg 
collagenase per g of tissue. In order to determine if one incubation period led to 
better cell health the number of cells per cm2 at day 8 following isolation with 25 
mg collagenase per g of tissue was compared. No significant difference in the 
cell number per cm2 was found between an overnight and acute incubation 
period (P > 0.05). Significance was determined using a Student’s t-test. 
Figure 3.4 shows the number of rat PTCs per cm2 over 8 days following an (a) 
overnight and (b) acute incubation with different concentrations of collagenase 
(n = 9, N = 3). Once again, cells isolated using 25 mg of collagenase per g of 
tissue displayed the highest rate of cell proliferation. At day 8 of culture the 
number of rat PTCs per cm2 was significantly greater for cells isolated overnight 
with 25 mg collagenase per g of tissue (242 000  2 589) compared to 10 (122 
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000  2 321, **** P < 0.0001), and 30 (174 000  7 982, ** P < 0.01) mg 
collagenase per g of tissue. Similarly, at day 8 following an acute incubation, the 
number of rat PTCs per cm2 was significantly greater for cells isolated using 25 
mg collagenase per g of tissue (192 000  3 044) compared to 10 (21 000  382, 
**** P < 0.0001), 20 (166 000  4 487, ** P < 0.01) and 30 (29 000  1 379, **** 
P < 0.0001) mg collagenase per g of renal cortex. When the number of cells per 
cm2 at day 8 following an overnight and acute incubation with 25 mg 
collagenase per g of renal cortex was compared, the number of cells at day 8 
following an overnight incubation was significantly greater (P < 0.001, ***). This 
suggests that an overnight enzymatic digestion of rat renal cortex is better for 
cell health. Significance was determined using a Student’s t-test. 
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Figure 3.3: The growth of isolated human PTCs over 8 days following an 
(a) overnight and (b) acute incubation with different concentrations of 
collagenase.  
The number of cells per cm2 was estimated at day 1, 2, 3, 4, 5, 6, 7, 
and 8 of culture using a haemocytometer. The results are expressed 
as the mean  SEM from 9 human PTC monolayers derived from 3 
individual kidneys. (a) Following an overnight incubation the highest 
number of cells per cm2 at each time point was cells isolated using 25 
mg of collagenase per g of human renal cortex. The number of human 
PTCs was 187 000  3 039 per cm2 at day 6, 207 000  2 321 per cm2 
at day 7 and 220 000  3 824 per cm2 at day 8. The number of human 
PTCs for 20 and 30 mg collagenase per g of renal cortex were very 
similar, 164 000  2 321 versus 153 000  5 478 per cm2 at day 6, 
171 000  4 020 versus 168 000  1 519 per cm2 at day 7 and 197 
000  4 558 versus 195 000 3 039 per cm2 at day 8, respectively. 
The lowest number of cells per cm2 at each time point was wells 
containing cells isolated using 10 mg of collagenase per g of human 
renal cortex. (b) After an acute incubation the highest number of cells 
per cm2 was cortex digested with 20 mg collagenase per g of human 
renal cortex at day 1 and 2 of cell culture, then cells isolated using 25 
mg collagenase per g of human renal cortex from day 3 of cell culture 
onwards. For cells isolated using 25 mg collagenase per g of renal 
cortex the number of human PTCs was 198 000  2 321 per cm2 at 
day 6, 209 000  2 321 per cm2 at day 7 and 221 000  3 039 per cm2 
at day 8. The number of human PTCs for 20 and 30 mg collagenase 
per g of renal cortex were very similar, 177 000  3 163 versus 159 
000  3 163 per cm2 at day 6, 182 000  2 321 versus 170 000  3 
163 per cm2 at day 7 and 188 000  4 642 versus 182 000 2 321 per 
cm2 at day 8, respectively. The lowest number of cells per cm2 at 
each time point was wells containing cells isolated using 10 mg of 
collagenase per g of human renal cortex. 
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Figure 3.4: The growth of isolated rat PTCs over 8 days following an (a) 
overnight and (b) acute incubation with different concentrations of 
collagenase.  
The number of cells per cm2 was estimated at day 1, 2, 3, 4, 5, 6, 7, 
and 8 of culture using a haemocytometer. The results are expressed 
as the mean  SEM from 9 rat PTC monolayers derived from 3 
individual kidneys.(a) In an overnight isolation the highest number of 
cell per cm2 at each time point, with the exception of day 3, was cell 
isolates using 25 mg of collagenase per g of tissue. The number of rat 
PTCs was 229 000  1 529 per cm2 at day 6, 230 000  12 281 per 
cm2 at day 7 and 242 000  2 589 per cm2 at day 8. The number of rat 
PTCs for 20 mg collagenase per g of renal cortex was 138 000  2 
191 per cm2 at day 6, 228 000  6 265 per cm2 at day 7 and 235 000 
 3 267 per cm2 at day 8. The number of rat PTCs for 30 mg 
collagenase per g of renal cortex was 85 000  2 339 per cm2 at day 6, 
122 000  3 824 per cm2 at day 7 and 174 000  7 982 per cm2 at day 
8. The lowest number of cells per cm2 at each time point was wells 
containing cells isolated using 10 mg of collagenase per g of human 
renal cortex. (b) In an acute isolation the highest numbers of cells per 
cm2 from day 2 to day 8 were cells isolated using 25 mg of 
collagenase per g of rat renal cortex. For cells isolated using 25 mg 
collagenase per g of renal cortex the number of rat PTCs was 154 000 
 2 510 per cm2 at day 6, 174 000  1 959 per cm2 at day 7 and 192 
000  3 044 per cm2 at day 8. The number of rat PTCs for 20 mg 
collagenase per g of renal cortex was 92 000  1 444 per cm2 at day 6, 
119 000  3 441 per cm2 at day 7 and 166 000  4 487 per cm2 at day 
8. The number of rat PTCs for 30 mg collagenase per g of renal 
cortex was 28 000  749 per cm2 at day 6, 34 000  608 per cm2 at 
day 7 and 29 000  1 379 per cm2 at day 8. The lowest number of 
cells per cm2 at each time point was wells containing cells isolated 
using 10 mg of collagenase per g of human renal cortex.  
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3.3.3. Cell yield per g of cortex. 
As a result of the growth study findings, human PTCs were isolated from human 
renal cortex by incubating tissue samples with 25 mg collagenase per g of renal 
cortex. Figure 3.5 is a summary of the number of isolated human PTCs per g of 
renal cortex (N = 100). The relationship between number of isolated human 
PTCs and weight of human renal cortex shows strong positive correlation. 
Correlation analysis of the sample data gave a Pearson correlation coefficient of 
0.90 and a coefficient of determination of 0.82. Due to the small p value (p < 
0.0001) we can conclude that the correlation is not due to random sampling. 
The numbers of isolated human PTCs from samples weighting less than 2 g 
were negligible.  
Due to the growth assay findings, rat PTCs were isolated from rat renal cortex 
by incubating tissue samples overnight with 25 mg collagenase per g of tissue. 
Figure 3.6 is a summary of the number of isolated rat PTCs per g of renal cortex 
(N = 100). The relationship between number of isolated rat PTCs and weight of 
rat renal cortex appears to have positive correlation. Correlation analysis of the 
sample data gave a Pearson correlation coefficient of 0.715 and a coefficient of 
determination of 0.511. Due to the small p value (p < 0.0001) we can conclude 
that the correlation is not due to random sampling.  
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Figure 3.5: A summary of the number of isolated human PTCs per g of 
human renal cortex.  
Correlation analysis of the sample data gave a Pearson correlation 
coefficient (r) of 0.90, coefficient of determination (r2) of 0.82 and p 
value < 0.0001. This suggests that the number of isolated human 
PTCs is strongly correlated to the weight of human renal cortex used 
and not the result of random sampling. The numbers of isolated 
human PTCs obtained from samples weighting less than 2 g were 
negligible. The sample size (n) was 100. 
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Figure 3.6: A summary of the number of isolated rat PTCs per g of rat 
renal cortex. 
Correlation analysis of the sample data gave a Pearson correlation 
coefficient (r) of 0.72, coefficient of determination (r2) of 0.51 and p 
value < 0.0001. This suggests that the number of isolated rat PTCs is 
correlated to the weight of rat renal cortex used and not the result of 
random sampling. The sample size (n) was 100. 
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3.3.4. TEER of human PTC, rat PTC and RPTEC monolayers. 
A characteristic feature of epithelial cells is the formation of intercellular 
junctions. Formation of these tight junctions results in a cellular barrier 
separating the apical membrane from the basolateral membrane and apical-
basal polarity. Epithelial cells connect to one another as they grow via these 
tight junctions to form polarised epithelial monolayers. TEER measurements are 
a convenient, reliable and non-destructive method of quantitatively evaluating 
the growth of epithelial tissue cultures on Transwell inserts and cell monolayer 
permeability in-vitro. 
Human PTCs, rat PTCs and RPTEC cells were seeded on to 24-well 
Transwell inserts at a density of 75 000 cells per insert with 200 L of culture 
medium in the apical chamber and a further 1000 L in the basolateral well. The 
TEER of each monolayer was measured daily using an epithelial voltohmmeter 
to determine growth and permeability.  
TEER values of human PTC monolayers grown on Transwell inserts are 
shown in Figure 3.7 (n = 72, N = 3). The human PTC monolayers developed 
TEER. TEER increased steadily from day 1 to 6. Resistance reached a plateau 
of around 120 .cm2 between day 6 and 8, with readings of 110.30  1.00 
.cm2 at day 6, 129.60  0.87 .cm2 at day 7, and 135.50  1.04 .cm2 at day 
8. Resistance then decreased at day 9 and 10 but was still significantly above a 
threshold value of 80 .cm2 . Mean rat PTC monolayer TEER values, shown in 
Figure 3.8, were very similar to that of the human monolayers (n = 72, N = 3). 
rat PTC TEER values plateaued around 110 .cm2. The mean TEER at day 6 
was 107.50  0.84 .cm2, day 7 was 114.30  1.09 .cm2, and 98.90  0.12 
.cm2 at day 8. RPTEC monolayers, on the other hand, had very low TEER 
readings in comparison to the primary cells, as shown in Figure 3.9 (n = 24, N = 
3). The highest individual reading was 27.92  0.33 .cm2 at day 9. The results 
are expressed as the mean  SEM.   
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Figure 3.7: TEER of human PTC monolayers grown on Transwell inserts.  
Human PTCs were seeded on to 24-well Transwell inserts at a 
density of 75 000 cells per insert with 200 L of culture medium in the 
apical chamber and a further 1000 L in the basolateral well. TEER of 
each monolayer was measured daily using an epithelial voltohmmeter 
to determine growth and permeability. TEER developed and increased 
steadily in culture from day 1 to 6 (Day 1: 3.35  0.14 .cm2, Day 2: 
6.93  0.15 .cm2, Day 3: 10.47  0.35 .cm2, Day 4: 18.96  0.18 
.cm2, Day 5: 51.97  0.52 .cm2, Day 6: 110.30  1.00 .cm2). 
Resistance reached a plateau of around 120 .cm2 between 6 and 8 
days in culture (Day 7: 129.60  0.87 .cm2, Day 8: 135.50  1.04 
.cm2). Then decreased to 106.9  1.39 .cm2 and 96.45  0.92 
.cm2 at day 9 and 10, respectively. The results are expressed as the 
mean  SEM from 72 monolayers derived from 3 individual kidneys. 
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Figure 3.8: TEER of rat PTC monolayers grown on Transwell inserts.  
Rat PTCs were seeded on to 24-well Transwell inserts at a density 
of 75 000 cells per insert with 200 L of culture medium in the apical 
chamber and a further 1000 L in the basolateral well. TEER of each 
monolayer was measured daily using an epithelial voltohmmeter to 
determine growth and permeability. TEER increased steadily from day 
1 to 7 (Day 1: 2.64  0.22 .cm2, Day 2: 6.76  0.20 .cm2, Day 3: 
19.19  0.30 .cm2, Day 4: 51.74  0.65 .cm2, Day 5: 74.65  1.14 
.cm2, Day 6: 107.50  0.84 .cm2, Day 7: 114.30 1.09 .cm2 ). 
Resistance then decreased from between 8 and 10 days in culture 
(Day 8: 98.90  0.12 .cm2, Day 9: 50.17  0.70 .cm2 and Day 10: 
27.35  0.22 .cm2). The results are expressed as the mean  SEM 
from 72 monolayers derived from 3 individual kidneys. 
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Figure 3.9: TEER of RPTEC monolayers grown on Transwell inserts. 
RPTEC cells were seeded on to 24-well Transwell inserts at a 
density of 75 000 cells per insert with 200 L of culture medium in the 
apical chamber and a further 1000 L in the basolateral well. TEER of 
each monolayer was measured daily using an epithelial voltohmmeter 
to determine growth and permeability. Resistance was low throughout 
culture. The highest reading was 27.92  0.33 .cm2 at day 9. The 
results are expressed as the mean  SEM from 24 monolayers derived 
from 3 individual passages. 
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3.3.5. The correlation between TEER and paracellular permeability. 
In order to determine the efficiency of TEER as a measurement of epithelial cell 
monolayer permeability, the correlation between TEER and paracellular 
permeability was investigated. Radiolabelled [1-14C]-mannitol D is a non-
metabolised small molecular weight probe (112 kiloDaltons) that can be used to 
determine paracellular permeability. Human and rat PTCs, as well as RPTEC 
cells, were seeded on to 24-well Transwell inserts. The TEER of monolayers 
was measured prior to mannitol flux experiments in the absorptive direction (JA-
B). Radiolabelled [1-14C]-mannitol D (10 M, radioactivity 0.1 Ci / mL) was 
introduced into the apical chamber of the Transwell inserts and its appearance 
in the basolateral well after 1 hr was measured to quantify the paracellular 
permeability of the monolayers. 
Figure 3.10 and Figure 3.11 show the inverse relationship between monolayer 
TEER and paracellular permeability (n = 200, N = 25). As human PTC and rat 
PTC monolayer TEER increased, the paracellular movement of mannitol 
decreased until it reached a plateau of 12.89  8.29 pmol / hr / cm2 and 7.24  
11.05 pmol / hr / cm2, respectively. In both species there was a mannitol flux of 
30 pmol / hr / cm2 or less when monolayer TEER was greater than 80 .cm2. 
This equated to a mannitol paracellular flux of less than 0.01 % of the total 
amount of mannitol used. As shown in Figure 3.12 , RPTEC monolayers that 
failed to develop a high TEER showed a high mannitol flux and permeability.  
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Figure 3.10: The correlation between TEER of human PTC monolayers and 
paracellular movement of radiolabelled 10 M [1-14C]-mannitol D. 
An inverse relationship between the TEER value and mannitol 
paracellular flux was observed. As monolayer TEER increased, the 
paracellular movement of mannitol decreased until it reached a 
plateau of 12.89  8.29 pmol / hr / cm2. Monolayers with TEER of 50 
.cm2 or lower showed a high amount of mannitol flux and thus had a 
high permeability. This is in contrast to monolayers with TEER of 80 
.cm2 or greater that showed low mannitol flux (30 pmol / hr / cm2 or 
less) and thus had a low permeability. Each dot represents the TEER 
of the monolayer and the paracellular movement of mannitol across 
the monolayer in the absorptive direction (JA-B). The sample size (n) 
was 200.  
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Figure 3.11: The correlation between TEER of rat PTC monolayers and 
paracellular movement of radiolabelled 10 M [1-14C]-mannitol D. 
An inverse relationship between TEER values and mannitol 
paracellular flux was observed. As monolayer TEER increased, the 
paracellular movement of mannitol decreased until it reached a 
plateau of 7.24  11.05 pmol / hr / cm2. Monolayers with TEER of 40 
.cm2 and lower had a high permeability, whereas monolayers with 
TEER of 80 .cm2 and greater had a low permeability. Each dot 
represents the TEER of the monolayer and the paracellular movement 
of mannitol across the monolayer in the absorptive direction (JA-B). 
The sample size (n) was 200. 
 
0 50 100 150 200 250
0
200
400
600
800
1000
TEER of rat PTC monolayers (.cm2)
Pa
ra
ce
llu
la
r m
ov
em
en
t o
f 1
0 
M
 [1
-1
4 C
]-m
an
ni
to
l D
 
(p
m
ol
 / 
hr
 / 
cm
2 )
 83 
 
 
Figure 3.12: The correlation between TEER of RPTEC monolayers and 
paracellular movement of radiolabelled 10 M [1-14C]-mannitol D. 
The monolayers failed to develop high TEER values. The maximum 
TEER value was 39 .cm2. Correspondingly, the monolayers showed 
a high paracellular flux of mannitol and thus permeability. Each dot 
represents the TEER of the monolayer and the paracellular movement 
of mannitol across the monolayer in the absorptive direction (JA-B). 
The sample size (n) was 200.  
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3.3.6. mRNA expression of key renal drug transporters. 
In order to understand how primary cell cultureware and immortalisation of 
primary proximal tubular cells may affect cellular mRNA expression of transport 
proteins, total cell RNA was isolated from  
 freshly isolated human and rat PTCs,  
 human and rat PTCs cultured on 24-well Transwell® inserts®,  
 human and rat PTCs cultured in plastic T25 flasks, and  
 RPTEC cells (immortalised human PTCs) cultured in plastic T25 flasks.  
The total cell RNA was reverse transcribed into cDNA using MMLV-RT before 
qPCR. The mRNA expression levels of human drug transporters, OAT1, OAT3, 
URAT1, OATP4C1, OCT2, BCRP, MATE1, MATE2-K, MDR1, MRP1, MRP2, 
MRP3, and MRP4 following culture on Transwell® inserts and plastic 
cultureware, and human PTC immortalisation with TERT (RPTEC cell line) 
relative to freshly isolated cells are shown in Figure 3.13, Figure 3.14, Figure 
3.15, Figure 3.16, Figure 3.17, Figure 3.18, Figure 3.19, Figure 3.20, Figure 
3.21, Figure 3.22, Figure 3.23, Figure 3.24, and Figure 3.25, respectively. The 
data are summarised in Table 3.1. The mRNA expression levels of rat drug 
transporters, Oat1, Urat1, Oatp4c1, Oct2, Bcrp, Mate1, Mdr1, and Mrp2, 
following culture on Transwell® inserts and plastic cultureware relative to freshly 
isolated cells are summarised in Table 3.2. This data was produced in 
collaboration with Git Chung. The expression levels had been normalised to 
reference gene GAPDH/Gapdh expression level prior to comparison. The data 
are presented as the mean ± SEM percentage change in expression levels from 
3 separate batches of RNA (N = 3).  
Human PTCs cultured on Transwell® inserts maintained expression of all the 
key renal transport proteins investigated. At day 8 in culture, there was however 
a significant fall in the mRNA expression of OAT1, URAT1, OATP4C1, OCT2, 
BCRP, MATE1, MDR1, MRP3 and MRP4 compared with mRNA expression 
levels in freshly isolated human PTCs. On average the human PTCs at day 7 
had expression levels around 40-50% of fresh tissue, with some exceptions. 
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Similarly, human PTCs cultured on plastic cultureware maintained a similar 
expression of all transporters proteins tested, again with a significant decrease 
in the expression of OAT1, OAT3, URAT1, OATP4C1, OCT2, BCRP, MATE1, 
MDR1, MRP1, MRP3 and MRP4 when compared with freshly isolated human 
PTCs. In stark contrast, immortalised primary proximal tubule cells (RPTEC) 
showed a profound loss of transporter expression compared with fresh tissue 
there was a significant fall in the expression of all transporters following 
immortalisation. 
Expression in human PTCs cultured on Transwell® inserts was compared 
against cells cultured on plastic. The data show expression of OAT3, OATP4C1, 
BCRP, MRP1, MRP3 and MRP4 was significantly higher following culture on 
Transwell® inserts suggesting that cells grown on Transwell® inserts may retain 
more differentiation than cells grown on plastic. 
Rat PTCs cultured on both Transwell® inserts and plastic showed an almost 
identical pattern with maintained expression of all the key renal transport 
proteins investigated, but with expression levels of all transporters significantly 
lower than freshly isolated rat PTCs, (approximately 80 to 70% lower). In 
contrast to the human PTC data, no significance in expression levels was 
observed between the two culture conditions with rat PTCs. Significance was 
determined using a Student’s t-test. 
Relative drug transporter gene expression was compared using human and rat 
drug transporter RT2 profiler PCR array plates. The plates screen expression of 
84 drug transporter genes and 5 reference genes. Drug transporter expression 
in freshly isolated human and rat PTCs, and human and rat PTCs cultured for 7 
days on plastic were charactersied. In correlation with the other data the results 
in Figure 3.26 and Figure 3.27 show drug transporter mRNA levels were lower 
in cells cultured on plastic.  
The data in Figure 3.26 show high expression of OAT1 and OCT2 in fresh 
human PTCs and expression of OAT2, OAT3, OATP1A2, OCT3, BCRP, MDR1, 
MRP1, MRP2, MRP3, MRP4, MRP5, and MRP6 at lower levels. Human PTCs 
cultured for 7 days on plastic showed expression of OCT2, MDR1, MRP1, 
MRP3, MRP4, and MRP5. Drug transporters of interest absent from the PCR 
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array panel include OAT4, URAT1, OATP4C1, MATE1 and MATE2-K. 
Expression had been normalised to the reference gene, GAPDH. The results 
are representative of a single batch of RNA derived from a single individual (N = 
1).  
Figure 3.27 shows high expression of Oat3 and Oct1 in fresh rat PTCs and 
expression of Oat1, Oat2, Oct2, Bcrp, Mdr1b, Mrp1, Mrp2, Mrp3, Mrp4, Mrp5, 
and Mrp6 at lower levels. Rat PTCs cultured for 7 days on plastic showed  
expression of Bcrp, Mdr1b, Mrp1, Mrp4, and Mrp5. Drug transporters of interest 
absent from the PCR array panel include Urat1, Oatp4c1, Oatp1a isoforms, and 
Mate1. Expression had been normalised to the reference gene, ß-actin. The 
results are representative of a single batch of RNA derived from a single 
individual (N = 1). 
The expression of non-proximal tubule drug transporters was also assessed to 
determine cell contamination. Expression of V-ATPase a marker of collecting 
duct cells and MCT8 a marker of loop of Henle and colecting duct cells was 
very low in all samples. This suggests that proximal tubule cells predominate 
the human and rat PTC cell populations.  
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Figure 3.13: The mRNA expression of OAT1 in human PTCs under 
different culture conditions.  
OAT1 mRNA expression levels are expressed as percentage 
expression relative to freshly isolated human PTCs. Human PTCs 
cultured for 7 days on Transwell inserts and plastic showed a 76.61  
5.10 % and 88.49  1.11 % decrease in expression in comparison to 
freshly isolated cells (100.00  5.72 %), respectively. The 
immortalised RPTEC cell line showed a 96.05  2.32 % decrease in 
expression in comparison to freshly isolated cells. The expression 
levels had been normalised to reference gene GAPDH expression 
level prior to comparison. The results are expressed as the mean ± 
SEM from 3 separate batches of RNA derived from 3 individual 
kidneys. One-way ANOVA statistical test was performed on the data 
set to determine significance, *** P < 0.001. 
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Figure 3.14: The mRNA expression of OAT3 in human PTCs under 
different culture conditions.  
OAT3 mRNA expression levels are expressed as percentage 
expression relative to freshly isolated human PTCs. Human PTCs 
cultured for 7 days on Transwell inserts and plastic showed a 35.88  
11.01 % and 94.93  1.99 % decrease in expression in comparison to 
freshly isolated cells (100.00  13.25 %), respectively. The 
immortalised RPTEC cell line showed a 93.90  5.98 % decrease in 
expression in comparison to freshly isolated cells. The expression 
levels had been normalised to reference gene GAPDH expression 
level prior to comparison. The results are expressed as the mean ± 
SEM from 3 separate batches of RNA derived from 3 individual 
kidneys. One-way ANOVA statistical test was performed on the data 
set to determine significance, *** P < 0.001. 
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Figure 3.15: The mRNA expression of URAT1 in human PTCs under 
different culture conditions.  
URAT1 mRNA expression levels are expressed as percentage 
expression relative to freshly isolated human PTCs. Human PTCs 
cultured for 7 days on Transwell inserts and plastic showed a 49.61  
9.79 % and 77.96  4.23 % decrease in expression in comparison to 
freshly isolated cells (100.00  5.12 %), respectively. The 
immortalised RPTEC cell line showed a 96.03  3.84 % decrease in 
expression in comparison to freshly isolated cells. The expression 
levels had been normalised to reference gene GAPDH expression 
level prior to comparison. The results are expressed as the mean ± 
SEM from 3 separate batches of RNA derived from 3 individual 
kidneys. One-way ANOVA statistical test was performed on the data 
set to determine significance, ** P < 0.01, *** P < 0.001. 
Fresh Transwell Plastic RPTEC
0
20
40
60
80
100
120
R
el
at
iv
e 
m
R
N
A 
ex
pr
es
si
on
 le
ve
l (
%
 o
f F
re
sh
)
URAT1
***
***
**
 90 
 
 
Figure 3.16: The mRNA expression of OATP4C1 in human PTCs under 
different culture conditions.  
OATP4C1 mRNA expression levels are expressed as percentage 
expression relative to freshly isolated human PTCs. Human PTCs 
cultured for 7 days on Transwell inserts and plastic showed a 48.63  
4.13 % and 95.62  1.21 % decrease in expression in comparison to 
freshly isolated cells, (100.00  7.77 %), respectively. The 
immortalised RPTEC cell line showed a 99.79  0.20 % decrease in 
expression in comparison to freshly isolated cells. The expression 
levels had been normalised to reference gene GAPDH expression 
level prior to comparison. The results are expressed as the mean ± 
SEM from 3 separate batches of RNA derived from 3 individual 
kidneys. One-way ANOVA statistical test was performed on the data 
set to determine significance, *** P < 0.001. 
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Figure 3.17: The mRNA expression of OCT2 in human PTCs under 
different culture conditions.  
OCT2 mRNA expression levels are expressed as percentage 
expression relative to freshly isolated human PTCs. Human PTCs 
cultured for 7 days on Transwell inserts and plastic showed a 62.04  
6.43 % and 48.16  13.99 % decrease in expression in comparison to 
freshly isolated cells, (100.00  16.67 %), respectively. The 
immortalised RPTEC cell line showed a 99.38  0.56 % decrease in 
expression in comparison to freshly isolated cells. The expression 
levels had been normalised to reference gene GAPDH expression 
level prior to comparison. The results are expressed as the mean ± 
SEM from 3 separate batches of RNA derived from 3 individual 
kidneys. One-way ANOVA statistical test was performed on the data 
set to determine significance, * P < 0.05, *** P < 0.001. 
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Figure 3.18: The mRNA expression of BCRP in human PTCs under 
different culture conditions.  
BCRP mRNA expression levels are expressed as percentage 
expression relative to freshly isolated human PTCs. Human PTCs 
cultured for 7 days on Transwell inserts and plastic showed a 78.21  
1.09 % and 93.41  1.52 % decrease in expression in comparison to 
freshly isolated cells, (100.00  13.46 %), respectively. The 
immortalised RPTEC cell line showed a 98.89  0.94 % decrease in 
expression in comparison to freshly isolated cells. The expression 
levels had been normalised to reference gene GAPDH expression 
level prior to comparison. The results are expressed as the mean ± 
SEM from 3 separate batches of RNA derived from 3 individual 
kidneys. One-way ANOVA statistical test was performed on the data 
set to determine significance, *** P < 0.001. 
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Figure 3.19: The mRNA expression of MATE1 in human PTCs under 
different culture conditions.  
MATE1 mRNA expression levels are expressed as percentage 
expression relative to freshly isolated human PTCs. Human PTCs 
cultured for 7 days on Transwell inserts and plastic showed a 51.44  
7.01 % and 75.86  9.42 % decrease in expression in comparison to 
freshly isolated cells, (100.00  11.28 %), respectively. The 
immortalised RPTEC cell line showed a 98.71  1.11 % decrease in 
expression in comparison to freshly isolated cells. The expression 
levels had been normalised to reference gene GAPDH expression 
level prior to comparison. The results are expressed as the mean ± 
SEM from 3 separate batches of RNA derived from 3 individual 
kidneys. One-way ANOVA statistical test was performed on the data 
set to determine significance, ** P < 0.01, *** P < 0.001. 
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Figure 3.20: The mRNA expression of MATE2-K in human PTCs under 
different culture conditions.  
MATE2-K mRNA expression levels are expressed as percentage 
expression relative to freshly isolated human PTCs. Human PTCs 
cultured for 7 days on Transwell inserts and plastic showed a 37.25  
15.80 % and 33.05  11.55 % decrease in expression in comparison 
to freshly isolated cells, (100.00  5.16 %), respectively. The 
immortalised RPTEC cell line showed an 87.66  11.37 % decrease in 
expression in comparison to freshly isolated cells. The expression 
levels had been normalised to reference gene GAPDH expression 
level prior to comparison. The results are expressed as the mean ± 
SEM from 3 separate batches of RNA derived from 3 individual 
kidneys. One-way ANOVA statistical test was performed on the data 
set to determine significance, ** P < 0.01. 
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Figure 3.21: The mRNA expression of MDR1 in human PTCs under 
different culture conditions.  
MDR1 mRNA expression levels are expressed as percentage 
expression relative to freshly isolated human PTCs. Human PTCs 
cultured for 7 days on Transwell inserts and plastic showed a 70.99  
3.12 % and 76.42  8.51 % decrease in expression in comparison to 
freshly isolated cells, (100.00  19.26 %), respectively. The 
immortalised RPTEC cell line showed a 96.13  2.62 % decrease in 
expression in comparison to freshly isolated cells. The expression 
levels had been normalised to reference gene GAPDH expression 
level prior to comparison. The results are expressed as the mean ± 
SEM from 3 separate batches of RNA derived from 3 individual 
kidneys. One-way ANOVA statistical test was performed on the data 
set to determine significance, ** P < 0.01, *** P < 0.001. 
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Figure 3.22: The mRNA expression of MRP1 in human PTCs under 
different culture conditions.  
MRP1 mRNA expression levels are expressed as percentage 
expression relative to freshly isolated human PTCs. Human PTCs 
cultured for 7 days on Transwell inserts and plastic showed a 7.71  
10.20 % and 84.87  2.56 % decrease in expression in comparison to 
freshly isolated cells, (100.00  7.91 %), respectively. The 
immortalised RPTEC cell line showed a 96.87  0.81 % decrease in 
expression in comparison to freshly isolated cells. The expression 
levels had been normalised to reference gene GAPDH expression 
level prior to comparison. The results are expressed as the mean ± 
SEM from 3 separate batches of RNA derived from 3 individual 
kidneys. One-way ANOVA statistical test was performed on the data 
set to determine significance, *** P < 0.001. 
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Figure 3.23: The mRNA expression of MRP2 in human PTCs under 
different culture conditions.  
MRP2 mRNA expression levels are expressed as percentage 
expression relative to freshly isolated human PTCs. Human PTCs 
cultured for 7 days on Transwell inserts and plastic showed a 9.44  
26.22 % and 46.03  17.97 % decrease in expression in comparison 
to freshly isolated cells, (100.00  8.38 %), respectively. The 
immortalised RPTEC cell line showed a 77.53  11.54 % decrease in 
expression in comparison to freshly isolated cells. The expression 
levels had been normalised to reference gene GAPDH expression 
level prior to comparison. The results are expressed as the mean ± 
SEM from 3 separate batches of RNA derived from 3 individual 
kidneys. One-way ANOVA statistical test was performed on the data 
set to determine significance, * P < 0.05. 
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Figure 3.24: The mRNA expression of MRP3 in human PTCs under 
different culture conditions.  
MRP3 mRNA expression levels are expressed as percentage 
expression relative to freshly isolated human PTCs. Human PTCs 
cultured for 7 days on Transwell inserts and plastic showed a 64.91  
4.26 % and 87.62  4.00 % decrease in expression in comparison to 
freshly isolated cells, (100.00  19.33 %), respectively. The 
immortalised RPTEC cell line showed a 99.00  0.96 % decrease in 
expression in comparison to freshly isolated cells. The expression 
levels had been normalised to reference gene GAPDH expression 
level prior to comparison. The results are expressed as the mean ± 
SEM from 3 separate batches of RNA derived from 3 individual 
kidneys. One-way ANOVA statistical test was performed on the data 
set to determine significance, ** P < 0.01, *** P < 0.001. 
 
Fresh Transwell Plastic RPTEC
0
20
40
60
80
100
120
R
el
at
iv
e 
m
R
N
A 
ex
pr
es
si
on
 le
ve
l (
%
 o
f F
re
sh
)
MRP3
***
***
**
 99 
 
 
Figure 3.25: The mRNA expression of MRP4 in human PTCs under 
different culture conditions.  
MRP4 mRNA expression levels are expressed as percentage 
expression relative to freshly isolated human PTCs. Human PTCs 
cultured for 7 days on Transwell inserts and plastic showed a 60.57 
3.76 % and 92.18  1.71 % decrease in expression in comparison to 
freshly isolated cells, (100.00  17.42 %), respectively. The 
immortalised RPTEC cell line showed a 96.20  2.05 % decrease in 
expression in comparison to freshly isolated cells. The expression 
levels had been normalised to reference gene GAPDH expression 
level prior to comparison. The results are expressed as the mean ± 
SEM from 3 separate batches of RNA derived from 3 individual 
kidneys. One-way ANOVA statistical test was performed on the data 
set to determine significance, ** P < 0.01, *** P < 0.001. 
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Table 3.1: Summary of the change in relative mRNA expression levels of 
key drug transporters when human PTCs are cultured on Transwell® 
inserts, plastic cultureware and immortalised in comparison to freshly 
isolated human PTCs.  
mRNA expression levels are expressed as percentage expression 
relative to freshly isolated human PTCs. The data show that 
expression of many of the key renal transporters was significantly 
lower in cultured cells. Expression of OAT3, OATP4C1, BCRP, MRP1, 
MRP3 and MRP4 was significantly higher following culture on 
Transwell® inserts when compared with plastic. The expression levels 
had been normalised to reference gene GAPDH expression level prior 
to comparison. The results are expressed as the mean ± SEM from 3 
separate batches of RNA derived from 3 individual kidneys. One-way 
ANOVA statistical test was performed on the data set to determine 
significance, * P < 0.05, ** P < 0.01, *** P < 0.001. 
Transporter 
% expression compared to fresh human PTCs (Mean ± SEM) 
Transwell® Plastic RPTEC 
OAT1 23.39 ± 5.10 *** 11.51 ± 1.11 *** 3.95 ± 2.32 *** 
OAT3 64.12 ± 11.01 5.07 ± 1.99 *** 6.11 ± 5.98 *** 
URAT1 50.39 ± 9.79 ** 22.04 ± 4.23 *** 3.97 ± 3.84 *** 
OATP4C1 51.37 ± 4.13 *** 4.38 ± 1.21 *** 0.21 ± 0.20 *** 
OCT2 37.96 ± 6.43 * 51.84 ± 13.99 * 0.62 ± 0.56 *** 
BCRP 21.79 ± 1.09 *** 6.59 ± 1.52 *** 1.12 ± 0.94 *** 
MATE1 48.56 ± 7.01 ** 24.14 ± 9.42 *** 1.29 ± 1.11 *** 
MATE-2K 62.75 ± 15.80 66.95 ± 11.55 12.34 ± 11.37 ** 
MDR1 29.01 ± 3.12 ** 23.58 ± 8.51 ** 3.87 ± 2.62 *** 
MRP1 92.29 ± 10.20 15.13 ± 2.56 *** 3.13 ± 0.81 *** 
MRP2 90.56 ± 26.22 53.97 ± 17.97 22.47 ± 11.54 * 
MRP3 35.09 ± 4.26 ** 12.38 ± 4.00 *** 1.00 ± 0.96 *** 
MRP4 39.43 ± 3.76 ** 7.82 ± 1.71 *** 3.80 ± 2.05 *** 
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Table 3.2: Summary of the change in relative mRNA expression levels of 
key drug transporters in rat PTCs cultured on Transwell® inserts and 
plastic cultureware compared to freshly isolated rat PTCs.  
mRNA expression levels are expressed as percentage expression 
relative to freshly isolated rat PTCs. The data show that expression of 
all key renal transporters was significantly lower in cultured cells. The 
expression levels had been normalised to reference gene Gapdh 
expression level prior to comparison. The results are expressed as 
the mean ± SEM from 3 separate batches of RNA derived from 3 
individual kidneys. One-way ANOVA statistical test was performed on 
the data set to determine significance, * P < 0.05, ** P < 0.01, *** P < 
0.001.  
Transporter 
% expression compared to fresh rat PTCs (Mean ± SEM) 
Transwell® Plastic 
Oat1 24.97 ± 7.51 *** 16.50 ± 4.93 *** 
Urat1 19.05 ± 6.20 ** 25.17 ± 4.53 ** 
Oatp4c1 22.81 ± 10.68 ** 12.46 ± 7.57 ** 
Oct2 36.98 ± 17.71 ** 27.68 ± 16.88 ** 
Bcrp 24.98 ± 8.50 ** 20.23 ± 6.32 ** 
Mate1 28.09 ± 6.00 ** 18.93 ± 9.44 ** 
Mdr1 72.81 ± 5.39 * 60.25 ± 7.07 * 
Mrp2 37.71 ± 4.30 ** 21.19 ± 10.33 ** 
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Figure 3.26: Characterisation of proximal and non-proximal tubular drug 
transporter expression using the human drug transporter RT2 Profiler PCR 
array.  
The human drug transporter RT2 profiler PCR array was used to 
characterise drug transporter gene expression in freshly isolated 
human PTCs and human PTCs cultured for 7 days on plastic. The 
data shows a fall in drug transporter expression in cell culture on 
plastic. Fresh human PTCs showed high expression of OAT1 (0.228) 
and OCT2 (0.289). OAT2 (0.009), OAT3 (0.074), OATP1A2 (0.022), 
OCT3 (0.029), BCRP (0.030), MDR1 (0.071), MRP1 (0.028), MRP2, 
(0.029), MRP3 (0.025), MRP4 (0.091), MRP5 (0.027), MRP6 (0.025) 
were expressed at lower levels. The expression of non-proximal 
markers was also assessed to determine cell contamination. 
Expression of V-ATPase (0.009), a marker of collecting duct cells, 
and MCT8 (0.006), a marker of loop of Henle and distal tubular cells 
was very low. Human PTCs cultured for 7 days on plastic showed low 
expression of OCT2 (0.009), MDR1 (0.004), MRP1 (0.007), MRP3 
(0.010), MRP4 (0.011) and MRP5 (0.002). Expression of the non-
proximal tubule cell markers V-ATPase (0.001) and MCT8 (0.001) was 
minimal. Drug transporters of interest absent from the PCR array 
panel include OAT4, URAT1, OATP4C1, MATE1 and MATE2-K. The 
expression levels had been normalised to the reference gene, GAPDH, 
prior to comparison. The results are representative of a single batch 
of RNA derived from a single individual. 
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Figure 3.27: Characterisation of proximal and non-proximal tubular drug 
transporter expression using the rat drug transporter RT2 Profiler PCR 
array. 
The rat drug transporter RT2 profiler PCR array was used to 
characterise drug transporter gene expression in freshly isolated rat 
PTCs and rat PTCs cultured for 7 days on plastic. The data shows a 
fall in drug transporter expression in cell culture on plastic. Fresh rat 
PTCs showed high expression of Oat3 (0.224) and Oct1 (0.356). Oat1 
(0.010), Oat2 (0.052), Oct2 (0.066), Bcrp (0.054), Mdr1b (0.002), 
Mrp1 (0.013), Mrp2, (0.013), Mrp3 (0.003), Mrp4 (0.026), Mrp5 
(0.002), Mrp6 (0.003) were expressed at lower levels. The expression 
of non-proximal markers was also assessed to determine cell 
contamination. Expression of V-ATPase (0.005) and Mct8 (0.009) was 
very low. Rat PTCs cultured for 7 days on plastic showed low 
expression of Bcrp (0.007), Mdr1b (0.005), Mrp1 (0.013), Mrp4 (0.001) 
and Mrp5 (0.002). Expression of the non-proximal tubule cell markers 
V-ATPase (0.002) and Mct8 (0.001) was minimal. Drug transporters of 
interest absent from the PCR array panel include Oat4, Urat1, 
Oatp4c1, Oatp1a isoforms, and Mate1. The expression level had been 
normalised to the reference gene, ß-actin, prior to comparison, as 
Gapdh was not included on the PCR array panel. The results are 
representative of a single batch of RNA derived from a single 
individual. 
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3.4. Discussion 
The proximal tubule plays a pivotal role in the renal clearance of xenobiotic and 
endogenous metabolites. The uptake and efflux of molecules across the cell 
membrane of proximal tubule epithelial cells are achieved by the polar 
distribution of transport proteins to either the basolateral or apical membrane. 
From a molecular approach, a good understanding of the substrate profiles of 
the transporters expressed in the proximal tubule has been obtained, but we 
have little knowledge of the contribution of individual transporters or how 
transporters integrate to produce an efficient secretory or absorptive 
mechanism. A holistic model of the proximal tubule epithelial is needed to 
address this problem.  
Many pre-clinical models of transport in the kidney are based on transfected or 
animal cells, which express a limited number of human renal transporters and 
consequently are not accurate models. In contrast, primary renal proximal 
tubule cells retain the full complement of key renal transporters. This makes 
them a more physiologically relevant and therefore predictive model of renal 
handling. Species differences in the properties and expression patterns of renal 
transporters are making data derived from animal studies difficult to extrapolate 
to humans. This highlights the importance of conducting parallel studies using 
primary human and rat models of the proximal tubule. In this chapter, a 
previously published method of isolating primary human proximal tubule cells 
was optimised, and was also adapted to isolate rat proximal tubule cells.  
Samples of renal cortex tissue were enzymatically digested with collagenase 
into a single cell suspension. The cell suspension was then divided in to the 
constituent cell types by sieving and Percoll density gradient centrifugation. In 
order to optimise the enzymatic digestion of the renal cortex, chopped samples 
(approximately 1 mm3) were incubated overnight or acutely with different 
concentrations of collagenase and the yield of isolated PTCs was compared. In 
both species, higher concentrations of collagenase resulted in greater 
enzymatic digestion of renal cortex, and naturally larger yields of PTCs. As 
shown in Figure 3.1 and Figure 3.2, the incubation period had no significant 
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effect on the cell yield when using 20, 25, or 30 mg collagenase per g of renal 
cortex. 
An issue of enzymatic digestion of renal cortex is that the enzyme mixtures 
contain protease enzymes that can be detrimental to cell viability at high 
concentrations (Boogaard et al., 1990; Cummings et al., 2000). In order to 
evaluate the effect of collagenase concentration upon cell health, growth assays 
were conducted on the isolated cells. The numbers of cells per cm2 over an 8-
day period of cell culture were quantified. As shown in Figure 3.3, human PTC 
growth was significantly greater when cells were incubated with 25 mg of 
collagenase per g of tissue. No significant difference was found in cell viability 
human PTC at day 8 of culture following an overnight or acute incubation with 
the same concentration of collagenase (P > 0.05). As a result of these findings, 
samples of human renal cortex were incubated with 25 mg of collagenase per g 
of renal cortex in the enzymatic digestion phase of human PTC isolation, 
despite 30 mg of collagenase per g of renal cortex producing a greater yield of 
cells. This concentration provides a good compromise on cell yield and viability, 
with the latter being crucial for downstream experiments. As the incubation 
period of the tissue with collagenase appeared to have no effect upon cell 
growth, convenience dictated the period of exposure of the human tissue to 
collagenase. Rat renal cortex tissues, on the other hand, were incubated with 
25 mg of collagenase per g of tissue and incubated overnight in this project. 
This is because when rat PTC numbers in Figure 3.4 at day 8 of culture 
following an overnight or acute incubation were compared, the former produced 
significantly greater number of viable cells rat PTC (P < 0.001).  
A limitation of this proximal tubule isolation technique is that the isolated cells 
are a mixture of proximal and distal tubular cells. Our research group has 
previously cultured and characterised transporter expression of pure human 
proximal and distal tubular / collecting duct cell monolayers (Brown et al., 2008). 
qPCR and immunohistochemistry studies of drug transporter expression found 
that pure cultures of distal tubule / collecting duct cells lack expression of key 
drug transport proteins and thus are effectively ‘silent’ in these co-cultures of 
proximal and distal tubular cells. In addition, pure proximal tubular cell 
monolayers have very low TEER values. Therefore, to improve cell yield and 
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monolayer permeability a mixture of proximal and distal tubule cells was used 
rather than a pure culture of proximal tubule cells. A further constraint is that 
this isolation technique is not efficient enough to isolate human PTCs from 
human renal tissue samples weighing less than 2 g. A number of renal cortex 
resection samples from the nephrology unit of the Freeman hospital were 
donated to our research cause, but we were unable to obtain cells from the 
majority of these samples. As shown in Figure 3.5 and Figure 3.6, the weight of 
renal cortex was positively correlated to the number of isolated PTCs.  
Isolated primary cells were then grown on plastic cell cultureware and 
Transwell polycarbonate inserts. Growth of cells on polycarbonate inserts with 
microporous membranes has numerous advantages over solid plastic cell 
growth platforms. Permeable Transwell inserts permit cells to take up and 
secrete molecules on both their basal and apical membranes. This environment 
is a closer representation of the in-vivo environment and thus improves cell 
polarisation, transporter expression and viability (Fulcher et al., 2005). Cellular 
functions such as transport, absorption and secretion can also be studied since 
cells grown on permeable supports provide access to their apical and 
basolateral plasma membranes. 
Cell confluency on plastic cell culture ware was assessed visually using a phase 
contrast microscope throughout the culture. Due to the opacity of the 
Transwell inserts, the confluency of cells grown on 24-well Transwell inserts 
was determined by measuring the TEER of the monolayer daily with an 
epithelial voltohmmeter. TEER is a reliable, quantitative measure of barrier 
strength. In this instance, TEER was used to indicate the confluency and 
permeability of the cell monolayers. TEER values of human PTC monolayers up 
to day 10 of cell culture are shown in Figure 3.7. The findings strongly correlate 
with the human PTC cell growth curves in Figure 3.3. The lag phase of cell 
growth characterised by low growth and TEER was from day 1 to 3 of cell 
culture. After this period of acclimatisation to the new environment, cell numbers 
and TEER increased exponentially until day 6. Cell growth and resistance 
plateaued at around 210 000 human PTCs per cm2 and 120 .cm2 between 
day 6 and 8. Then cell number and TEER decreased from day 9 onwards as 
cell death began. Cell growth and TEER of rat PTCs shown in Figure 3.4 and 
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Figure 3.8 showed very similar trends. Cell growth and TEER plateaued at 230 
000 rat PTCs per cm2 and 110 .cm2 from day 6 to 7 of cell culture.  
In order to determine the efficiency of TEER as a measure of epithelial cell 
monolayer permeability, the correlation between TEER and paracellular flux of 
radiolabelled [1-14C]-mannitol D was studied. Figure 3.10 and Figure 3.11 show 
an inverse relationship between the two. As human PTC and rat PTC 
monolayer TEER increased, the paracellular movement of mannitol decreased 
until it reached a plateau of 12.89  8.29 pmol / hr / cm2 and 7.24  11.05 pmol / 
hr / cm2 respectively. In both primary cell culture models there was a mannitol 
flux of 30 pmol / hr / cm2 or less when monolayer TEER was greater than 80 
.cm2, which equates to a mannitol paracellular flux of less than 0.01% of the 
total amount of mannitol used. These results indicate confluent monolayer 
formation, high tight junction integrity and low paracellular permeability. As a 
consequence of these findings, only monolayers with a TEER greater than 80 
.cm2 were used in transporter absorption and secretion studies.  
The mRNA expression levels of several transporters following incubation on two 
different cell cultureware materials were analysed by qPCR. Human and rat 
PTCs cultured on Transwell® inserts and plastic were compared to freshly 
isolated PTCs. The freshly isolated cells were considered to be representative 
of the native proximal tubule in-vivo. The findings shown in Table 3.1 and Table 
3.2 show that human and rat PTCs cultured on both Transwell® inserts and 
plastic maintained expression of all the key renal transport proteins investigated. 
Including the basolateral uptake transporters OAT1/Oat1, OAT3, and 
OCT2/Oct2 commonly absent from immortalised renal epithelial cell lines 
(Gstraunthaler et al., 1985; Pfaller and Gstraunthaler, 1998; Jenkinson et al., 
2012; Jansen et al., 2014). Although there was a significant fall in the 
expression of most transporters in comparison to freshly isolated cells the 
expression levels are substantially higher than those seen in any previous in-
vitro kidney model. Comparison of mRNA drug transporter expression in human 
and rat PTCs using drug transporter RT2 profiler array plates in Figure 3.26 and 
Figure 3.27 showed little expression of non-proximal tubular cell markers. This 
suggests that proximal tubular cells perdominate the human and rat PTC cell 
populations.  
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A limitation of using primary cell cultures is the finite lifespan of the isolated cells. 
As our results have shown, renal primary cells have a short life span, cell death 
occurred from day 9 onwards regardless of nutrient availability. A number of 
preservation techniques were attempted unsuccessfully. For instance, cells 
were subcultured once confluency was reached. However, many subcultured 
cells were unable to adhere to the culture vessel, and attached cells failed to 
proliferate. Isolated proximal-distal cells were also cryopreserved. 
Cryopreservation involved suspending cells in serum rich medium containing 
DMSO as a cryoprotectant, then cooling cells to -135 C. However, upon 
thawing, the primary cells also failed to attach to the cell culture vessel. 
Due to the difficulties of primary cell preservation, primary proximal tubule cells 
have been immortalised. There are several publications in the literature that 
highlights the advantages of using the immortalised cells. A good example is 
that of the renal proximal tubule epithelial cells transfected with TERT1 
(RPTEC). However, contradictory to some of the publications, RPTEC 
monolayers exhibited very low TEER values (Figure 3.9), when compared to 
human or rat PTCs (Wieser et al., 2008) and high paracellular permeability 
(Figure 3.12) making if difficult to perform transepithelial studies with this cell 
line. Furthermore, the cells appear to lose differentiation. mRNA expression of 
key renal transport proteins were analysed in RPTEC cells. Expression relative 
to freshly isolated human PTCs is shown in Table 3.1. Transporter mRNA 
expression in RPTEC was very low in comparison to freshly isolated cells. In all 
these findings suggest that this cell line may not be a suitable in-vitro model of 
the proximal tubule in this instance. 
3.5. Summary 
Primary cultures of human and rat PTCs were successfully isolated. The 
enzymatic digestion phase of the isolation procedure was optimised to improve 
cell viability. When grown on Transwell® inserts the primary cultures formed 
confluent monolayers of good tight junction integrity and low paracellular 
permeability. When mRNA expression of transporters following culture on 
Transwell® inserts and plastic were compared, human PTCs cultured on 
Transwell® inserts showed greater expression of many transporters. However, 
 109 
 
there was a significant fall in the mRNA expression of most transporters in 
cultured cells comparison to freshly isolated cells. In comparison, the 
immortalised human proximal tubule epithelial cell line, RPTEC, failed to form a 
monolayer with low paracellular permeability and transporter mRNA expression 
was very low in comparison to freshly isolated cells. Suggesting that primary 
PTCs are a better in-vitro cell model of the proximal tubule for safety 
pharmacology studies.  
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4. TFV handling by PTCs 
4.1. Background 
The previous chapter characterised transporter mRNA expression in human 
and rat primary PTC monolayers, this chapter expands on this to demonstrate 
the utility of human and rat PTC monolayers as predictive in-vitro models of 
proximal tubule drug handling with a focus on the proximal tubule handling of 
TFV. Pharmacokinetic in-vivo studies in animals and man had previously shown 
that the elimination of TFV is a combination of glomerular filtration and tubular 
secretion (Shaw et al., 1997; Kearney et al., 2004). As such, this molecule was 
an ideal candidate for use in demonstrating the models as suitable screening 
platforms for drug transporter and DDI studies by investigating the renal 
handling of TFV. 
TFV is widely prescribed as part of a combination therapy for the treatment of 
human immunodeficiency 1 (HIV-1) infection in patients 10 years of age and 
older, and chronic hepatitis B virus (HBV) infection in patients 12 years of age 
and older (Gilead Sciences, 2015). TFV alone has poor oral bioavailability, due 
to a negatively charged phosphonate moiety. In order to improve bioavailability 
it is administered as a pro-drug formulation named tenofovir disoproxil fumarate 
(TDF, Viread). In the pro-drug form the two negative charges of the TFV 
phosphonic group are masked by isopropyloxycarbonyloxymethyl moieties, 
which increase the lipophilicity of the compound and thus its permeation across 
membranes (van Gelder et al., 2002). The chemical structure of these 
molecules can be seen in Figure 4.1. 
The enzymatic activation of TDF into its active component is shown in Figure 
4.1. TDF is rapidly converted to TFV in the intestine and systemic circulation 
through esterase hydrolysis (van Gelder et al., 2002). TFV is then di-
phosphorylated by adenylate kinase and nucleoside diphosphate kinase to form 
the active metabolite TFV diphosphate (TFVpp) (Merta et al., 1992; De Clercq 
and Holy, 2005). TFVpp inhibits the activity of HIV reverse transcriptase by 
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competing with the natural substrate deoxyadenosine 5’-triphosphate. The 
incorporation of a molecule of TFVpp at the 3’ end causes replication of the viral 
DNA to cease. TFV can be activated in both living and resting cells to TFVpp 
(Robbins et al., 1998). TFVpp inhibits HIV replication in macrophages and other 
non-dividing cells (Kearney et al., 2004). TFVpp is also a weak inhibitor of 
mammalian DNA polymerases α, β, and mitochondrial DNA polymerase γ 
(Birkus et al., 2002). 
The pharmacokinetics of TDF are dose-proportional, and similar in healthy 
individuals and HIV-1 infected patients. The oral bioavailability of TFV from TDF 
is approximately 25 %. Following oral administration of a single 300 mg dose to 
fasted HIV-1 patients, maximum serum concentrations (Cmax) are achieved in 
1.0  0.4 hrs. Cmax and area under the curve (AUC) values are 0.3  0.1 g/mL 
and 2.29  0.69 g.h.mL, respectively. Following the achievement of Cmax, TFV 
concentration decline in a biphasic manner, with an apparent elimination half-
life of 17 hrs. TFV Cmax and AUC are dose-proportional over a dose range of 75 
to 600 mg and unaffected by repeated dosing. In-vitro binding studies found that 
binding of TFV to human plasma or serum proteins is less than 0.7 and 7.2%, 
respectively, over the TFV concentration range of 0.01 to 0.25 g/mL. The 
volume of distribution at steady state is 1.3  0.6 L/kg. In-vitro and in-vivo 
studies indicate that neither TFV nor TDF are substrates, inducers or inhibitors 
of cytochrome P450 enzymes. Following steady-state dosing, 32  10 % of the 
administered dose is recovered in urine over 24 hrs. Studies have shown that 
the pharmacokinetics of TDF are unaltered by most other antiretroviral agents 
or by concomitant medications that are frequently prescribed to the HIV-1 
infected population. Although clinically important pharmacokinetic interactions 
do occur with didanosine and atazanavir, adjustment of the dosages of these 
agents can readily be accomplished using commercially available dosage forms. 
In HIV-1 infected patients with renal impairment, adjustment of the TDF is 
warranted and accomplished by extension of the dosage interval. This clinical 
pharmacology data has been published by the department of pharmacology and 
pharmacokinetics at Gilead Sciences, Inc (Kearney et al., 2004; Gilead 
Sciences, 2015). 
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Figure 4.1: The enzymatic activation of TDF into its active component, 
TFVpp. 
Figure created using ChemDraw. 
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Post-marketing safety data covering 455 392 patient years of TDF exposure 
showed renal serious adverse events (acute/chronic renal failure, Fanconi 
syndrome) in only 0.5 % of patients and graded elevations in serum creatinine 
in 2.2 % of patients (Nelson et al., 2007; Herlitz et al., 2010; Fernandez-
Fernandez et al., 2011). Reports of proximal tubule dysfunction, Fanconi 
syndrome and acute kidney injury associated with TDF have been published in 
multiple individual case reports and case series. Retrospective histological and 
ultrastructural studies conducted in renal biopsies have demonstrated a 
distinctive pattern of proximal tubule injury characterised by severe 
mitochondrial damage, supporting a mechanism of drug induced-mitochondrial 
toxicity (Cote et al., 2006; Kohler et al., 2009; Herlitz et al., 2010; Perazella, 
2010). Pathology studies indicate that the accumulation of TFV within proximal 
tubule cells results in host cell toxicity (Kohler et al., 2009; Fernandez-
Fernandez et al., 2011; Kohler et al., 2011). At high intracellular concentrations 
TFV inhibits mitochondrial DNA polymerase  (Martin et al., 1994; Birkus et al., 
2002; Fernandez-Fernandez et al., 2011). As a result, a number of the encoded 
enzymes involved in the electron transport chain and oxidative phosphorylation 
become depleted, resulting in disturbed mitochondrial cell function, a deficit in 
ATP production, impaired cell function, cell injury and apoptosis. This in turn 
leads to proximal tubular cell death, and endogenous metabolites such as 
glucose, amino acids, uric acid, phosphate and bicarbonate are passed into the 
urine instead of being reabsorbed. These manifest as polyuria, glycosuria, 
proteinuria, hyperuricosuria, hypophosphatemia, osteomalacia, hypokalemia 
and acidosis in patients. TFV discontinuation has been associated with 
significant renal recovery, however, many patients may suffer from chronic 
kidney disease (Herlitz et al., 2010). 
The literature proposes the uptake of TFV from the basolateral circulation into 
epithelial proximal tubule cells is predominantly mediated by OAT1 with minor 
contribution from OAT3 (Cihlar et al., 1999; Cihlar and Ho, 2000; Ho et al., 
2000; Cihlar et al., 2001; Cihlar et al., 2007; Uwai et al., 2007; Mandikova et al., 
2013). TFV is then effluxed into the urine through apical transporters MRP2 and 
MRP4 (Schuetz et al., 1999; Izzedine et al., 2006; Cihlar et al., 2007; Imaoka et 
al., 2007; Uwai et al., 2007; Mandikova et al., 2013). However, a critique of the 
current proposition is that these studies were performed in poor renal 
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experimental models. Heterologous expression of individual renal transporters 
in expression systems and transfected cells have given crucial information 
about substrate specificities and the potential for DDIs at the level of an 
individual transport system. However, there are no studies in physiologically 
relevant intact cell models to investigate how a plethora of individual 
transporters combine and integrate to form an efficient secretory pathway. In 
addition to investigating the renal handling of TFV by primary models, the 
results from this study may also elucidate the mechanism behind TFV 
accumlation within the proximal tubules, and validate the use of the models in 
drug development studies. 
4.2. Aims 
The aim of this chapter was to demonstrate the utility of human and rat PTC 
monolayers as predictive in-vitro models of proximal tubule drug handling, using 
TFV as a model substrate.  
Firstly, the uptake and flux of [3H]-TFV in human PTC and rat PTC monolayers 
over time were studied to select a suitable time point to conduct transport 
experiments under initial rate conditions. Once a time point had been selected, 
the unidirectional transepithelial fluxes of [3H]-TFV were measured in the 
secretory and absorptive direction across paired human and rat PTC 
monolayers. Uptake of [3H]-TFV across the basolateral and apical membrane of 
human and rat PTC monolayers were also measured. Kinetics parameters such 
as the maximum rate of [3H]-TFV uptake (Vmax) and the affinity of [3H]-TFV for 
PTC uptake transporters (Km) were determined in both models. Then to identify 
the transporters responsible for the uptake of TFV across the basolateral 
membrane, the secretory flux and uptake of [3H]-TFV were measured in the 
presence of various competitive substrates of basolateral uptake transport. 
Similarly, the transporters responsible for the efflux of TFV across the apical 
membrane were characterised by measuring the secretory flux and intracellular 
accumulation of [3H]-TFV in the presence of various competitive substrates of 
apical efflux transport proteins. 
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4.3. Results 
4.3.1. Flux and uptake of TFV by human PTC monolayers over time. 
In order to ensure the renal handling of TFV was measured under initial rate 
conditions, the rate of TFV unidirectional fluxes and uptake over time were 
studied. The secretory and absorptive fluxes of 10 M [3H]-TFV across human 
PTC monolayers following 20, 40, and 60 min of exposure were measured. 
Additionally, the uptake of [3H]-TFV across the basolateral membrane of human 
PTC monolayers was measured at 15, 30, 45, 60, and 90 min of exposure. 
Figure 4.2 shows the secretory, absorptive and net fluxes of [3H]-TFV increased 
linearly between the defined time-points (n = 9, N = 3). Correspondingly, the 
uptake of [3H]-TFV increased linearly between 0 and 90 min, with a gradient of 
0.50  0.01 pmol / cm2 / min (n = 9, N = 3), as shown in Figure 4.3. We can thus 
deduce that 0 to 90 min lies within the linear rate of TFV transport, and 
subsequent experiments of TFV renal handling were performed within the 60-
min time point. The non-specific binding of [3H]-TFV to the Transwell insert 
was also found to be 0.96  0.11 pmol / cm2, which was considered to be 
negligible.  
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Figure 4.2: Time course of unidirectional fluxes of 10 M [3H]-TFV across 
human PTC monolayers.  
The fluxes of 10 M [3H]-TFV across human PTC monolayers over the 
defined periods of time are shown. The fluxes of [3H]-TFV were within 
the initial rate period between 0 and 60 min as secretory, absorptive 
and net fluxes were linear over this time period. The results are 
expressed as the mean ± SEM from 9 human PTC monolayers derived 
from 3 individual kidneys.  
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Figure 4.3: Time course of 10 M [3H]-TFV uptake across the basolateral 
membrane of human PTC monolayers.  
The basolateral membranes of the monolayers were incubated with 10 
μM [3H]-TFV for 0, 15, 30, 45, 60 or 90 min. The rate of uptake of 
[3H]-TFV was linear within the time period investigated. Linear 
regression analysis of the data gave a slope of 0.50  0.01 pmol / cm2 
/ min (R2: 0.96). The non-specific binding of [3H]-TFV to the 
Transwell insert was 0.96  0.11 pmol / cm2. The results are 
expressed as the mean ± SEM from 9 human PTC monolayers derived 
from 3 individual kidneys.  
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4.3.2. Flux and uptake of TFV by human PTC monolayers. 
Unidirectional transepithelial fluxes of 10 M [3H]-TFV over 60 min in both the 
secretory (JB-A) and absorptive (JA-B) direction were studied in the human PTC 
monolayer model. The net flux (Jnet) was calculated from the difference between 
the two fluxes. Uptake of TFV across the basolateral or apical membranes were 
also determined by assaying the amount of intracellular [3H]-TFV accumulated 
within the human PTC monolayers at the end of the experiment.  
Figure 4.4 shows a net absorption of TFV (50.69  1.35 pmol / hr / cm2) across 
human PTC monolayers. The absorptive movement of [3H]-TFV (131.16  2.15 
pmol / hr / cm2) was 1.63-fold greater than the secretory movement of [3H]-TFV 
(80.47 ± 1.00 pmol / hr / cm2) (**** P < 0.0001, n = 9, N = 3). Figure 4.5 shows 
the intracellular concentration of [3H]-TFV, which was representative of [3H]-TFV 
uptake across the basolateral or apical membranes of the human PTC 
monolayers. [3H]-TFV uptake across the basolateral and apical membrane were 
39.09 ± 1.31 pmol / hr / cm2 and 6.67 ± 0.46 pmol / hr / cm2, respectively; 
uptake across the basolateral membrane was 5.86-fold greater than across the 
apical membrane (**** P < 0.0001, n = 9, N = 3). When cellular uptake was 
expressed as cell-to-medium ratio, see calculation below, the findings indicated 
a cell to media ratio greater than 1. Implying TFV is accumulated into the 
proximal tubule cells across the basolateral membrane. 
The cell-to-medium ratio was calculated by dividing the intracellular 
concentration of TFV (µM) by the concentration of test compound in the 
transport medium (µM). Assumptions made in this calculation are the height of a 
proximal tubule epithelial cell is 10 microns i.e. 0.001 cm as measured by 
transmission electron microscopy (Dorup and Maunsbach, 1997), cell 
monolayers form a cylinder, and intracellular space does not contain subcellular 
compartments. These assumptions give ratios which probably substantially 
underestimate the true accumulation  
Volume occupied by a monolayer per 24-well Transwell® insert (surface area 
0.33 cm2) = π.radius2.height 
If radius = 0.32 cm, and height = 0.001 cm,  
Volume (per 0.33cm3)= 0.00032 cm3 = 0.332 µL 
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Volume (per cm3) = 0.332 µL x 3 = 0.996 µL 
TFV concentration per cm3 = 39.09 pmol / cm3 
Intracellular concentration of TFV = 39.09 pmol / 0.996 µL i.e. 39.25 µM 
Extracellular concentration of TFV = 10 µM 
Cell-to-medium ratio = 39.25 µM ÷ 10 µM = 3.93 
 
 
Figure 4.4: Unidirectional fluxes of 10 M [3H]-TFV by human PTC 
monolayers. 
In order to determine the secretory and absorptive fluxes of TFV 
through human PTC monolayers, paired monolayers were incubated 
with 10 μM [3H]-TFV at either the basolateral or apical chamber. 
Buffer samples were collected from the opposing chambers after a 60 
min incubation period. The amount of [3H]-TFV in each sample was 
measured using scintillation counting. The results show a net 
absorptive flux (50.69 ± 1.35 pmol / hr / cm2). The absorptive 
movement of [3H]-TFV (131.16 ± 2.15 pmol / hr / cm2) was 1.63-times 
greater than the secretory movement (80.47 ± 1.00 pmol / hr / cm2) 
(**** P < 0.0001). The results are expressed as the mean ± SEM from 
9 human PTC monolayers derived from 3 individual kidneys. 
Significance was determined by a Student’s t-test. 
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Figure 4.5: Uptake of 10 M [3H]-TFV across the basolateral and apical 
membrane of human PTC monolayers.  
Paired monolayers were incubated with 10 μM [3H]-TFV at either the 
basolateral or apical chamber for 60 min. The data show that the 
uptake of [3H]-TFV across the basolateral membrane (39.09 ± 1.31 
pmol / hr / cm2) was 5.86-times greater than across the apical 
membrane (6.67 ± 0.46 pmol / hr / cm2) (**** P < 0.0001). The results 
are expressed as the mean ± SEM from 9 human PTC monolayers 
derived from 3 individual kidneys. Significance was determined by a 
Student’s t-test. 
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4.3.3. The effect of pH upon TFV renal handling. 
In order to ascertain if pH had an effect upon TFV renal handling, the 
unidirectional fluxes and uptake of [3H]-TFV by human PTC monolayers at pH 
6.80 and 7.40 were compared. The results in Figure 4.6 show pH had no effect 
upon the secretory, absorptive and thus net movement of [3H]-TFV across 
human PTC monolayers (P > 0.05, n = 9, N = 3). In accordance with these 
findings, the data in Figure 4.7 show pH had no effect upon the uptake of [3H]-
TFV across the basolateral and apical membrane of human PTC monolayers 
(P > 0.05, n = 9, N = 3). 
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Figure 4.6: Unidirectional fluxes of 10 M [3H]-TFV at pH 6.80 and 7.40 by 
human PTC monolayers.  
The effects of extracellular pH upon the secretory and absorptive 
fluxes of TFV by human primary tubular cells were investigated. The 
results show no significant difference in the secretory flux; 82.83  
0.88 pmol / hr / cm2 at pH 6.80 versus 80.47 ± 1.09 pmol / hr / cm2 at 
pH 7.40. Absorptive fluxes of [3H]-TFV at pH 6.8 (130.38  1.79 pmol / 
hr / cm2) and at pH 7.4 (131.16 ± 2.15 pmol / hr / cm2) were also not 
significantly different. The results are expressed as the mean ± SEM 
from 9 human PTC monolayers derived from 3 individual kidneys. 
Significance was determined by a Student’s t-test. 
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Figure 4.7: Uptake of 10 M [3H]-TFV across the basolateral and apical 
membrane of human PTC monolayers at pH 6.80 and 7.40. 
The effect of extracellular pH upon the uptake of TFV across the 
basolateral and apical membrane of human PTC monolayers were 
investigated. The results show uptake of [3H]-TFV across the 
basolateral and apical membrane were not affected by extracellular 
pH. Uptake of [3H]-TFV across the basolateral membrane at pH 6.80 
was 39.27  1.48 pmol / hr / cm2 compared with 39.09 ± 1.31 pmol / hr 
/ cm2 at pH 7.40, and uptake of [3H]-TFV across the apical membrane 
at pH 6.80 was 5.78  0.27 pmol / hr / cm2 compared with 6.67 ± 0.46 
pmol / hr / cm2. The results are expressed as the mean ± SEM from 9 
human PTC monolayers derived from 3 individual kidneys. 
Significance was determined by a Student’s t-test. 
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4.3.4. Kinetics of TFV transport by human PTC monolayers. 
The kinetic parameters of TFV transport by human PTC monolayers were 
calculated. Human PTC monolayers were incubated at the basolateral 
membrane with various concentrations of [3H]-TFV (1 to 5000 M) for 60 min 
and the intracellular accumulation of [3H]-TFV was measured. Figure 4.8 shows 
the relationship between [3H]-TFV concentration and uptake of [3H]-TFV across 
the basolateral membrane of human PTC monolayers (n = 9, N = 3). Non-linear 
regression analysis of the data gave a Vmax of 1214.11  134.57 pmol / hr / cm2 
and an apparent Km value of 756.86  166.48 M. 
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Figure 4.8: Kinetic data on [3H]-TFV uptake across the basolateral 
membrane of human PTC monolayers under initial rate conditions.  
In order to obtain kinetic data on TFV uptake under initial rate 
conditions, the monolayers were incubated with a range of [3H]-TFV 
concentrations (1 to 5000 M) for 60 min. Non-linear regression 
analysis of the data gave a Vmax of 1214.11  134.57 pmol / hr / cm2 
and an apparent Km value of 756.86  166.48 M. The results are 
expressed as the mean ± SEM from 9 human PTC monolayers derived 
from 3 individual kidneys. 
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4.3.5. Identifying the transporters mediating the uptake of TFV 
across the basolateral membrane of human PTC monolayers. 
The contributions of various uptake transport proteins in the tubular handling of 
TFV were quantified by measuring unidirectional fluxes and uptake of 10 M 
[3H]-TFV in the presence and absence of various competitive substrates of 
uptake transport proteins. A schematic of this technique is shown in Figure 4.9. 
The inhibitors were added at concentrations that would as selectively as 
possible inhibit the activity of transporters that were expected to be involved in 
the uptake of TFV. Table 4.1 shows the competitive substrates and their affinity 
values (Km) for the corresponding transporter(s).  
The effect of competitive substrates on the secretory and absorptive fluxes of 
[3H]-TFV by human PTC monolayers is shown in Figure 4.10 (n = 9, N = 3). The 
presence of 50 µM PAH, an OAT1 and OAT3 substrate, reduced [3H]-TFV 
secretory flux by 27.64 ± 1.69 % of control (**** P < 0.0001), whilst the presence 
of the OAT3 substrate rosuvastatin (RSV, 20 µM) had no significant effect (P > 
0.05). The presence of the OATP4C1 substrates triiodothyronine (T3, 10µM) 
and chenodeoxycholic acid (CDC, 10µM) also resulted in a marked decrease in 
[3H]-TFV secretory flux (69.26 ± 1.33 % **** P < 0.0001 and 74.34 ± 0.99 % **** 
P < 0.0001, respectively). The presence of the competitive substrates had no 
effect on absorptive flux (P > 0.05).  
Figure 4.11 shows the effect of competitive substrates on the uptake of [3H]-
TFV across the basolateral and apical membrane of human PTC monolayers (n 
= 9, N = 3). The presence of 50 µM PAH reduced [3H]-TFV uptake across the 
basolateral membrane by 23.11 ± 1.10 % of control (**** P < 0.0001), whilst 20 
µM RSV had no effect (P > 0.05). The presence 10 µM T3 and 10 µM CDC 
decreased basolateral [3H]-TFV uptake by 74.47 ± 1.90 % of control (**** P < 
0.0001) and 81.92 ± 2.07 % (**** P < 0.0001), respectively. The presence of the 
competitive substrates had no effect on apical uptake of TFV. In agreement with 
the flux experimental data, these results suggest both OATP4C1 and OAT1 
mediate the initial uptake of TFV across the basolateral membrane in TFV renal 
secretion.  
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A substantial role for OATP4C1 in the basolateral uptake of TFV had not 
previously been reported. In order to determine if the apparent important role for 
OATP4C1 resulted from a loss of OAT1 and OAT3 expression and function as 
the cells were maintained in culture, the inhibition study was repeated in freshly 
isolated human PTCs. The results are shown in Figure 4.12 (n = 9, N = 3). In 
corroboration with the previous findings, 50 µM PAH, 10 µM T3 and 10 µM CDC 
reduced TFV uptake by 18.16 ± 0.84 % (**** P < 0.0001), 57.25 ± 2.19 % (**** P 
< 0.0001) and 44.64 ± 2.02 % of control (**** P < 0.0001), respectively. 
Additionally , a role of OCTs in the basolateral uptake of TFV was ruled out as 
the presence of 1.5 mM cimetidine (CIM, OCT2 substrate) had no effect on the 
uptake of [3H]-TFV across the basolateral membrane of human PTC cells. 
In Figure 4.13 the uptake of [3H]-TFV in (a) fresh and (b) cultured human PTC 
monolayers is compared. The results are normalised to uptake per 300 000 
cells. The data show that uptake of 10 M [3H]-TFV in the cells cultured for 7-
days on Transwell inserts was around 20% of that in freshly isolated cells 
(19.81  0.79 pmol / hr / 300 000 cells v 89.35  2.30 pmol / hr / 300 000 cells). 
The presence of 50 µM PAH reduced [3H]-TFV accumulation by 18.16  0.84 % 
in freshly isolated cells and 23.11  1.10 % in cultured cells, which suggests a 
similar contribution of OATs. In contrast, the presence of 10 µM T3 and CDC 
reduced [3H]-TFV uptake by 57.25  2.19 % and 44.64  2.02 % in freshly 
isolated cells, respectively, and by 74.47  1.90 % and 81.92  2.07 % in 
cultured cells, respectively. 
The identification of OATP4C1 as a transporter of TFV is novel. This important 
discovery can be used to identify potentially toxic DDIs.  
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Figure 4.9: Substrate inhibition scheme to determine the contributions of 
OAT1, OAT3, OATP4C1 and OCT2 to TFV uptake and flux in human and rat 
PTC monolayers. 
 
 
Table 4.1: Competitive substrates used to identify transporters mediating 
the uptake of TFV.  
Listed are competitive substrate of hOAT1, hOAT3 and hOATP4C1. 
The apparent affinity (Km) values of the substrates for transporters are 
shown.  
  
Substrate Transporter System Km (M) Reference 
PAH hOAT1 X.Laevis oocytes 9.3  1.0 (Hosoyamada et 
al., 1999) 
PAH hOAT3 X.Laevis oocytes 87.2  11.1 (Cha et al., 2001) 
RSV hOAT3 X.Laevis oocytes 7.4  2.5 (Windass et al., 
2007) 
T3 hOATP4C1 MDCK 5.9  2.1 (Mikkaichi et al., 
2004) 
CDC hOATP4C1 _ _ 
(Yamaguchi et al., 
2010) 
CIM hOCT2 HEK293 72.6  13.9 (Tahara et al., 
2005) 
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Figure 4.10: Identifying the transporters mediating the uptake of TFV in 
the unidirectional fluxes of [3H]-TFV across the human PTC monolayer.  
The secretory and absorptive fluxes of 10 M [3H]-TFV were 
measured in the presence of various competitive substrates of uptake 
transport proteins. The presence of 50 µM PAH reduced [3H]-TFV 
secretory flux (27.64 ± 1.69 %, **** P < 0.0001), whilst 20 µM RSV 
had no effect. The presence of T3 (10 µM, substrate of OATP4C1) 
and CDC (10 µM, substrate of OAT1) also resulted in a marked 
decrease in [3H]-TFV tubular secretion (69.26 ± 1.33 % **** P < 
0.0001 and 74.34 ± 0.99 % **** P < 0.0001, respectively). The 
presence of the competitive substrates had no effect on absorptive 
flux. These findings suggest both OATP4C1 and OAT1 mediate the 
uptake of TFV across the basolateral membrane. The results are 
expressed as the mean ± SEM from 9 human PTC monolayers derived 
from 3 individual kidneys. Significance was determined using ANOVA 
and a Dunnett’s post-test. 
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Figure 4.11: Identifying the transporters mediating the uptake of [3H]-TFV 
in to human PTC monolayers. 
Uptake of 10 M [3H]-TFV was measured across either the apical or 
basolateral membrane in the presence of various competitive 
substrates of uptake transport proteins. The presence of 50 µM PAH 
reduced [3H]-TFV uptake across the basolateral membrane (23.11 ± 
1.10 % decrease, **** P < 0.0001), whilst 20 µM RSV had no effect. 
The presence of 10 µM T3 and CDC also resulted in a marked 
decrease in [3H]-TFV basolateral uptake (74.47 ± 1.90 % **** P < 
0.0001 and 81.92 ± 2.07 % **** P < 0.0001, respectively). The 
presence of the competitive substrates had no effect on apical uptake 
of TFV. These findings suggest both OATP4C1 and OAT1 mediate the 
basolateral uptake of TFV in the tubular secretion. The results are 
expressed as the mean ± SEM from 9 human PTC monolayers derived 
from 3 individual kidneys. Significance was determined using ANOVA 
and a Dunnett’s post-test. 
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Figure 4.12: Identifying the transporters mediating the uptake of [3H]-TFV 
in freshly isolated human PTCs. 
The presence of 1.5 mM CIM (OCT2 substrate) had no effect on 
intracellular accumulation of [3H]-TFV. 50 µM PAH reduced [3H]-TFV 
accumulation by 18.16 ± 0.84 % of control (**** P < 0.0001). The 
presence of 10 µM T3 and 10 µM CDC reduced [3H]-TFV uptake to 
57.25 ± 2.19 % (**** P < 0.0001) and 44.64 ± 2.02 % of control (**** P 
< 0.0001), respectively. These findings suggest both OATP4C1 and 
OAT1 mediate the uptake of TFV across the basolateral membrane in 
the tubular secretion of TFV in freshly isolate human PTCs. The 
results are expressed as the mean ± SEM from 9 human PTCs 
samples derived from 3 individual kidneys. Significance was 
determined using ANOVA and a Dunnett’s post-test. 
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Figure 4.13: A comparison of the uptake of [3H]-TFV in 300 000 (a) fresh 
and (b) cultured human PTC monolayers.  
The uptake of 10 M [3H]-TFV was 4.51-fold lower in the cells 
cultured for 7-days on Transwell inserts (19.81  0.79 pmol / hr / 
300 000 cells) when compared to freshly isolated cells (89.35  2.30 
pmol / hr / 300 000 cells). 50 µM PAH reduced [3H]-TFV accumulation 
by 18.16  0.84 % in freshly isolated cells and 23.11  1.10 % in 
cultured cells. 10 µM T3 reduced [3H]-TFV accumulation by 57.25  
2.19 % in freshly isolated cells and 74.47  1.90 % in cultured cells. 
10 µM CDC reduced [3H]-TFV accumulation by 44.64  2.02 % in 
freshly isolated cells and 81.92  2.07 % in cultured cells. The results 
are expressed as the mean ± SEM from 9 human PTCs samples 
derived from 3 individual kidneys. 
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4.3.6. Transport of TFV mediated by OATP4C1 
OATP4C1 is known to possess multiple substrate recognition sites. So far, two 
distinct recognition sites for DX and E3S have been characterised. The affinity 
values (Km) of these substrates for OATP4C1 are listed in  
Substrate Transporter System Km (M) Reference 
E3S hOATP4C1 MDCK 26.6  4.9 (Yamaguchi et al., 2010) 
DX hOATP4C1 MDCK 7.8  2.0 (Mikkaichi et al., 2004) 
 
Table 4.2. In order to determine if TFV binds to the same recognition site as DX 
or E3S, the basolateral uptake of 10 M [3H]-TFV across human PTC 
monolayers in the presence of various concentrations of DX and E3S (0.1 to 50 
M) were measured. 
The uptake of 10 M [3H]-TFV across the basolateral membrane of human PTC 
monolayers in the presence of various concentrations of E3S and DX are 
shown in Figure 4.14 (n = 9, N = 3). At concentrations of 1 M DX and greater, 
basolateral uptake of TFV was significantly inhibited, whilst concentrations of 10 
M E3S and greater significantly inhibited uptake. Non-linear regression 
analysis of the data suggested that DX and E3S are only able to bind one 
binding site. With apparent IC50 values of 0.38  0.10 M for DX and 1198 M 
for E3S. These findings indicate that TFV has a higher affinity for the DX 
recognition site compared with the E3S recognition site. 
Substrate Transporter System Km (M) Reference 
E3S hOATP4C1 MDCK 26.6  4.9 (Yamaguchi et al., 2010) 
DX hOATP4C1 MDCK 7.8  2.0 (Mikkaichi et al., 2004) 
 
Table 4.2: Competitive substrates used to identify which hOATP4C1 
recognition site mediates the uptake of TFV.  
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Two distinct recognition sites of hOATP4C1 have been identified 
using E3S and DX. The affinity values (Km) of these substrates for 
OATP4C1 are listed. 
 
Figure 4.14: Identifying the recognition site of OATP4C1 mediating the 
uptake of [3H]-TFV across the basolateral membrane of human PTC 
monolayers. 
To identify which substrate recognition site of OATP4C1 TFV binds, 
basolateral uptake of 10 M [3H]-TFV in the presence various 
concentrations (0.1 to 50 M) of E3S and DX was measured. DX 
inhibition of [3H]-TFV uptake was greater than E3S inhibition at each 
concentration. Non-linear regression analysis of the data suggested 
that DX and E3S are only able to bind one binding site, with apparent 
IC50 values of 0.38  0.10 M for DX and 1198 M for E3S. These 
findings indicate that TFV has a higher affinity for the DX recognition 
site compared with the E3S binding site. The results are expressed as 
the mean ± SEM from 9 human PTC monolayers derived from 3 
individual kidneys. 
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4.3.7. Identifying the transporters mediating the efflux of TFV 
across the apical membrane of human PTC monolayers. 
The contributions of various efflux transport proteins in the tubular handling of 
TFV were characterised by measuring unidirectional fluxes and intracellular 
concentrations of [3H]-TFV in the presence and absence of various inhibitors of 
apical efflux transport proteins. A schematic of this technique is shown in Figure 
4.15. The inhibitors were added at concentrations that would selectively inhibit 
the activity of transporters. Reported IC50 values for the inhibitors are shown in 
Table 4.3.  
The effect of efflux transport protein inhibitors on the secretory and absorptive 
fluxes of [3H]-TFV across human PTC monolayers are shown in Figure 4.16 (n 
= 9, N = 3). The presence of the MRP2/MRP4 inhibitor MK-571 (5 µM), BCRP 
inhibitor Ko 143 (2 µM), and MDR1 inhibitor GF120918 (5 µM) had no effect on 
the secretory and absorptive fluxes of 10 µM [3H]-TFV. Similarly, these 
compounds had no effect on the intracellular accumulation of 10 µM [3H]-TFV, 
as shown in Figure 4.17 (n = 9, N = 3). These findings imply that TFV has a low 
affinity for MRP2, MRP4, BCRP, and MDR1 under physiological conditions. 
In order to determine if the poor affinity of TFV for efflux transport proteins 
resulted from a loss of MRP2, MRP4, MDR1 or BCRP expression in culture, the 
functionality of MRPs, MDR1, and BCRP, in cultured human PTCs were 
investigated. H33342 is a fluorescent substrate of MDR1 and BCRP. Figure 
4.18 shows the presence of the BCRP inhibitor Ko 143 (2 µM) and MDR1 
inhibitor GF120918 (2 M) increased human PTC intracellular retention of 
H33342 2.11-fold (**** P < 0.0001) and 1.43-fold (**** P < 0.0001), respectively. 
The CMFDA metabolite GSMF is a fluorescent substrate of MRPs. Figure 4.19 
shows the presence of the MRP inhibitor MK-571 (5 M) increased the 
intracellular retention of GSMF 2.39-fold (**** P < 0.0001). This information 
confirms functional expression of BCRP, MDR1 and the MRP transport family in 
human PTCs. 
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Figure 4.15: Substrate inhibition scheme to determine the contributions of 
MRP2, MRP4, BCRP and MDR1 to TFV efflux and flux in human and rat 
PTC monolayers. 
 
Inhibitor Transporter System Substrate IC50 (M) Reference 
MK-571 hMRP2 Caco-2 IRT 50.0 (Luo et al., 2002) 
MK-571 hMRP4 
HEK293 
vesicles 
PMEA 10 (Reid et al., 2003) 
Ko 143 hBCRP MDCK-II PH-A 0.01 (Weiss et al., 2007)
GF120918 hBCRP HEK293 MT 0.31 
(Ahmed-Belkacem 
et al., 2005) 
GF120918 hMDR1 MDCK-II DX 0.18 
(Keogh and Kunta, 
2006) 
 
Table 4.3: Inhibitors used to characterise the efflux pathway of TFV in 
human PTC monolayers. 
Listed are inhibitors of MRP2, MRP4, BCRP and MDR1 used to 
characterise efflux transport of TFV. Reported IC50 values for the 
inhibitors are shown. Acronyms – IRT: Irinotecan, PMEA: para-
methoxyethylamphetamine, PH-A: Phenophorbide, MT: mitoxantrone 
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Figure 4.16: Identifying the transporters mediating the efflux of TFV in 
[3H]-TFV flux across the human PTC monolayer. 
Secretory and absorptive fluxes of 10 M [3H]-TFV were measured in 
the presence of various competitive substrates of apical efflux 
transport proteins. The presence of 5 µM MK-571, 2 µM Ko 143, and 2 
µM GF120918 had no effect on the secretory flux of [3H]-TFV. This 
indicates that TFV has a low affinity for MRP2, MRP4, BCRP, and 
MDR1 under physiological conditions. The presence of the 
competitive substrates also had no effect on absorptive flux. The 
results are expressed as the mean ± SEM from 9 human PTC 
monolayers derived from 3 individual kidneys Significance was 
determined using ANOVA and a Dunnett’s post-test. 
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Figure 4.17: Identifying the transporters mediating the efflux of [3H]-TFV 
from the human PTC monolayer.  
Intracellular accumulation of [3H]-TFV by the monolayers was 
measured in the presence of various competitive substrates of apical 
efflux transport proteins. The presence of 5 µM MK-571, 2 µM Ko 143, 
and 2 µM GF120918 at both the apical and basolateral membrane had 
no effect on the intracellular concentration of [3H]-TFV. This suggests 
TFV has a low affinity for MRP2, MRP4, BCRP, and MDR1 under 
physiological conditions. The results are expressed as the mean ± 
SEM from 9 human PTC monolayers derived from 3 individual kidneys. 
Significance was determined using ANOVA and a Dunnett’s post-test. 
 
Basolateral Apical
0
25
50
75
100
125
150
Membrane exposed to 10M [3H]-TFV
In
tra
ce
llu
la
r a
cc
um
ul
at
io
n 
of
 [3
H
]-T
FV
(%
)
10 µM [3H}-TFV
+ 5 µM MK-571
+ 2 µM Ko 143
+ 2 µM GF120918
 139 
 
 
Figure 4.18: Measurement of H33342 retention in human PTCs to 
demonstrate functional activity of BCRP and MDR1. 
Intracellular retention of H33342 was measured in the presence of 
various competitive substrates of apical efflux transport proteins. The 
presence of 2 M Ko143 increased the intracellular retention of 
H33342 2.11-fold (**** P < 0.0001). The presence of 2 M GF120918 
increased the intracellular retention of H33342 1.43-fold (**** P < 
0.0001). The results are expressed as the mean ± SEM from 18 
human PTC monolayers derived from 3 individual kidneys. 
Significance was determined using ANOVA and a Dunnett’s post-test. 
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Figure 4.19: Measurement of GSMF retention in human PTCs to 
demonstrate functional activity of MRP transporters.  
Intracellular retention of GSMF was measured in the presence of 
presence of 5 M MK-571. The presence of 5 M MK-571 increased 
the intracellular retention of GSMF 2.39-fold (**** P < 0.0001). The 
results are expressed as the mean ± SEM from 18 human PTC 
monolayers derived from 3 individual kidneys. Significance was 
determined by a Student’s t-test. 
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4.3.8. The effect of TFV on metabolic activity of human PTCs. 
The effect of TFV on the metabolic activity of human PTC monolayers was 
measured using the CellTiter 96 AQueous assay (MTS). Monolayers were 
incubated for 2 or 7 days with a range of concentrations (0 to 500 M) of TFV in 
the culture medium. The metabolic activity of monolayers was quantified by 
measuring the cellular production of a coloured formazan product via an 
absorbance reading. Formazan is produced through the reduction of MTS by 
NAD(P)H-dependent cellular oxidoreductase enzymes. 
Figure 4.20 shows the effect of prolonged incubation with the concentrations of 
TFV on the metabolic activity of human PTC monolayers (n = 18, N = 3). At 
physiologically relevant concentrations of TFV there was no inhibition of human 
PTC metabolic activity. An extracellular TFV concentration of 50 M or greater 
significantly reduced metabolic activity following a two day incubation period 
(**** P < 0.0001). In comparison, an extracellular TFV concentration of 10 M or 
greater significantly reduced metabolic activity after a 7 day incubation period 
(**** P < 0.0001). Non-linear regression analysis of the data gave an apparent 
IC50 value of 354.20  60.74 M following a 2 day and 113.20  1.30 M 
following a 7 day incubation with TFV. 
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Figure 4.20: The effect of TFV on metabolic activity of human PTC 
monolayers. 
In order to determine the effect of TFV on cellular metabolic activity, 
human PTC monolayers were incubated with a range of 
concentrations of TFV (0 to 500 M) for 2 or 7 days. The metabolic 
activity of cells was measured using MTS. Exposure to high 
concentrations of TFV significantly reduced human PTC metabolic 
activity. However, there was no inhibition of human PTC metabolic 
activity at physiologically relevant concentrations. Non-linear 
regression analysis of the data gave an apparent IC50 value of 354.20 
 60.74 M following two days and 113.20  1.30 M following 7 days 
incubation with TFV. The results are expressed as the mean ± SEM 
from 18 human PTC monolayers derived from 3 individual kidneys. 
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4.3.9. Flux and uptake of TFV by rat PTC monolayers over time. 
The rate of TFV unidirectional fluxes and uptake over time were studied by 
measuring the secretory and absorptive fluxes of 10 M [3H]-TFV across rat 
PTC monolayers following 20, 40, and 60 min of exposure. Additionally, the 
uptake of [3H]-TFV across the basolateral membrane of rat PTC monolayers 
was measured at 15, 30, 45, 60, and 90 min of exposure.  
Figure 4.21 shows the secretory, absorptive and net fluxes of [3H]-TFV 
increased linearly between 0 and 60 min (n = 12, N = 3). Furthermore, as 
shown in Figure 4.22, uptake of [3H]-TFV increased linearly between 0 and 90 
min, with a gradient of 0.43  0.01 pmol / cm2 / min (n = 9, N = 3). From these 
findings we can deduce the initial rate period of TFV transport lies within 0 to 90 
min. A time point of 60 min was therefore selected to conduct future studies to 
ensure linearity in rate of flux and uptake. 
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Figure 4.21: Time course of 10 M [3H]-TFV flux by rat PTC monolayers. 
The flux of 10 M [3H]-TFV across rat PTC monolayers over time is 
shown. The flux of [3H]-TFV was within the initial rate period between 
0 and 60 min as flux was linear over this time period. The results are 
expressed as the mean ± SEM from 12 rat PTC monolayers derived 
from 3 individual kidneys.  
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Figure 4.22: Time course of 10 M [3H]-TFV uptake across the basolateral 
membrane of rat PTC monolayers.  
A progress curve was created by measuring the uptake of 10 M [3H]-
TFV across the basolateral membrane of rat PTC monolayers over 
time. The uptake of [3H]-TFV between 0 and 90 min was linear. Linear 
regression analysis of the data gave a slope of 0.43  0.01 pmol / cm2 
/ min (R2: 0.96). The non-specific binding of [3H]-TFV to the 
Transwell insert was 0.68  0.04 pmol / cm2. The results are 
expressed as the mean ± SEM from 9 rat PTC monolayers derived 
from 3 individual kidneys.  
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4.3.10. Flux and uptake of TFV by rat PTC monolayers. 
Unidirectional transepithelial fluxes of 10 M [3H]-TFV the secretory and 
absorptive direction were studied in the rat PTC monolayer model. Furthermore, 
uptake of [3H]-TFV across the basolateral and apical membranes was 
determined from intracellular accumulation of [3H]-TFV in rat PTC monolayers. 
The results in Figure 4.23 exhibit a net absorption of TFV (62.34 ± 4.70 pmol / 
hr / cm2) by rat PTC monolayers. Absorption of [3H]-TFV (217.20 ± 1.66 pmol / 
hr / cm2) was 1.40-fold greater than secretion (154.80 ± 5.09 pmol / hr / cm2, 
**** P < 0.0001, n = 12, N = 3). Figure 4.24 shows the amount of [3H]-TFV taken 
up across the basolateral and apical membranes of the rat PTC monolayers 
were 25.89 ± 0.68 pmol / hr / cm2 and 18.15 ± 0.28 pmol / hr / cm2, respectively; 
uptake of TFV was 1.43-fold greater across the basolateral membrane (**** P < 
0.0001, n = 9, N = 3). These findings, coupled with the human data, indicate a 
cell to media ratio greater than 1 (See calculation below). This implies TFV is 
accumulated within the proximal tubule cells via the basolateral membrane. 
The cell-to-medium ratio was calculated by dividing the intracellular 
concentration of TFV (µM) by the concentration of test compound in the 
transport medium (µM). Assumptions made in this calculation are the height of a 
proximal tubule epithelial cell is 10 microns i.e. 0.001 cm as measured by 
transmission electron microscopy (Dorup and Maunsbach, 1997), cell 
monolayers form a cylinder, and intracellular space does not contain subcellular 
compartments. These assumptions give ratios which probably substantially 
underestimate the true accumulation. 
 
Volume occupied by a monolayer per 24-well Transwell® insert (surface area 
0.33 cm2) = π.radius2.height 
If radius = 0.32 cm, and height = 0.001 cm,  
Volume (per 0.33cm3)= 0.00032 cm3 = 0.332 µL 
Volume (per cm3) = 0.332 µL x 3 = 0.996 µL 
TFV concentration per cm3 = 25.89 pmol / cm3  
Intracellular concentration of TFV = 25.89 pmol / 0.996 µL i.e. 25.99 µM 
Extracellular concentration of TFV = 10 µM 
Cell-to-medium ratio = 26:10 µM = 2.60 
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Figure 4.23: Unidirectional flux of 10 M [3H]-TFV by rat PTC monolayers. 
In order to determine the secretory and absorptive flux of TFV through 
rat PTC monolayers, paired monolayers were incubated with 10 M 
[3H]-TFV at either the basolateral or apical chamber. The results show 
a net absorptive flux (62.34 ± 4.70 pmol / hr / cm2). The absorptive 
movement of [3H]-TFV (217.20 ± 1.66 pmol / hr / cm2) was 
significantly greater than the secretory movement (154.80 ± 5.09 pmol 
/ hr / cm2) (**** P < 0.0001). The results are expressed as the mean ± 
SEM from 12 rat PTC monolayers derived from 3 individual kidneys. 
Significance was determined by a Student’s t-test. 
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Figure 4.24: Uptake of 10 M [3H]-TFV across the basolateral and apical 
membrane of rat PTC monolayers.  
In order to measure the uptake of TFV across the basolateral and 
apical membrane of rat PTC monolayers, paired monolayers were 
incubated with 10 μM [3H]-TFV at either the basolateral or apical 
chamber for 60 min. The data show that the uptake of [3H]-TFV across 
the basolateral membrane (25.89 ± 0.68 pmol / hr / cm2) was 
significantly greater than the apical membrane (18.15 ± 0.28 pmol / hr 
/ cm2) (**** P < 0.0001). The results are expressed as the mean ± 
SEM from 9 rat PTC monolayers derived from 3 individual kidneys. 
Significance was determined by a Student’s t-test. 
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4.3.11. Kinetics of TFV flux and uptake by rat PTC monolayers. 
Rat PTC monolayers were incubated at the basolateral membrane with a range 
of [3H]-TFV concentrations (1 to 5000 M) for 60 min and the intracellular 
accumulation of [3H]-TFV was measured, so as to calculate the kinetic 
parameters of TFV transport. Figure 4.25 shows the sigmoidal relationship 
between [3H]-TFV concentration and uptake of [3H]-TFV across the basolateral 
membrane of rat PTC monolayers (n = 9, N = 3). Non-linear regression analysis 
of the data gave a Vmax of 1597.62  131.70 pmol / hr / cm2 and an apparent Km 
value of 2482.40  404.87 M.  
 
Figure 4.25: Kinetic data on the uptake of [3H]-TFV across the basolateral 
membrane of rat PTC monolayers under initial rate conditions.  
Rat PTC monolayers were incubated with a range of [3H]-TFV 
concentrations (1 to 5000 M) for 60 min. Non-linear regression 
analysis of the data gave a Vmax of 1597.62  131.70 pmol / hr / cm2 
and an apparent Km value of 2482.40  404.87 M. The results are 
expressed as the mean ± SEM from 9 rat PTC monolayers derived 
from 3 individual kidneys. 
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4.3.12. Identifying the transporters mediating the uptake of 
TFV across the basolateral membrane of rat PTC monolayers. 
The contributions of various uptake transport proteins in the rat tubular handling 
of TFV were quantified by measuring unidirectional fluxes and uptake of 10 M 
[3H]-TFV in the presence and absence of various competitive substrates of 
uptake transport proteins. The inhibitors were added at concentrations that 
would selectively inhibit the activity of transporters that were expected to be 
involved in the uptake of TFV. Table 4.4 shows the competitive substrate and its 
affinity value (Km) for its corresponding transporter(s).  
The effect of competitive substrates on the secretory and absorptive fluxes of 
[3H]-TFV across rat PTC monolayers is shown in Figure 4.26 (n = 9, N = 3). The 
presence of PAH (50 µM) reduced [3H]-TFV secretory flux to 19.07 ± 1.36 % 
(**** P < 0.0001), whilst RSV (20 µM) had no effect. Additionally, the presence 
of T3 (10 µM), CDC (10 µM) and DX (10 µM) reduced [3H]-TFV secretory fluxes 
to 52.68 ± 2.03 % (**** P < 0.0001), 58.42 ± 2.29 % (**** P < 0.0001), and 53.15 
± 1.03 % (**** P < 0.0001), respectively, when compared to the control. The 
presence of the competitive substrates had no effect on absorptive flux. 
Figure 4.27 shows the effect of competitive substrates on the uptake of [3H]-
TFV across the basolateral and apical membrane of rat PTC monolayers (n = 9, 
N = 3). The presence of 50 µM PAH reduced [3H]-TFV uptake across the 
basolateral membrane to 18.78 ± 0.67 % of control (**** P < 0.0001), whilst 20 
µM RSV had no effect. The presence of 10 µM T3, 10 µM CDC, and 10 µM DX 
decreased basolateral [3H]-TFV uptake to 70.51 ± 1.22 % (**** P < 0.0001), 
68.75 ± 0.88 % and 63.36 ± 1.44 % (**** P < 0.0001) of the control, respectively. 
The presence of the competitive substrates had no effect on apical uptake of 
TFV. In agreement with the flux experimental data, these findings suggest both 
Oatp4c1 and Oat1 mediate the uptake of TFV across the basolateral membrane.  
As with the human transporter characterisation studies, in order to determine if 
the low contribution of rOat1 and rOat3 were the result of a loss of functionality 
or expression during cell culture, the inhibition study was repeated in freshly 
isolated rat PTCs (Figure 4.28). The presence of the Oct2 substrate CIM 
(1.5mM) had no effect on the uptake of [3H]-TFV. Like the previous findings, 50 
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µM PAH, 10 µM T3 and 10 µM CDC reduced TFV uptake to 19.36 ± 2.31 % 
(**** P < 0.0001), 54.13 ± 1.93 % (**** P < 0.0001) and 44.41 ± 2.90 % (**** P < 
0.0001) of control, respectively. 
 
Table 4.4: Competitive substrates used to identify transporters mediating 
the uptake of TFV.  
Listed are competitive substrate of rOat1, rOat3 and Oatp4c1. The 
apparent affinity (Km) values of the substrates for transporters are 
shown. 
   
Substrate Transporter System Km (M) Reference 
PAH rOat1 
X.Laevis 
oocytes 
14.3  2.9 (Sekine et al., 1997) 
PAH rOat3 
X.Laevis 
oocytes 
64.7  10.0 (Kusuhara et al., 
1999) 
RSV rOat3 
X.Laevis 
oocytes 
4.7  0.7 (Windass et al., 
2007) 
T3 rOatp4c1 MDCK 1.9  0.6 (Mikkaichi et al., 
2004) 
CDC rOatp4c1 _ _ _ 
DX rOatp4c1 MDCK 8.0  2.2 (Mikkaichi et al., 
2004) 
CIM rOct2 HEK293 68.8  8.0 (Tahara et al., 2005) 
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Figure 4.26: Identifying the transporters mediating the uptake of [3H]-TFV 
in [3H]-TFV flux across the rat PTC monolayer. 
Secretory and absorptive fluxes of 10 M [3H]-TFV were measured in 
the presence of various competitive substrates of uptake transport 
proteins. The presence of 50 µM PAH significantly reduced TFV 
secretory flux when compared to the control (19.07 ± 1.37 %, **** P < 
0.0001), while 20 µM RSV had no effect. The presence of 10 µM T3, 
10 µM CDC, and 10 µM DX also resulted in a marked decrease in TFV 
secretory flux (52.68 ± 2.03 % **** P < 0.0001, 58.42 ± 2.29 % **** P 
< 0.0001, and 53.15 ± 1.03 % **** P < 0.0001, respectively). The data 
suggest both Oatp4c1 and Oat1 are transporters that mediate the 
uptake of TFV across the basolateral membrane. The presence of the 
competitive substrates had no effect on the absorptive flux. The 
results are expressed as the mean ± SEM from 9 rat PTC monolayers 
derived from 3 individual kidneys. Significance was determined by a 
Student’s t-test.  
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Figure 4.27: Identifying the transporters mediating the uptake of [3H]-TFV 
in to rat PTC monolayers.  
Uptake of 10 M [3H]-TFV across the apical and basolateral 
membrane in the presence of various competitive substrates of uptake 
transport proteins was measured. At the basolateral membrane of rat 
PTC monolayers 50 µM PAH reduced [3H]-TFV uptake to 18.78 ± 
0.35 % of control (**** P < 0.0001). 20 µM RSV had no effect while 10 
µM T3 reduced uptake to 70.51 ± 1.22 % of control (**** P < 0.0001), 
10 µM CDC reduced uptake to 68.75 ± 0.88 % of control (**** P < 
0.0001) and 10 µM DX reduced uptake to 63.46 ± 1.44 % (**** P < 
0.0001). In agreement with the flux data these findings suggest 
Oatp4c1 and Oat1 are the transporters that mediate the uptake of 
TFV across the basolateral membrane. The presence of the 
competitive substrates had no effect on apical uptake of TFV. The 
results are expressed as the mean ± SEM from 9 rat PTC monolayers 
derived from 3 individual kidneys. Significance was determined by a 
Student’s t-test. 
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Figure 4.28: Identifying the transporters mediating the uptake of [3H]-TFV 
in freshly isolated rat PTCs. 
Uptake of 10 M [3H]-TFV was measured in suspended rat PTCs in 
the presence of various competitive substrates of uptake transport 
proteins The presence of 1.5 mM CIM had no effect on intracellular 
accumulation of [3H]-TFV. 50 µM PAH reduced TFV accumulation to 
19.36 ± 2.31 % when compared to the control (**** P < 0.0001). 10 µM 
T3 and 10 µM CDC resulted in a marked decrease in TFV 
accumulation when compared to the control (54.13 ± 1.93 % **** P < 
0.0001 and 44.41 ± 2.90 % **** P < 0.0001, respectively). These 
findings suggest both Oatp4c1 and Oat1 are the transporters that 
mediate the uptake of TFV across the basolateral membrane. The 
results are expressed as the mean ± SEM from 12 rat PTCs samples 
derived from 3 individual kidneys. Significance was determined by a 
Student’s t-test. 
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4.3.13. Identifying the transporters mediating the efflux of TFV 
across the apical membrane of rat PTC monolayers. 
The contributions of various efflux transport proteins in the tubular handling of 
TFV by rat PTC monolayers were characterised by measuring unidirectional 
fluxes and intracellular concentrations of [3H]-TFV in the presence and absence 
of various inhibitors of apical efflux transport proteins. The inhibitors were added 
at concentrations that would selectively inhibit the activity of transporters.. 
The effect of efflux transport protein inhibitors on the secretory and absorptive 
fluxes of [3H]-TFV across rat PTC monolayers are shown in Figure 4.29 (n = 9, 
N = 3). The presence of MK-571 (5 µM), and Ko 143 (2 µM) had no effect on 
the secretory and absorptive fluxes of 10 µM [3H]-TFV. The same compounds 
also had no effect on the intracellular accumulation of 10 µM [3H]-TFV when 
compared to the control (Figure 4.30). The functionality of these transporters 
within rat PTC monolayers have previously been confirmed. Therefore, these 
findings imply that TFV has a poor affinity for Mrp2, Mrp4 and Bcrp under 
physiological conditions. 
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Figure 4.29: Identifying the transporters mediating the efflux of [3H]-TFV 
by rat PTC monolayers.  
Secretory and absorptive fluxes of 10 M [3H]-TFV were measured in 
the presence of various competitive substrates of apical efflux 
transport proteins. The presence of 5 µM MK-571 and 2 µM Ko 143 
had no effect on the secretory nor the absorptive flux of [3H]-TFV. 
This indicates that TFV has a poor affinity for Mrp2, Mrp4 and Bcrp 
under physiological conditions. The results are expressed as the 
mean ± SEM from 9 rat PTC monolayers derived from 3 individual 
kidneys. Significance was determined by a Student’s t-test. 
  
JB-A JA-B
0
25
50
75
100
125
150
Direction of flux
Fl
ux
 o
f [
3 H
]-T
FV
(%
)
10µM [3H]-TFV
+ 5 µM MK-571
+ 2 µM Ko 143
 157 
 
 
Figure 4.30: Identifying the transporters mediating the efflux of [3H]-TFV 
from the rat PTC monolayer. 
Intracellular accumulation of [3H]-TFV in the monolayers was 
measured in the presence of various competitive substrates of apical 
efflux transport proteins. The monolayers were incubated at either the 
basolateral or apical membrane with 10 M [3H]-TFV in the presence 
or absence of competitive substrates for 60 min. The presence of 5 
µM MK-571 and 2 µM Ko 143 had no effect on the intracellular 
concentration of [3H]-TFV, suggesting that TFV has a poor affinity for 
Mrp2, Mrp4, and Bcrp under physiological conditions. The results are 
expressed as the mean ± SEM from 9 rat PTC monolayers derived 
from 3 individual kidneys. Significance was determined by a Student’s 
t-test. 
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4.4. Discussion 
In this chapter the renal handling of TFV by human and rat PTC monolayers 
was studied to investigate their use as platforms to predict renal drug handling, 
DDIs and nephrotoxicity. From in-vivo studies it is known that TFV is cleared in 
the kidney by a combination of glomerular filtration and tubular secretion, and 
that it is a substrate of multiple transporters in the kidney. Following on from 
marketing approval, a low rate of nephrotoxicity has been reported with long-
term TFV therapy. 
Unidirectional transepithelial fluxes of radiolabelled [3H]-TFV (10 µM) in both the 
secretory and absorptive direction were measured over 1 hr in paired 
monolayers of human and rat PTCs grown on 24-well Transwell® inserts. In the 
human PTC monolayers, we observed net absorption of TFV (50.69  1.35 
pmol / hr / cm2) as shown in Figure 4.4. The absorptive movement of [3H]-TFV 
(131.16  2.15 pmol / hr / cm2) was 1.63-fold greater than the secretory 
movement of [3H]-TFV (80.47 ± 1.00 pmol / hr / cm2). Figure 4.5 shows uptake 
of TFV across the basolateral membrane (39.09 ± 1.31 pmol / hr / cm2) was 
5.86-fold higher than apical uptake (6.67 ± 0.46 pmol / hr / cm2). Similarly, in rat 
PTC monolayers, Figure 4.23 and Figure 4.24, the absorptive movement of 
[3H]-TFV (217.20 ± 1.66 pmol / hr / cm2) was 1.40-fold greater than the 
secretory movement of [3H]-TFV (154.80 ± 5.09 pmol / hr / cm2) and the uptake 
of TFV across the basolateral membrane (25.89 ± 0.68 pmol / hr / cm2) was 
1.43-fold higher than apical uptake (18.15 ± 0.28 pmol / hr / cm2). Within the 
PTCs these findings would result in a cell to media ratio greater than 1 across 
the basolateral membrane suggesting that TFV is accumulated within the 
proximal tubule cells. These findings support the in-vivo pathology studies 
which have reported an accumulation of TFV within the same cells (Cote et al., 
2006; Kohler et al., 2009; Herlitz et al., 2010; Perazella, 2010; Fernandez-
Fernandez et al., 2011; Kohler et al., 2011). 
The rate of transporter-mediated movement of a drug molecule is approximately 
linear for a period of time once exposure begins; this is known as the initial rate 
period. As the rate of transport proceeds the substrate concentration decreases, 
consequently the rate decelerate. In order to measure the maximum rate of 
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transport, transporter assays are typically carried out in the ‘linear’ initial rate 
period. The length of the initial rate period for each molecule depends on the 
assay conditions and can be milliseconds to hrs. To ensure the flux and uptake 
of TFV was measured under initial rate conditions, the experiments were 
performed at defined time points. From the findings in Figure 4.2, Figure 4.3, 
Figure 4.21 and Figure 4.22 we can deduce the linear initial rate period of TFV 
transport was between 0 to 90 min for both human and rat. Therefore, a time 
point of 60 min was selected to conduct subsequent studies as it was within the 
linear initial rate. This would also ensure the reactions had progressed enough 
to be measured within the radiation detection instrument’s sensitivity. 
The kinetic parameters, Vmax and Km, of TFV uptake across the basolateral 
membrane of both human and rat PTC monolayers were quantified by 
incubating the monolayers with various concentrations of [3H]-TFV. In order to 
determine the maximum rate of TFV uptake, the limiting factor must be the 
transporter activity and not the amount of substrate. Between 0 to 2000 µM [3H]-
TFV in the human monolayers and 0 to 3000 µM [3H]-TFV in the rat, there was 
an exponential increase in the rate of uptake with increasing substrate 
concentration. Within these conditions the rate limiting factor was the 
concentration of TFV, as the substrate recognition site of the transporters 
mediating uptake were unsaturated. As the concentration of [3H]-TFV increased 
beyond 2000 µM in man and 3000 µM in rat, the transporters mediating TFV 
uptake were saturated with substrate and the rate limiting factor was transporter 
activity. Adding more TFV did not significantly affect the rate of uptake. On the 
graph this is represented as a plateau. The maximum rate of TFV uptake when 
the transporter is saturated with a substrate is known as the maximum initial 
velocity (Vmax). Non-linear regression analysis of the data in Figure 4.8 and 
Figure 4.25 gave a Vmax of 1214.11  134.57 pmol [3H]-TFV / hr / cm2 in human 
PTC monolayers and 1597.62  131.70 pmol [3H]-TFV / hr / cm2 in rat PTC 
monolayers. 
The relationship between the rate of uptake and concentration of TFV depends 
on the affinity of the transporter for the substrate. This is usually expressed as 
the Km of the transporter for the substrate. In this instance, Km is the 
concentration of TFV which permits the uptake of TFV to achieve half of Vmax. A 
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transporter with a high Km has a low affinity for its substrate, and requires a 
greater concentration of substrate to achieve Vmax. The basolateral membrane 
transporters within rat and human PTC appeared to have low affinities for TFV. 
Non-linear regression analysis of the data in Figure 4.8 and Figure 4.25 gave an 
apparent Km value of 756.86  166.48 M [3H]-TFV in human PTC monolayers 
and 2482.40  404.87 M [3H]-TFV in rat PTC monolayers. The kinetic 
parameters from previously published in-vitro studies modelling TFV uptake are 
shown in  
Table 4.5. The reason why the Km values generated in our models were higher 
than those published is that our system expresses a full complement of renal 
transporters involved in the renal handling of TFV whilst the published studies 
conducted in transfected cells only expressed a single transporter, for instance 
hOAT1 or hMRP4.  
 
Table 4.5: A summary of published Vmax and Km values for TFV uptake. 
 
TFV is reported to be a substrate for multiple transporters in the kidney. There 
are two methods to elucidate the contribution of individual transporters in the 
renal handling of TFV. The first is the relative activity factor method: selective 
substrates for each individual transporter are used to estimate the contribution 
of transporters to the flux and uptake of drugs when multiple transporters are 
involved (Hirano et al., 2004). However, this method is commonly infeasible due 
to the overlapping substrate specificity of many transporters. Alternatively, a 
method in which the use of available transporter specific inhibitors in 
System Km (µM) Vmax Reference 
hOAT1 oocyte 25.0 129 pmol / oocyte / h (Moss et al., 2011) 
hOAT1 HEK293 400.0 ± 80.0 
5500 ± 400 pmol / min / 
mg 
(Riches, 2010) 
hOAT1 CHO 33.8 ± 3.4 
110 ± 12 pmol / 106 
cells. min 
(Cihlar et al., 2001) 
hMRP4 HEK293 
vesicles 
>1000  (Imaoka et al., 2007) 
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combination with a cocktail of inhibitors with known but overlapping inhibitory 
potencies toward multiple transporters can be used. The method is depicted in 
Figure 4.9 and Figure 4.15. 
The transporters that were initially considered to be involved in the renal 
handling of TFV were OAT1, OAT3, MRP2 and MRP4. Current literature 
proposes that TFV secretion in the kidney begins with the basolateral uptake of 
the compound from general circulation into the epithelial proximal tubule cells 
via OAT1 and OAT3. It is then effluxed into urine through apically located MRP2 
and MRP4. This is also the secretory pathway proposed for similar molecules 
such as adefovir and cidofovir (Cihlar et al., 1999; Schuetz et al., 1999; Cihlar 
and Ho, 2000; Ho et al., 2000; Cihlar et al., 2001; Izzedine et al., 2006; Cihlar et 
al., 2007; Imaoka et al., 2007; Uwai et al., 2007; Weiss et al., 2007; Kohler et al., 
2011; Moss et al., 2011; Mandikova et al., 2013). 
The transporters responsible for the uptake of TFV across the basolateral 
membrane of human and rat PTC monolayers were identified with a 
combination of substrates for those transporters. The findings revealed that a 
significant component of carrier mediated basolateral uptake of TFV was 
unaccounted for. Uptake studies with RSV showed that TFV was not a 
substrate for OAT3. This finding is highly significant as OAT3 is highly 
expressed within the kidney (Hilgendorf et al., 2007). OAT1 was identified as a 
key transporter in the uptake to TFV using a combination of PAH and RSV. 
However, the relative contribution of this transporter in the basolateral uptake of 
TFV was lower than expected. The contribution of OAT1 in human PTC 
monolayers was around 20 to 30 % (Figure 4.10 and Figure 4.11) and around 
20 % in rat PTC monolayers (Figure 4.26 and Figure 4.27). Hence other 
proteins known to transport anions were considered, and OATP4C1 was 
chosen for further investigation.  
OATP4C1 was confirmed as a transporter in the basolateral uptake of TFV with 
the co-administration of TFV with T3 and CDC. The contribution of OATP4C1 in 
TFV uptake was around 70 to 80 % in human monolayers (Figure 4.10 and 
Figure 4.11) and, 50 to 70 % in rat monolayers (Figure 4.26 and Figure 4.27). It 
was thus shown that OAT1 and OATP4C1 were responsible for the basolateral 
uptake of TFV. In order to determine if TFV transport via OATP4C1 was the 
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result of a loss in OAT1 and OAT3 expression or functionality during PTC cell 
culture, the inhibition study was repeated in freshly isolated human and rat 
PTCs. The findings in Figure 4.12 and Figure 4.28, confirmed that OATP4C1 
was the predominant transporter of TFV; it mediated the 45 to 55 % of the 
basolateral uptake of TFV whereas OAT1 contributed only around 20 %. Uptake 
of 10 M [3H]-TFV was 4.51-fold lower in the human cells cultured for 7-days on 
Transwell inserts when compared to freshly isolated cells. The data shown in 
Figure 4.13 suggested that the loss of OATP4C1 expression in cultured cells is 
not as great as loss of OAT expression. This result is consistent with the mRNA 
data in Table 3.1, which reported a 4.27-fold decrease in expression of OAT1 
and a 1.95 decrease in the expression OATP4C1 in human PTCs cultured on 
Transwell® inserts when compared to freshly isolated cells. The identification of 
OATP4C1 as a key transporter in the renal elimination of TFV is novel. 
OATP4C1 is reported to possess multiple substrate recognition sites. Two 
distinct recognition sites for DX and E3S have been characterised (Mikkaichi et 
al., 2004). Apparent Km values of these substrates for OATP4C1 are listed in 
Table 4.2. In order to determine if TFV binds to the same recognition site as DX 
or E3S, the basolateral uptake of 10 M [3H]-TFV across human PTC 
monolayers in the presence of various concentrations of DX and E3S (0.1 to 50 
M) were plotted to generate IC50 values. IC50 represents the concentration of 
an inhibitor required for 50 % inhibition of a cellular response. Non-linear 
regression analysis of the data in Figure 4.14 suggested that DX and E3S are 
only able to bind one binding site. With apparent IC50 values of 0.38  0.10 M 
for DX and 1198 M for E3S. These findings indicate that TFV has a higher 
affinity for the DX recognition site of OATP4C1 than the E3S recognition site.  
Using the Cheng-Prusoff equation, these information, in combination with the 
kinetic data of TFV uptake in human PTC monolayers, the inhibition constants 
(Ki) were calculated. Ki is the concentration of the inhibitor that is required to 
decrease the maximal rate of reaction by half. Therefore, the smaller the Ki the 
smaller the amount of drug was needed to inhibit the basolateral uptake of TFV 
in human PTC monolayers. The calculated Ki values for DX and E3S were 0.38 
± 0.10 and 1182.38 µM, respectively. If the Ki value is much larger than the 
maximal plasma drug concentrations a patient is exposed to from typical dosing, 
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as is the case in this example, then the drug is not likely to inhibit the uptake of 
TFV in-vivo. 
OATP4C1 is the only member of the OATP family expressed on the basolateral 
membrane of proximal tubules in humans and rodents. The overall homology 
between human OATP4C1 and rat Oatp4c1 was found to be 80.4% at the 
amino acid level (Mikkaichi T, 2004). OATP4C1 and Oatp4c1 also have a 
moderate sequence homology with other OATP family members (below 35%) 
(Mikkaichi T, 2004). Oatp4c1 mRNA expression is male-predominat in mouse 
kidneys (Cheng X and Klaassen CD, 2009). Using gonadectomized and lit/lit 
mouse models, gender divergent regulation of Oatp4c1 in mouse kidneys was 
shown to be controlled by sex hormones (Cheng X and Klaassen CD, 2009). 
Based upon these findings, males could be more prone to tenofovir induced 
nephrotoxicity as a result of greater renal expression of OATP4C1.  
The transporters responsible for the efflux of TFV across the apical membrane 
were characterised by measuring the secretory flux and intracellular 
concentration of TFV in the absence and presence of various competitive 
substrates of apical efflux transport proteins. The presence of MK-571 (5µM, 
MRP substrate), Ko 143 (2 µM, BCRP substrate) or GF120918 (5 µM, MDR1 
substrate) had no effect on the secretory flux and intracellular concentration of 
[3H]-TFV in human (Figure 4.16 and Figure 4.17, respectively) and rat PTC 
monolayers (Figure 4.29 and Figure 4.30, respectively). We have confirmed in 
Figure 4.18 and Figure 4.19 that human PTC monolayers exhibit functional 
expression of apical MRP, BCRP and MDR1. Their functional expression in rat 
PTC monolayers has also been characterised by colleagues. Therefore, these 
findings, in contrast to the majority of the published literature, suggest TFV is a 
weak substrate of MRP, BCRP and MDR1 under physiological conditions.  
In conjunction with our findings that the absorptive flux of TFV was significantly 
greater than the secretory flux, the information suggests that TFV accumulates 
within the proximal tubule cells due to the lack of an efficient secretory route. 
TFV enters the tubular cells at the basolateral membrane through OATP4C1 
and OAT1, at a higher rate than the efflux of TFV due to the low affinity for 
efflux transporters; TFV thus accumulates or exits through membrane 
permeation. Similarly, adefovir and cidofovir have been reported to accumulate 
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in the proximal tubule cells and cause nephrotoxicity. The expression of hOAT1 
has been observed to induce the cytotoxicity in the presence of adefovir and 
cidofovir in hOAT1-CHO cells (Ho et al., 2000). Co-administration of cidofovir 
with the OAT1/OAT3 inhibitor has been shown to ameliorate nephrotoxicity. In 
animal toxicity studies, oral probenecid treatment decreased the concentration 
of cidofovir in the cortex of the kidney, whilst levels in other tissues have 
remained unaffected as a result of the reduced renal clearance (Cundy et al., 
1995; Cundy et al., 1996; Lacy et al., 1998; Ho et al., 2000; Mandikova et al., 
2013). Probenecid inhibition studies have also found that tubular secretion of 
low doses of cidofovir are unaffected by probenecid co-administration (Cundy et 
al., 1995). This suggests another unknown transporter maybe involved in 
cidofovir tubular secretion, which could be OATP4C1 based on our findings. At 
low cidofovir doses, the drug may be cleared from the serum by this high-affinity 
unknown transporter (OATP4C1), while at higher cidofovir doses this system 
may be saturated, requiring cidofovir to be transported by a probenecid-
sensitive mechanism (OAT1 and 3). 
The literature associates TFV accumulation with proximal tubulopathies such as 
acute kidney, injury and Fanconi syndrome by disrupting proximal tubule cell 
mitochondrial function (Rifkin and Perazella, 2004; Cote et al., 2006; Kohler et 
al., 2009). The mitochondrial activity of human PTC monolayers following a 2 
and 7 day exposure to different concentrations of TFV was assessed using 
MTS. In metabolically active cells MTS is reduced by NAD(P)H-dependent 
cellular oxidoreductase enzymes into a soluble coloured formazan product. As 
shown in Figure 4.20, at physiologically relevant concentrations of TFV there 
was no inhibition of human PTC metabolic activity. Non-linear regression 
analysis of the data gave an apparent IC50 value of 354.20 ± 60.74 M TFV 
following a 2 day and 113.20 ± 1.30 M TFV following a 7 day incubation. A 
limitation of conducting this study and other measures of nephrotoxicity in our 
primary human PTC model is that the length of exposure to the nephrotoxic 
molecule is limited by the finite lifespan of the cells. 
The information gathered on the renal handling of TFV in the human and rat 
PTC monolayers will have a large translational impact. TFV in combination with 
other antivirals is a first line therapy for both HIV-1 and HBV infected patients, 
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as recommended by the World Health Organisation (WHO, 2014; WHO, 2015a). 
The organisation estimates that in 2014, 36.9 million people were living with HIV 
and 240 million with HBV globally (WHO, 2015c; WHO, 2015b). Approximately 
14.9 million people living with HIV (40.4%) were receiving HIV antiretroviral 
therapy (ART) in 2014 (WHO, 2015c). The number of people taking this 
medication is certain to increase in the future due to the substantial progress in 
access to HIV-1 treatment and the introduction of ‘pre-exposure prophylaxis’. 
The novel identification of OATP4C1 as a key transporter in the renal 
elimination of TFV using the primary models has led Gilead to invest in 
developing assays for OATP4C1 DDI. The life expectancy of HIV-1 and HBV 
infected patients is now comparable to the general population. Therefore, it is 
important to be aware of any potential DDIs that may occur with co-medication. 
Known substrates of OATP4C1 include cardiac glycosides (DX and ouabain), 
thyroid hormones (T3 and T4), cAMP and methotrexate. In addition, the work 
has generated commercial renal drug screening contracts with Gilead and 
Chimerix, which in turn has resulted in a reduction in animal use at both 
companies. Furthermore, this work in combination with other studies has led to 
the FDA flagging OATP4C1 as a key renal drug transporter. The use of the 
primary models as screening platforms for drug transporter and DDI studies 
have thus been validated in this chapter. 
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4.5. Summary 
In both human and rat PTC monolayers the uptake of TFV was greater across 
the basolateral membrane in comparison to the apical. We also observed a 
predominant absorptive pathway of TFV. Within the PTCs this would result in a 
cell to media ratio greater than 1 across the basolateral membrane suggesting 
that TFV is accumulating with the tubular cells. The transporters mediating the 
transport of TFV were identified using a cocktail of transporter inhibitors. The 
predominant basolateral uptake transporter was OATP4C1, followed by OAT1, 
with a negligible contribution from OAT3. TFV had low affinities for the apical 
efflux transporters MRP2, MRP4, MDR1 and BCRP. The novel identification of 
OATP4C1 as a TFV transporter has led Gilead to develop assays for 
investigating OATP4C1 DDI and also the FDA to recognise OATP4C1 as a key 
renal transporter. The primary models has thus been validated as a good model 
for such studies. 
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5. Pi handling by PTCs 
5.1. Background 
Phosphorus is an essential mineral. In mammals, it is required for cell structural 
integrity (phospholipid membranes and skeletal tissue), protein synthesis (DNA), 
energy production (ADP, ATP), and cell signalling (IP3, cAMP, cGMP). 
Phosphorus exists freely in plasma as either monovalent (H2PO4-) or divalent 
(HPO42-) phosphate and these are collectively referred to as inorganic 
phosphate (Pi). Plasma Pi is maintained within a narrow range of 0.8 to 1.5 mM 
(Biber et al., 2013).  
As summarised in Figure 5.1, this balance is achieved by four separate but 
intertwined physiological systems – the gastrointestinal, renal, musculoskeletal 
and endocrine systems. On average, 1200 mg of phosphorus is ingested in 
dietary products each day (Hruska et al., 2008). Of this intake, around 950 mg 
is absorbed at the small intestine into the exchangeable Pi pool by either 
paracellular movement or active transport across the intestinal mucosa, whilst 
the remainder is excreted with faeces (Hruska et al., 2008). In-vitro preparations 
of rat small intestine have demonstrated the duodenum and jejunum are 
responsible for the bulk of Pi absorption (Walling, 1977; Marks et al., 2007). The 
active uptake of Pi is mediated by a series of specialised sodium dependent Pi 
transporters NaPi-IIb (SLC34A2), PiT1 (SLC20A1), and PiT2 (SLC20A2). Once 
absorbed Pi enters the exchangeable phosphorus pool which consists of 
intracellular Pi (70 %), the skeletal mineralisation store (29 %), and plasma Pi 
(1 %) (Hruska et al., 2008). Pi exits the pool via changes in skeletal disposition, 
renal excretion and intestinal secretion. Approximately 300 mg day-1 of serum Pi 
undergoes continuous exchange with the conjugates of phosphate that make up 
bone (Hruska et al., 2008). This constant balance between bone reabsorption 
and formation is a process known as bone turnover. The kidney plays a key role 
in regulating plasma Pi. Within the kidney, Pi is freely filtered in the glomeruli of 
the kidney. Approximately 800 mg day-1 (80%) of the filtered load is reabsorbed 
in the proximal tubule by the specialised sodium dependent Pi transporters 
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NaPi-IIa (SLC34A1), NaPi-IIc (SLC34A3) and PiT2 (SLC20A2), whilst the rest is 
excreted in urine. The endocrine system uses hormones to regulate the 
processes of gastrointestinal absorption, bone turnover and tubular 
reabsorption to keep serum Pi levels normal despite fluctuations in dietary 
intake, elimination and physiologic need. 
 
Figure 5.1: Overview of human Pi homeostasis. 
The major source of phosphorus is the diet. Dietary Pi is absorbed in 
the small intestine. The skeleton is the major storage pool for Pi, it 
contains around 85% of the total body phosphorous. The main route 
by which Pi is lost from the body is excretion in the urine. Diagram 
taken from Hruska et al., 2008. 
 
The three major hormones that regulate Pi homeostasis are parathyroid 
hormone (PTH), fibroblast growth factor 23 (FGF-23) and calcitriol (the active 
form of vitamin D: 1,25-(OH)2 cholecalciferol). PTH is produced by chief cells of 
the parathyroid glands. It acts through the PTH receptor 1 (PTHR1) in the 
kidney to downregulate the key renal transporters, NaPi-IIa, NaPi-IIc and PiT2, 
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which are abundantly expressed in the proximal tubule, and mediates the 
reabsorption of Pi (Traebert et al., 2000; Yang et al., 2004; Bacic et al., 2006; 
Forster et al., 2006). More Pi is excreted in the urine in response to the down 
regulation of these transporters. Through the same receptors, PTH also 
stimulates the production of calcitriol through stimulation of 1α-hydroxylase 
(Torres and De Brauwere, 2011). 
Calcitriol acts in the negative feedback loop to inhibit the secretion of PTH, in 
addition to stimulating NaPi-IIb and PiT2 in the GI tract, which mediate the 
dietary Pi absorption (Ritter et al., 2006; Torres and De Brauwere, 2011). 
Calcitriol also stimulates the production of FGF-23 in osteocyte cells of the bone 
(Torres and De Brauwere, 2011). FGF-23 acts on the kidney through FGF 
receptors in conjunction with the co-factor, klotho-α (Kuro-o et al., 1997; Hu et 
al., 2010; Kuro, 2011). FGF-23 also down regulates NaPi-IIa, NaPi-IIc and PiT2 
expression in the proximal tubules (Biber et al., 2013). Removal of these 
transporters reduces the proximal tubule reabsorption of Pi and that enhances 
urinary Pi excretion. In contrast to PTH, FGF-23 is a potent inhibitor of 1α-
hydroxylase and thus calcitriol production (Kuro-o et al., 1997; Prie et al., 2009; 
Torres and De Brauwere, 2011). Dentrin matrix acidic phosphoprotein 1, 
Ectonucleotide pyrophosphatase/phosphodiesterase 1 and phosphate-
regulating neutral endopeptidase are several regulators of FGF-23 that have 
been identified (Martin et al., 2012).  
Serum Pi levels in healthy adults ranges from 2.5 to 4.5 mg/dL (0.81 to 1.45 
mmol/L). A drop in this level can lead to hypophosphatemia, and can be defined 
as mild (2 to 2.5 mg/dL, or 0.65 to 0.81 mmol/L), moderate (1 to 2.5 mg/dL or 
0.32 -0.65 mmol/L), or severe (<1 mg/dL, or <0.32 mmol/L). Moderate to severe 
hypophosphatemia is observed in 4 to 32 % of HIV-1 patients on ART (Badiou 
et al., 2006; Buchacz et al., 2006). This adverse reaction is generally related to 
increased urinary excretion of phosphorous (hyperphosphaturia), but the 
underlying aetiology is not completely understood, although HIV infection and 
ART are risk factors for the development of hypophosphatemia (Paccou et al., 
2009). In a study of hypophosphatemia prevalence in HIV-positive patients, 
hypophosphatemia was more frequent in those who were on ART than ART-
naïve (35% versus 10%, n = 123, P = 0.0001) (Wainwright et al., 2013). Of the 
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ARTs, TDF is most frequently associated with hypophosphatemia, 
hyperphosphaturia, and osteomalacia (defective bone mineralisation) (Buchacz 
et al., 2006; Labarga et al., 2009; Cooper et al., 2010; Judd et al., 2010; Calza 
et al., 2011; Havens et al., 2013; Ezinga et al., 2014; Giacomet et al., 2015; Lim 
et al., 2015).  
In drug development toxicology studies conducted in rats, dogs, and monkeys, 
TDF administration caused bone toxicity at exposures greater than those 
observed in humans (based on AUCs) (Gilead Sciences, 2015). In monkeys the 
bone toxicity was diagnosed as osteomalacia and appeared to be reversible 
upon dose reduction or discontinuation of TDF. In rats and dogs, bone toxicity 
manifested as reduced bone mineral density. In addition, increases in 
phosphaturia, calciuria and decreases in serum Pi were observed to varying 
degrees in all species at exposures 2 to 20 times higher than those observed in 
humans. Disappointingly, the mechanism underlying bone toxicity was not 
investigated further.  
In a human clinical phase study conducted in 600 HIV-1 infected adults over 
144 weeks, significant decrease in bone mineral density was reported at the 
lumbar spine in subjects receiving a cocktail of medications containing TDF, 
compared to subjects taking medications with a TDF substitute (Gilead 
Sciences, 2015). The majority of the reduction in bone mineral density occurred 
in the first 24 to 48 weeks of the trial and this reduction was sustained through 
to week 144. In addition, there were more biochemical markers of bone 
metabolism, higher serum PTH levels, and higher calcitriol levels in the TDF-
treatment group relative to the non-TDF-treatment group. However, except for 
bone-specific alkaline phosphatase, despite the increase in levels, the values 
remained within the normal range. Similar findings were observed in other 
paediatric HIV-1 clinical studies (Gilead Sciences, 2015). Indeed, since the 
approval of TDF use, there have been over 45 published cases that reports the 
association of TDF treatment with hypophosphatemia. TDF discontinuation is 
associated with a significant increase in serum Pi levels (Herlitz et al., 2010; 
Judd et al., 2010; Bech et al., 2012b; Lim et al., 2015; Magalhaes-Costa et al., 
2015). But there is no conclusive evidence of a causal link. 
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Predominantly, the literature suggests that TDF-induced hypophosphatemia is 
the result of TFV induced Fanconi syndrome. TFV accumulation within the 
proximal tubular cells results in inhibition of mitochondrial DNA polymerase-γ. 
As a result, the enzymes involved in the electron transport chain and oxidative 
phosphorylation become depleted. Mitochondrial function is disturbed, followed 
by a deficit in ATP production, impaired cell function, cell injury, and eventually 
apoptosis. Endogenous metabolites such Pi and calcium are passed in urine 
instead of being reabsorbed (hyperphosphaturia) with proximal tubule cell death 
(Martin et al., 1994; Birkus et al., 2002; Cote et al., 2006; Kohler et al., 2009; 
Herlitz et al., 2010; Perazella, 2010; Fernandez-Fernandez et al., 2011; Kohler 
et al., 2011). A decrease in Pi reabsorption from ultrafiltrate results in low serum 
Pi levels (hypophosphatemia). When the body recognises there is a low Pi 
serum concentration, bone demineralisation can occur to increase serum Pi 
levels, which could lead to osteomalacia. However medically induced renal 
tubular damage leading to Fanconi syndrome occurs in less than 0.1% of 
patients on TDF and thus cannot account for the high prevalence of 
hypophosphatemia (Nelson et al., 2007; Herlitz et al., 2010; Fernandez-
Fernandez et al., 2011). Recent clinical studies in HIV+ patients on TDF found 
that renal Pi loss was not caused by hyper-secretion of PTH or FGF-23, nor by 
calcium or vitamin D deficiency either (Saidenberg-Kermanac'h et al., 2011; 
Bech et al., 2012a; Bech et al., 2012b). This suggests that other factors, 
possibly a transporter-related one, may be involved in the aetiology of the 
clinical symptoms (Nelson et al., 2007; Hall et al., 2011; Bech et al., 2012a; 
Bech et al., 2012b). 
In fact, a trend between the years of TDF therapy and Pi reabsorption rate of 
patients has suggested that TFV may inhibit Pi reabsorption (Bech et al., 2012a), 
which could lead to the observed TDF related adverse effects. This chapter 
shall therefore consider the renal handling of Pi using the human and rat PTC 
monolayers, and assess their suitability as in-vitro models for the investigation 
of TFV-induced toxicity.  
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5.2. Aims 
The aims of the chapter were threefold (i) to investigate the handling of Pi, (ii) to 
investigate the regulation of Pi handling by PTH, FGF-23 and -klotho, and (iii) 
to investigate the impact of acute exposure to TFV upon the kinetics of Pi 
transport in human and rat PTC monolayers.  
Firstly, the uptake and flux of radiolabelled [32P]-Pi in human and rat PTC 
monolayers over time were studied to select a suitable time point to conduct 
transport experiments under initial rate conditions. Once a time point had been 
selected, the unidirectional transepithelial fluxes of [32P]-Pi were measured in 
the secretory and absorptive direction across paired human and rat PTC 
monolayers. Uptake of [32P]-Pi across the basolateral and apical membrane of 
human and rat PTC monolayers were also measured. Kinetics parameters such 
as the maximum rate of [32P]-Pi uptake (Vmax) and the affinity of [32P]-Pi for PTC 
uptake transporters (Km) were determined in both models. Following this the 
effect of the following compounds on [32P]-Pi uptake across the apical 
membrane of human and rat PTC monolayers were measured: 
 Sodium  
 extracellular pH  
 phosphonoformic acid (PFA) 
 PTH  
 FGF-23 
 Klotho-α 
 TFV 
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5.3. Results 
5.3.1. mRNA expression of Pi transporters in human PTC 
monolayer. 
qPCR was performed to confirm mRNA expression of Pi transporters by human 
PTCs in different culture conditions (N = 3). The mRNA expression levels of 
NaPi-IIa, NaPi-IIc, PiT2, NPT1, NPT4 and NPT5 following culture on 
Transwell® inserts and plastic cultureware relative to freshly isolated cells are 
shown in Figure 5.2, Figure 5.3, Figure 5.4, Figure 5.5, Figure 5.6 and Figure 
5.7, respectively. The data are summarised in Table 5.1 The expression levels 
had been normalised to the reference gene GAPDH prior to comparison. 
Human PTCs maintained expression of key renal Pi transporters, NaPi-IIa, 
NaPi-IIc and PiT2, as well as NPT1, NPT4 and NPT5 under both culture 
conditions. However, there was a significant fall in the expression of NaPi-IIc, 
PiT2 and NPT1 when compared with freshly human PTCs. No statistical 
difference in expression level was observed between the two culture conditions 
for any of the transporters.  
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Figure 5.2: The mRNA expression of NaPi-IIa in human PTCs under 
different culture conditions.  
NaPi-IIa mRNA expression levels are expressed as percentage 
expression relative to freshly isolated human PTCs. Human PTCs 
cultured for 7 days on Transwell inserts and plastic showed a 36.31  
9.18 % and 33.91  2.60 % decrease in expression in comparison to 
freshly isolated cells (100.00  29.28 %), respectively. The expression 
levels had been normalised to reference gene GAPDH expression 
level prior to comparison. The results are expressed as the mean ± 
SEM from 3 separate batches of RNA derived from 3 individual 
kidneys. One-way ANOVA statistical test was performed on the data 
set to determine significance. 
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Figure 5.3: The mRNA expression of NaPi-IIc in human PTCs under 
different culture conditions.  
NaPi-IIc mRNA expression levels are expressed as percentage 
expression relative to freshly isolated human PTCs. Human PTCs 
cultured for 7 days on Transwell inserts and plastic showed a 65.62  
4.75 % and 76.13  4.12 % decrease in expression in comparison to 
freshly isolated cells (100.00  16.74 %), respectively. The expression 
levels had been normalised to reference gene GAPDH expression 
level prior to comparison. The results are expressed as the mean ± 
SEM from 3 separate batches of RNA derived from 3 individual 
kidneys. One-way ANOVA statistical test was performed on the data 
set to determine significance, ** P < 0.01. 
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Figure 5.4: The mRNA expression of PiT2 in human PTCs under different 
culture conditions.  
PiT2 mRNA expression levels are expressed as percentage 
expression relative to freshly isolated human PTCs. Human PTCs 
cultured for 7 days on Transwell inserts and plastic showed a 62.71  
8.95 % and 85.01  5.13 % decrease in expression in comparison to 
freshly isolated cells (100.00  6.04 %), respectively. The expression 
levels had been normalised to reference gene GAPDH expression 
level prior to comparison. The results are expressed as the mean ± 
SEM from 3 separate batches of RNA derived from 3 individual 
kidneys. One-way ANOVA statistical test was performed on the data 
set to determine significance, ** P < 0.01, *** P < 0.001. 
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Figure 5.5: The mRNA expression of NPT1 in human PTCs under different 
culture conditions.  
NPT1 mRNA expression levels are expressed as percentage 
expression relative to freshly isolated human PTCs. Human PTCs 
cultured for 7 days on Transwell inserts and plastic showed a 43.26  
9.26 % and 45.89  1.82 % decrease in expression in comparison to 
freshly isolated cells (100.00  4.65 %), respectively. The expression 
levels had been normalised to reference gene GAPDH expression 
level prior to comparison. The results are expressed as the mean ± 
SEM from 3 separate batches of RNA derived from 3 individual 
kidneys. One-way ANOVA statistical test was performed on the data 
set to determine significance, ** P < 0.01. 
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Figure 5.6: The mRNA expression of NPT4 in human PTCs under different 
culture conditions.  
NPT4 mRNA expression levels are expressed as percentage 
expression relative to freshly isolated human PTCs. Human PTCs 
cultured for 7 days on Transwell inserts and plastic showed a 16.72  
12.78 % and 24.15  5.32 % decrease in expression in comparison to 
freshly isolated cells (100.00  6.06 %), respectively. The expression 
levels had been normalised to reference gene GAPDH expression 
level prior to comparison. The results are expressed as the mean ± 
SEM from 3 separate batches of RNA derived from 3 individual 
kidneys. One-way ANOVA statistical test was performed on the data 
set to determine significance. 
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Figure 5.7: The mRNA expression of NPT5 in human PTCs under different 
culture conditions.  
NPT5 mRNA expression levels are expressed as percentage 
expression relative to freshly isolated human PTCs. Human PTCs 
cultured for 7 days on Transwell inserts and plastic showed a 25.08  
10.99 % and 1.24  9.12 % decrease in expression in comparison to 
freshly isolated cells (100.00  7.77 %), respectively. The expression 
levels had been normalised to reference gene GAPDH expression 
level prior to comparison. The results are expressed as the mean ± 
SEM from 3 separate batches of RNA derived from 3 individual 
kidneys. One-way ANOVA statistical test was performed on the data 
set to determine significance. 
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Transporter 
% Expression compared to fresh PTCs 
Transwell® Plastic 
NaPi-IIa 63.69  9.18 66.09  2.60 
NaPi-IIc 34.38  4.75 ** 23.87  4.12 ** 
PiT2 37.29  8.95 ** 14.99  5.13 *** 
NPT1 56.74  9.26 ** 54.11  1.82 ** 
NPT4 83.28  12.77 75.85  5.34 
NPT5 74.90  10.99 98.70  9.12 
 
Table 5.1: Percentage change in mRNA expression of Pi transporters in 
human PTCs cultured on plastic and Transwell® inserts when compared 
to freshly isolated PTCs. 
mRNA expression levels of NaPi-IIa, NaPi-IIc, PiT2, NPT1, NPT4 and 
NPT5 were measured using qPCR and shown as a percentage of 
freshly isolated cells. Expression levels had been normalised to 
GAPDH expression levels. Data are the mean  SEM of expression 
levels determined from 3 batches of RNA derived from 3 individual 
kidneys. One-way ANOVA statistical test was performed on the data 
set to determine significance, ** P < 0.01, *** P < 0.001. 
 
5.3.2. Flux and uptake of Pi by human PTC monolayers over time. 
In order to ensure the renal handling of Pi was measured under initial rate 
conditions, the rate of Pi unidirectional transepithelial flux and uptake over fixed 
periods of time were studied. The secretory and absorptive flux of 100 M [32P]-
Pi across human PTC monolayers at 20, 40, and 60 min of exposure were 
measured. Additionally the apical uptake of 100 M [32P]-Pi in human PTC 
monolayers was measured at 0, 1, 5, 10, and 20 min of exposure.  
Figure 5.8 shows the secretory, absorptive and net fluxes of 100 M [32P]-Pi 
increased linearly between the defined time-points (n = 9, N = 3). 
Correspondingly, the uptake of 100 M [32P]-Pi increased linearly between 0 
and 20 min, with a gradient of 70.18  1.38 pmol / cm2 / min (n = 9, N = 3), as 
shown in Figure 5.9. Non-specific binding of [32P]-Pi to the Transwell insert 
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was also found to be 1.62  0.14 pmol / cm2, which was considered to be 
negligible.  
 
Figure 5.8: Time course of unidirectional transepithelial fluxes of 100 M 
[32P]-Pi across human PTC monolayers. 
The fluxes of 100 M [32P]-Pi across human PTC monolayers at 20, 40 
and 60 min of exposure are shown. The secretory, absorptive and net 
fluxes of [32P]-Pi were within the linear initial rate period between 0 
and 60 min. The results are expressed as the mean ± SEM from 12 
human PTC monolayers derived from 3 individual kidneys.  
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Figure 5.9: Time course of 100 M [32P]-Pi uptake across the apical 
membrane of human PTC monolayers. 
The apical membranes of the monolayers were incubated with 100 μM 
[32P]-Pi for 0, 1, 2, 5, 10 or 20 min. The intracellular accumulation of 
[32P]-Pi was linear over this time period. Linear regression analysis of 
the data gave a slope of 70.18  1.38 pmol / cm2 / min (R2: 0.97). The 
non-specific binding of [32P]-Pi to the Transwell insert was 1.62  
0.14 pmol / cm2. The results are expressed as the mean ± SEM from 
12 human PTC monolayers derived from 3 individual kidneys. 
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5.3.3. Flux and uptake of Pi by human PTC monolayers 
Unidirectional transepithelial fluxes of 100 M [32P]-Pi over 60 min in both the 
secretory (basolateral to apical, JB-A) and absorptive (apical to basolateral, JA-B) 
direction were studied in the human PTC monolayer model. The net flux was 
calculated from the difference between the two fluxes. Initial rates of uptake of 
Pi across the basolateral or apical membrane of monolayer was also 
determined by measuring the intracellular accumulation of [32P]-Pi in human 
PTC monolayers after a 5-minute incubation time. 
Figure 5.10 shows a net absorption of Pi (300.94 ± 5.56 pmol / minute / cm2) 
predominates across human PTC monolayers. The absorptive and secretory 
movement of [32P]-Pi were 301.46 ± 5.56 pmol / minute / cm2 and 0.52 ± 0.02 
pmol / minute / cm2, respectively (**** P < 0.0001, n = 12, N = 3). Figure 5.11 
shows the intracellular accumulation of [32P]-Pi, which was representative of 
[32P]-Pi uptake across the basolateral or apical membranes of human PTC 
monolayers. [32P]-Pi uptake across the apical membrane (312.36 ± 5.13 pmol / 
minute / cm2) was 4.72-times greater than across the basolateral membrane 
(66.22 ± 1.50 pmol / minute / cm2) (**** P < 0.0001, n = 12, N = 3). This 
information suggests the transporters responsible for Pi uptake are 
predominantly located on the apical membrane of human PTC monolayers. 
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Figure 5.10: Unidirectional transepithelial fluxes of 100 M [32P]-Pi across 
human PTC monolayers. 
In order to determine the secretory and absorptive fluxes of Pi across 
human PTC monolayers, paired monolayers were incubated with 100 
μM [32P]-Pi at either the basolateral or apical chamber for 60 min. The 
results show a net absorptive flux (300.94 ± 5.56 pmol / minute / cm2). 
The absorptive movement of [32P]-Pi was 301.46 ± 5.56 pmol / minute 
/ cm2, whilst the secretory movement was negligible (0.52 ± 0.02 pmol 
/ minute / cm2) (**** P < 0.0001). The results are expressed as the 
mean ± SEM from 12 human PTC monolayers derived from 3 
individual kidneys. Significance was determined by a Student’s t-test. 
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Figure 5.11: Uptake of 100 M [32P]-Pi across the basolateral and apical 
membrane of human PTC monolayers. 
Paired monolayers were incubated with 100 μM [32P]-Pi at either the 
basolateral or apical chamber for 5 min. The data show that the initial 
rates of uptake of [32P]-Pi across the apical membrane (312.36 ± 5.13 
pmol / minute / cm2) was 4.72-times greater than across the 
basolateral membrane (66.22 ± 1.50 pmol / minute / cm2) (**** P < 
0.0001). The results are expressed as the mean ± SEM from 12 
human PTC monolayers derived from 3 individual kidneys. 
Significance was determined by a Student’s t-test. 
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5.3.4. Kinetics of Pi transport by human PTC monolayers. 
Kinetic parameters of Pi uptake across the apical membrane of human PTC 
monolayers were also calculated. Monolayers were incubated at the apical 
membrane with a range of [32P]-Pi concentrations (10 to 500 M) for 5 min and 
the intracellular accumulation of [32P]-Pi was measured. Figure 5.12 shows the 
relationship between extracellular [32P]-Pi concentration and intracellular 
accumulation of [3H]-TFV (n = 9, N = 3). Non-linear regression analysis of the 
data gave a Vmax of 562.90  99.18 pmol / minute / cm2 and an apparent Km 
value of 106.05  36.40 M.  
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Figure 5.12: Kinetic data on [32P]-Pi uptake across the apical membrane of 
human PTC monolayers under initial rate conditions. 
In order to obtain kinetic data on Pi uptake under initial rate 
conditions, the monolayers were incubated with a range of [32P]-Pi 
concentrations (10 to 500 M) for 5 min. Non-linear regression 
analysis of the data gave a Vmax of 562.90  99.18 pmol / minute / cm2 
and an apparent Km value of 106.05  36.40 M. The results are 
expressed as the mean ± SEM from 9 human PTC monolayers derived 
from 3 individual kidneys. 
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5.3.5. The effect of sodium concentration upon Pi renal handling by 
human PTC monolayers. 
The key renal Pi transporters expressed in proximal tubule cells are sodium 
(Na+) dependent. Therefore the Na+ dependence of Pi uptake at the apical 
membrane was investigated in human PTC monolayers. The uptake of 100 M 
[32P]-Pi was measured in the presence and absence of Na+ over several time 
points. In addition, the kinetics of apical Pi uptake in the presence of a range of 
Na+ concentrations (0 to 150 mM) were also determined. 
Figure 5.13 shows the apical uptake of Pi was significantly attenuated by the 
absence of Na+ (n = 12, N = 3). Linear regression analysis of the data gave a 
slope of 70.18  1.38 pmol / cm2 / minute in the presence of 137 mM Na+, and 
0.66  0.11 pmol / cm2 / minute in the absence of Na+. Furthermore, a strong 
correlation between Na+ concentration and apical uptake of 100 M [32P]-Pi was 
observed in Figure 5.14 and Figure 5.15 (n = 12, N = 3). Na+ uptake increased 
linearly with Na+ concentration up to 120 mM. Uptake then plateaued between 
120 and 137 mM Na+. The buffer solution used in this experiment was 
hypertonic at 150 mM Na+, which resulted in cell crenation and little uptake of Pi. 
The maximum rate of Pi uptake was 312.36  5.13 pmol / minute / cm2 at 137 
mM Na+. When the data was plotted as shown in Figure 5.15, non-linear 
regression analysis of the data gave an estimated Hill coefficient of 1.88  0.16, 
and Km value of 38.15  1.89 mM Na+. 
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Figure 5.13: The effect of Na+ on uptake of 100 M [32P]-Pi across the 
apical membrane of human PTC monolayers. 
Uptake of 100 M [32P]-Pi across the apical membrane of human PTC 
monolayers was measured in the presence and absence of Na+ over 
several time points (0 to 20 min). The results show uptake of [32P]-Pi 
across the apical membrane was Na+ dependent. Linear regression 
analysis of the data gave a slope of 70.18  1.38 pmol / cm2 / min in 
the presence of 137 mM Na+, and 0.66  0.11 pmol / cm2 / min in the 
absence (0 mM) Na+. The results are expressed as the mean ± SEM 
from 12 human PTC monolayers derived from 3 individual kidneys.  
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Figure 5.14: The effect of Na+ concentration on uptake of 100 M [32P]-Pi 
across the apical membrane of human PTC monolayers. 
Uptake of 100 M [32P]-Pi across the apical membrane of human PTC 
monolayers was measured over a range of Na+ concentrations (0 to 
150 mM). The results show uptake of [32P]-Pi across the apical 
membrane was Na+ dependent. Uptake of [32P]-Pi was 11.93  1.09 
pmol / minute / cm2 at 0 mM Na+, 111.56  4.10 pmol / minute / cm2 at 
25 mM Na+, 175.29  10.31 pmol / minute / cm2 at 50 mM Na+, 244.63 
 12.90 pmol / minute / cm2 at 100 mM Na+, 306.88  7.48 pmol / 
minute / cm2 at 120 mM Na+, 312.36  5.13 pmol / minute / cm2 at 137 
mM Na+, and 33.07  8.46 pmol / minute / cm2 at 150 mM Na+. The 
results are expressed as the mean ± SEM from 12 human PTC 
monolayers derived from 3 individual kidneys. 
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Figure 5.15: The kinetics of Na+ and uptake of 100 M [32P]-Pi across the 
apical membrane of human PTC monolayers. 
Uptake of 100 M [32P]-Pi across the apical membrane of human PTC 
monolayers was measured in a range of concentrations of Na+ (0 to 
137 mM). The results show uptake of [32P]-Pi across the apical 
membrane was Na+ dependent. The Vmax was constrained to 312.36 
pmol / min / cm2 based upon previous findings. Non-linear regression 
analysis of the data gave an estimated Hill coefficient of 1.88  0.16, 
and Km value of 38.15  1.89 mM Na+. The results are expressed as 
the mean ± SEM from 12 human PTC monolayers derived from 3 
individual kidneys. 
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5.3.6. The effect of pH upon Pi renal handling by human PTC 
monolayers. 
The effect of pH on the rate of Pi uptake was studied in human PTC monolayers. 
The apical uptake of 100 M [32P]-Pi was measured in experimental buffer of pH 
6.0, 6.5, 7.0, 7.5 and 8.0. As shown in Figure 5.16, the rate of Pi uptake was 
dependent on pH. For instance increasing the pH from 6.0 (154.45  12.64 
pmol / minute / cm2) to 7.5 (317.09  4.43 pmol / minute / cm2) doubled the rate 
of Pi uptake.  
 
Figure 5.16: The effect of pH on uptake of 100 M [32P]-Pi across the apical 
membrane of human PTC monolayers. 
The uptake of 100 M [32P]-Pi across the apical membrane of human 
PTC monolayers was measured in experimental buffer of pH 6.0, 6.5, 
7.0, 7.5 and 8.0. The results show uptake of [32P]-Pi across the apical 
membrane was pH dependent. Uptake of [32P]-Pi was 154.45  12.64 
pmol / minute / cm2 at pH 6.0, 216.37  14.71 pmol / minute / cm2 at 
pH 6.5, 246.28  13.66 pmol / minute / cm2 at pH 7.0, 317.09  4.43 
pmol / minute / cm2 at pH 7.5, and 324.83  11.51 pmol / minute / cm2 
at pH 8.0. The results are expressed as the mean ± SEM from 12 
human PTC monolayers derived from 3 individual kidneys. 
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5.3.7. The effect of PFA upon Pi renal handling by human PTC 
monolayers. 
PFA has been shown to competitively inhibit both NaPi-IIa and NaPi-IIc 
cotransport. In order to confirm expression of NaPi-IIa, NaPi-IIc or both, the 
effect of PFA on the rate of Pi uptake was studied in human PTC monolayers. 
Apical uptake of 100 M [32P]-Pi was measured in the presence of a range of 
PFA concentrations (100 to 1500 M). The results in Figure 5.17 show the 
presence of PFA significantly inhibited Pi uptake (n = 9, N = 3). Non-linear 
regression analysis of the data gave an apparent IC50 value of 570.35  62.50 
M. This observation confirms human PTC monolayers express NaPi-IIa and/or 
NaPi-IIc at a functional level.  
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Figure 5.17: The effect of PFA on the renal handling of 100 M [32P]-Pi by 
human PTC monolayers.  
The uptake of 100 M [32P]-Pi across the apical membrane of human 
PTC monolayers was measured in the presence of a range of 
concentrations of PFA (10 to 1500 M). The presence of PFA 
significantly inhibited Pi uptake. Non-linear regression analysis of the 
data gave an apparent IC50 value of 570.35  62.50 M. The results 
are expressed as the mean ± SEM from 9 human PTC monolayers 
derived from 3 individual kidneys. 
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5.3.8. The effect of PTH upon Pi renal handling by human PTC 
monolayers. 
As previously mentioned, PTH binding to PTHR1 on the basolateral membrane 
of proximal tubular cells down regulates expression of NaPi-IIa, NaPi-IIc, and 
PiT2. In order to confirm human PTC cells retain PTH intracellular signalling 
pathways, the effect of PTH on the rate of Pi uptake was studied in human PTC 
monolayers. The uptake of 100 M [32P]-Pi across the apical membrane of 
human PTC monolayers was measured in the presence of a range of PTH 
concentrations (0 to 10 nM). The presence of PTH significantly inhibited Pi 
uptake in a concentration dependent manner, as illustrated by the results in 
Figure 5.18 (n = 12, N = 3). These findings confirm the PTH intracellular 
signalling pathways were retained during culture of human PTCs. 
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Figure 5.18: The effect of PTH on the renal handling of 100 M [32P]-Pi by 
human PTC monolayers.  
The uptake of 100 M [32P]-Pi across the apical membrane of human 
PTC monolayers was measured in the presence of a range of 
concentrations of PTH (0 to 10 nM). The presence of PTH significantly 
inhibited Pi uptake in a concentration dependent manner. The results 
are expressed as the mean ± SEM from 12 human PTC monolayers 
derived from 3 individual kidneys. Significance was determined using 
ANOVA and a Dunnett’s post-test. 
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5.3.9. The effect of FGF-23 and -klotho upon Pi renal handling by 
human PTC monolayers. 
FGF-23 and serum soluble α-klotho also down regulate proximal tubular cell 
expression of NaPi-IIa, NaPi-IIc, and PiT2. In order to confirm human PTC cells 
retain FGF-23 and α-klotho intracellular signalling pathways, the effects of FGF-
23 and α-klotho on the rate of Pi uptake were studied in human PTC 
monolayers. FGFs are heparin-binding proteins. Interactions with cell-surface-
associated heparin sulphate proteoglycans have been shown to be essential for 
FGF signal transduction. Therefore an excess of heparin was included in FGF 
experiments. 
The uptake of 100 M [32P]-Pi across the apical membrane of human PTC 
monolayers was measured in the presence 0.89 nM FGF-23 and 0.55 mM 
heparin at either the apical or basolateral membrane. As shown in Figure 5.19, 
the presence of FGF-23 and heparin at the basolateral membrane inhibited Pi 
uptake by 20.33 ± 0.64 %, whereas the presence of FGF-23 and heparin at the 
apical membrane did not have a significant effect (0.15 ± 0.25 % inhibition) (n = 
12, N = 3). These results imply that the FGF receptors were located at the 
basolateral membrane of the human PTC monolayers, and that membrane-
bound α-klotho and the FGF-23 intracellular signalling pathways were retained 
during culture. 
This study was repeated by replacing 0.89 nM FGF-23 with 0.90 nM α-klotho 
and the results are shown in Figure 5.20. The presence of -klotho at the 
basolateral membrane inhibited Pi uptake by 29.04 ± 1.27 %, whilst the 
presence of -klotho at the apical membrane did not have a significant effect 
(5.54 ± 1.50 % inhibition) (n = 12, N = 3). These findings suggest that soluble α-
klotho bound to FGF receptor 1 (FGFR1) at the basolateral membrane of 
human PTC monolayers and caused a decrease in Pi absorption, and the cells 
retained α-klotho intracellular signalling pathway in culture. 
In Figure 5.21, the uptake of 100 M [32P]-Pi across the apical membrane of 
human PTC monolayers in the presence of 0.89 nM FGF-23, 0.90 nM α-klotho 
and 0.55 mM heparin is shown. The presence of FGF-23, heparin and -klotho 
at the basolateral membrane inhibited Pi uptake significantly greater than the 
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presence of each alone (39.18 ± 1.39 % inhibition) suggesting an additive effect 
(n = 12, N = 3). 
The effect of -klotho concentration on the rate of Pi uptake was also studied in 
human PTC monolayers. The uptake of 100 M [32P]-Pi across the apical 
membrane of human PTC monolayers was measured in the presence of a 
range of -klotho concentrations (0.18 to 5.4 nM). Figure 5.22 shows the 
presence of -klotho significantly inhibited Pi uptake in a concentration 
dependent manner (n = 8, N = 2). 
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Figure 5.19: The effect of FGF-23 on the renal handling of 100 M [32P]-Pi 
by human PTC monolayers.  
The uptake of 100 M [32P]-Pi across the apical membrane of human 
PTC monolayers was measured in the presence and absence of 0.89 
nM FGF-23. 0.55 mM heparin was in all conditions. A positive control 
of 1 mM PFA was included. The presence of 1 mM PFA inhibited 
uptake of 100 M [32P]-Pi across the apical membrane by 31.06 ± 
2.96 %. The presence of 0.89 nM FGF-23 at the basolateral 
membrane inhibited Pi uptake by 20.33 ± 0.64 %, whilst the presence 
of 0.89 nM FGF-23 at the apical membrane did not have a significant 
effect (0.15 ± 0.25 % inhibition). The results are expressed as the 
mean ± SEM from 12 human PTC monolayers derived from 3 
individual kidneys. Significance was determined using ANOVA and a 
Dunnett’s post-test. 
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Figure 5.20: The effect of –klotho on the renal handling of 100 M [32P]-Pi 
by human PTC monolayers.  
The uptake of 100 M [32P]-Pi across the apical membrane of human 
PTC monolayers was measured in the presence and absence of 0.90 
nM -klotho. 0.55 mM heparin was used in all conditions. A positive 
control of 1 mM PFA was included. The presence of 1 mM PFA 
inhibited uptake of 100 M [32P]-Pi across the apical membrane by 
31.06 ± 2.96 %. The presence of 0.90 nM -klotho at the basolateral 
membrane inhibited Pi uptake by 29.04 ± 1.27 %, whilst the presence 
of 0.90 nM -klotho at the apical membrane did not have a significant 
effect (5.54 ± 1.50 % inhibition). The results are expressed as the 
mean ± SEM from 12 human PTC monolayers derived from 3 
individual kidneys. Significance was determined using ANOVA and a 
Dunnett’s post-test. 
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Figure 5.21: The effect of FGF-23 and –klotho on the renal handling of 
100 M [32P]-Pi by human PTC monolayers. 
The uptake of 100 M [32P]-Pi across the apical membrane of human 
PTC monolayers was measured in the presence and absence of 1 mM 
PFA, 0.89 nM FGF-23 and 0.90 nM -klotho. 0.55 mM heparin was 
included in all experiments. The presence of 1 mM PFA inhibited 
uptake of 100 M [32P]-Pi across the apical membrane by 31.06 ± 
2.96 %. The presence of 0.89 nM FGF-23 and 0.55 mM heparin at the 
basolateral membrane inhibited Pi uptake by 20.33 ± 0.64 %. The 
presence of 0.90 nM -klotho and 0.55 mM heparin at the basolateral 
membrane inhibited Pi uptake by 29.04 ± 1.27 %. The presence of 
0.89 nM FGF-23, 0.90 nM -klotho and 0.55 mM heparin at the 
basolateral membrane inhibited Pi uptake significantly greater than 
the presence of each alone (39.18 ± 1.39 % inhibition). The results 
are expressed as the mean ± SEM from 12 human PTC monolayers 
derived from 3 individual kidneys. Significance was determined using 
ANOVA and a Dunnett’s post-test. 
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Figure 5.22: The effect of –klotho on the renal handling of 100 M [32P]-Pi 
by human PTC monolayers. 
The uptake of 100 M [32P]-Pi across the apical membrane of human 
PTC monolayers was measured in the presence of a range of 
concentrations of -klotho (0.18 to 0.54 nM). The presence of -
klotho significantly inhibited Pi uptake in a concentration dependent 
manner. The results are expressed as the mean ± SEM from 8 human 
PTC monolayers derived from 2 individual kidneys. Significance was 
determined using ANOVA and a Dunnett’s post-test. 
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5.3.10. The effect of TFV upon Pi renal handling by human PTC 
monolayers. 
The effect of TFV on the rate of Pi uptake was studied in human PTC 
monolayers. Initially, the uptake of 100 M [32P]-Pi across the apical membrane 
of human PTC monolayers was measured in the presence and absence of 10 
µM TFV. As shown in Figure 5.23, apical uptake of Pi was 312.40 ± 5.13 pmol / 
minute /cm2 in the absence of TFV, and 201.80 ± 3.28 pmol / minute / cm2 in 
the presence of 10 M TFV, which equates to a 35.40 ± 1.05 % decrease in Pi 
uptake. The kinetics of inhibition were determined by measuring Pi uptake in the 
presence of a range of TFV concentrations (1 to 500 µM). TFV inhibited Pi 
uptake in a concentration dependent manner, Figure 5.24. Non-linear 
regression analysis of the data gave an apparent IC50 value of 52.25  4.71 M 
TFV. 
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Figure 5.23: The effect of 10 M TFV on the renal handling of 100 M [32P]-
Pi by human PTC monolayers.  
The uptake of 100 M [32P]-Pi across the apical membrane of human 
PTC monolayers was measured in the presence and absence of 10 
M TFV. The presence of TFV inhibited uptake of 100 M [32P]-Pi 
across the apical membrane by 35.40 ± 1.05 %; apical uptake of Pi 
was 312.40 ± 5.13 pmol / minute /cm2 in the absence of TFV, 
compared to 201.80 ± 3.28 pmol / minute / cm2 in the presence of 10 
M TFV. The results are expressed as the mean ± SEM from 12 
human PTC monolayers derived from 3 individual kidneys. 
Significance was determined by a Student’s t-test. 
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Figure 5.24: The kinetics of TFV inhibition of apical uptake of 100 M [32P]-
Pi across human PTC monolayers.  
The uptake of 100 M [32P]-Pi across the apical membrane of human 
PTC monolayers was measured in the presence of a range of TFV 
concentrations. TFV inhibited Pi uptake in a concentration dependent 
manner. Non-linear regression analysis of the data gave an apparent 
IC50 value of 52.25  4.71 M TFV. The results are expressed as the 
mean ± SEM from 12 human PTC monolayers derived from 3 
individual kidneys. 
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5.3.11. Flux and uptake of Pi by rat PTC monolayers over time. 
To ensure the renal handling of Pi was measured under initial rate conditions, 
the rate of Pi unidirectional transepithelial fluxes and uptake over time were 
studied. The secretory and absorptive fluxes of 100 M [32P]-Pi across rat PTC 
monolayers following 20, 40, and 60 min of exposure were measured. 
Additionally the uptake of 100 M [32P]-Pi across the apical membrane of rat 
PTC monolayers was measured at 0, 1, 5, 10, and 20 min of exposure.  
Figure 5.25 shows the secretory, absorptive and net fluxes of 100 M [32P]-Pi 
increased linearly between the defined time-points (n = 9, N = 3). 
Correspondingly, the uptake of 100 M [32P]-Pi increased linearly between 0 
and 20 min, with a gradient of 2.86  0.12 pmol / cm2 / minute (n = 9, N = 3), as 
shown in Figure 5.26. We can thus deduce that 0 to 60 min lies within the linear 
rate of Pi transport. Non-specific binding of [32P]-Pi to the Transwell insert was 
also found to be 0.19  0.03 pmol / cm2, which was considered to be negligible.  
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Figure 5.25: Time course of unidirectional fluxes of 100 M [32P]-Pi across 
rat PTC monolayers.  
The fluxes of 100 M [32P]-Pi across rat PTC monolayers over the 
defined periods of time are shown. The fluxes of [32P]-Pi were within 
the initial rate period between 0 and 60 min as secretory, absorptive 
and net fluxes were linear over this time period. The results are 
expressed as the mean ± SEM from 12 rat PTC monolayers derived 
from 3 individual kidneys.  
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Figure 5.26: Time course of 100 M [32P]-Pi uptake across the apical 
membrane of rat PTC monolayers. 
The apical membranes of the monolayers were incubated with 100 μM 
[32P]-Pi for 0, 1, 2, 5, 10 or 20 min. The rate of uptake of [32P]-Pi was 
linear within the time period investigated. Linear regression analysis 
of the data gave a slope of 2.86  0.12 pmol / cm2 / minute (R2: 0.89). 
The non-specific binding of [32P]-Pi to the Transwell insert was 0.19 
 0.03 pmol / cm2. The results are expressed as the mean ± SEM from 
12 rat PTC monolayers derived from 3 individual kidneys. 
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5.3.12. Flux of Pi by rat PTC monolayers. 
Unidirectional transepithelial fluxes of 100 M [32P]-Pi over 60 min in both the 
secretory and absorptive direction were also studied in the rat PTC monolayer 
model. The findings in Figure 5.27 show a net absorption of Pi (1101.15 ± 24.84 
pmol / minute / cm2) across the rat PTC monolayers. The absorptive and 
secretory movement of [32P]-Pi was 1129.06 ± 25.01 pmol / minute / cm2 and 
27.91 ± 1.09 pmol / minute / cm2, respectively (**** P < 0.0001, n = 12, N = 3). 
These findings suggest the transporters responsible for Pi uptake are 
predominantly located on the apical membrane of rat PTC monolayers. 
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Figure 5.27: Unidirectional fluxes of 100 M [32P]-Pi by rat PTC monolayers. 
To determine the secretory and absorptive fluxes of Pi by rat PTC 
monolayers, paired monolayers were incubated with 100 μM [32P]-Pi at 
either the basolateral or apical chamber. The results show a net 
absorptive flux (1101.15 ± 24.84 pmol / minute / cm2). The absorptive 
movement of [32P]-Pi was 1129.06 ± 25.01 pmol / minute / cm2, whilst 
the secretory movement was very small (27.91 ± 1.09 pmol / minute / 
cm2) (**** P < 0.0001). The results are expressed as the mean ± SEM 
from 12 rat PTC monolayers derived from 3 individual kidneys. 
Significance was determined by a Student’s t-test. 
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5.3.13. Kinetics of Pi transport by rat PTC monolayers. 
The kinetic parameters of Pi transport across the apical membrane of rat PTC 
monolayers were also investigated.  
Rat PTC monolayers were incubated at the apical membrane with a range of 
[32P]-Pi concentrations (100 to 1000 M) for 5 min and the intracellular 
accumulation of [32P]-Pi was measured. Figure 5.28 shows the relationship 
between [32P]-Pi concentration and uptake of [3H]-TFV across the apical 
membrane of rat PTC monolayers (n = 9, N = 3). Non-linear regression analysis 
of the data gave a Vmax of 433.90  30.42 pmol / minute / cm2 and an apparent 
Km value of 1221.36 133.23 M. 
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Figure 5.28: Kinetic data on [32P]-Pi uptake across the apical membrane of 
rat PTC monolayers under initial rate conditions. 
In order to obtain kinetic data on Pi uptake under initial rate 
conditions, the monolayers were incubated with a range of [32P]-Pi 
concentrations (100 to 1000 M) for 5 min. Non-linear regression 
analysis of the data gave a Vmax of 433.90  30.42 pmol / minute / cm2 
and an apparent Km value of 1221.36 133.23 M Pi. The results are 
expressed as the mean ± SEM from 9 rat PTC monolayers derived 
from 3 individual kidneys. 
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5.3.14. The effect of Na+ concentration upon Pi renal handling 
by rat PTC monolayers. 
The Na+ dependence of Pi uptake at the apical membrane was investigated 
using rat PTC monolayers. The uptake of 100 M [32P]-Pi was measured in the 
presence and absence of Na+ over a range of time points. In addition to this the 
kinetics of apical Pi uptake in the presence of a range of Na+ concentrations (0 
to 137 mM) were also investigated. 
Figure 5.29 shows the apical uptake of Pi was significantly reduced in the 
absence of Na+ (n = 12, N = 3). Linear regression analysis of the data gave a 
slope of 2.86  0.12 pmol / cm2 / minute in the presence of 137 mM Na+, and 
0.64  0.04 pmol / cm2 / minute with no Na+. Furthermore, Figure 5.30 shows a 
strong correlation between Na+ concentration and apical uptake of 100 M 
[32P]-Pi (n = 12, N = 3). The maximum rate of Pi uptake was 25.99  1.24 pmol / 
minute / cm2 at 137 mM Na+. Non-linear regression analysis of the data gave an 
estimated Hill coefficient of 2.80  0.29, and Km value of 58.26  2.61 mM Na+. 
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Figure 5.29: The effect of Na+ upon uptake of 100 M [32P]-Pi across the 
apical membrane of rat PTC monolayers.  
Uptake of 100 M [32P]-Pi across the apical membrane of rat PTC 
monolayers was measured in the presence and absence of Na+ over 
several time points (0 to 20 min). The results show uptake of [32P]-Pi 
across the apical membrane was Na+ dependent. Linear regression 
analysis of the data gave a slope of 2.86  0.12 pmol / cm2 / minute in 
the presence of 137 mM Na+, and 0.64  0.04 pmol / cm2 / minute in 
its absence. The results are expressed as the mean ± SEM from 12 
rat PTC monolayers derived from 3 individual kidneys. 
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Figure 5.30: The kinetics of Na+ and uptake of 100 M [32P]-Pi across the 
apical membrane of rat PTC monolayers.  
Uptake of 100 M [32P]-Pi across the apical membrane of rat PTC 
monolayers was measured in a range of concentrations of Na+ (0 to 
137 mM). The results show uptake of [32P]-Pi across the apical 
membrane was Na+ dependent. The Vmax was constrained to 25.99 
pmol / min / cm2 based upon previous findings. Non-linear regression 
analysis of the data gave an estimated Hill coefficient of 2.80  0.29, 
and Km value of 58.26 ± 2.61 mM Na+. The results are expressed as 
the mean ± SEM from 12 rat PTC monolayers derived from 3 
individual kidneys. 
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5.3.15. The effect of pH upon Pi renal handling by rat PTC 
monolayers. 
The effect of pH on the rate of Pi uptake was studied in rat PTC monolayers. 
The apical uptake of 100 M [32P]-Pi was measured in experimental buffer of pH 
6.0, 6.5, 7.0, 7.5 and 8.0. As shown in Figure 5.31, the rate of Pi uptake was 
dependent on pH. For instance increasing the pH from 6.0 (12.27  0.48 pmol / 
minute / cm2) to 7.5 (27.86  0.54 pmol / minute / cm2) more than doubled the 
rate of Pi uptake.  
 
Figure 5.31: The effect of pH upon uptake of 100 M [32P]-Pi across the 
apical membrane of rat PTC monolayers. 
The uptake of 100 M [32P]-Pi across the apical membrane of rat PTC 
monolayers was measured in experimental buffer of pH 6.0, 6.5, 7.0, 
7.5 and 8.0. The results show uptake of [32P]-Pi across the apical 
membrane was pH dependent. Uptake of [32P]-Pi was 12.27  0.48 
pmol / minute / cm2 at pH 6.0, 18.24  0.31 pmol / minute / cm2 at pH 
6.5, 21.71  0.41 pmol / minute / cm2 at pH 7.0, 27.86  0.54 pmol / 
minute / cm2 at pH 7.5, and 31.82  0.83 pmol / minute / cm2 at pH 
8.0. The results are expressed as the mean ± SEM from 12 rat PTC 
monolayers derived from 3 individual kidneys. 
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5.3.16. The effect of PFA upon Pi renal handling by rat PTC 
monolayers. 
In order to confirm expression of NaPi-IIa and/or NaPi-IIc, the effect of PFA on 
the rate of Pi uptake was studied in rat PTC monolayers. Apical uptake of 100 
M [32P]-Pi was measured in the presence of a range of PFA concentrations 
(100 to 1500 M). The results in Figure 5.32 show the presence of PFA 
significantly inhibited Pi uptake (n = 9, N = 3). Non-linear regression analysis of 
the data gave an apparent IC50 value of 1046.08 ± 158.42 M. This observation 
confirms rat PTC monolayers expressed NaPi-IIa and/or NaPi-IIc at the 
functional level. 
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Figure 5.32: The effect of PFA on the renal handling of 100 M [32P]-Pi by 
rat PTC monolayers. 
The uptake of 100 M [32P]-Pi across the apical membrane of rat PTC 
monolayers was measured in the presence of a range of 
concentrations of PFA (100 to 1500 M). The presence of PFA 
significantly inhibited Pi uptake. Non-linear regression analysis of the 
data gave an apparent IC50 value of 1046.08 ± 158.42 M PFA. The 
results are expressed as the mean ± SEM from 9 rat PTC monolayers 
derived from 3 individual kidneys. 
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5.3.17. The effect of PTH upon Pi renal handling by rat PTC 
monolayers. 
In order ascertain the retention of PTH intracellular signalling pathways in 
culture rat PTCs, the effect of PTH on the rate of Pi uptake was studied in rat 
PTC monolayers. The uptake of 100 M [32P]-Pi across the apical membrane of 
monolayers was measured in the presence of a range of PTH concentrations (0 
to 10 nM). The presence of PTH significantly inhibited Pi uptake in a 
concentration dependent manner (Figure 5.33, n = 12, N = 3). These findings 
confirm the PTH intracellular signalling pathways were retained during culture. 
 
Figure 5.33: The effect of PTH on the renal handling of 100 M [32P]-Pi by 
rat PTC monolayers.  
The uptake of 100 M [32P]-Pi across the apical membrane of rat PTC 
monolayers was measured in the presence of a range of 
concentrations of PTH (0 to 10 nM). The presence of PTH significantly 
inhibited Pi uptake in a concentration dependent manner. The results 
are expressed as the mean ± SEM from 12 rat PTC monolayers 
derived from 3 individual kidneys. Significance was determined using 
ANOVA and a Dunnett’s post-test. 
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5.3.18. The effect of FGF-23 and -klotho upon Pi renal 
handling by rat PTC monolayers. 
In order to confirm FGF-23 and α-klotho intracellular signalling pathways in 
cultured rat PTCs, the effect of FGF-23 and α-klotho on the rate of Pi uptake 
was studied in rat PTC monolayers.  
The uptake of 100 M [32P]-Pi across the apical membrane of rat PTC 
monolayers was measured in the presence of 0.89 nM FGF-23 and 0.55 mM 
heparin at either the apical or basolateral membrane. As shown in Figure 5.34, 
the presence of FGF-23 and heparin at the basolateral membrane inhibited Pi 
uptake by 13.97 ± 1.18 %, whereas the presence of FGF-23 and heparin at the 
apical membrane did not have a significant effect (2.45 ± 1.19 % inhibition) (n = 
12, N = 3). These results imply that the Fgf receptors were located at the 
basolateral membrane of the rat proximal tubular cells, the monolayers express 
membrane-bound α-klotho and the FGF-23 intracellular signalling pathways 
were retained during culture. 
This study was repeated by replacing 0.89 nM FGF-23 with 0.90 nM α-klotho 
and the results are shown in Figure 5.35. The presence of -klotho at the 
basolateral membrane inhibited Pi uptake by 20.28 ± 1.64 %, whilst the 
presence of -klotho at the apical membrane did not have a significant effect 
(4.30 ± 1.87 % inhibition) (n = 12, N = 3). These findings suggest that binding of 
soluble α-klotho to Fgfr1 at the basolateral membrane of rat PTC monolayers 
caused a decrease in Pi reabsorption. This also implies the cells retained the α-
klotho intracellular signalling pathways in culture. 
In Figure 5.36, the uptake of 100 M [32P]-Pi across the apical membrane of rat 
PTC monolayers in the presence of 0.89 nM FGF-23, 0.90 nM α-klotho and 
0.55 mM heparin is shown. The presence of FGF-23, heparin and -klotho at 
the basolateral membrane inhibited Pi uptake significantly more than the 
presence of each alone (38.81 ± 1.23 % inhibition) suggesting an additive effect 
(n = 12, N = 3). 
The effect of different -klotho concentrations on the rate of Pi uptake was 
studied in rat PTC monolayers. The uptake of 100 M [32P]-Pi across the apical 
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membrane of monolayers was measured in the presence of a range of -klotho 
concentrations (0.18 to 5.4 nM). As shown in Figure 5.37, the presence of -
klotho significantly inhibited Pi uptake in a concentration dependent manner (n = 
8, N = 2). 
 
Figure 5.34: The effect of FGF-23 on the renal handling of 100 M [32P]-Pi 
by rat PTC monolayers. 
The uptake of 100 M [32P]-Pi across the apical membrane of rat PTC 
monolayers was measured in the presence and absence of FGF-23. A 
positive control of 1 mM PFA was included. The presence of 1 mM 
PFA inhibited uptake of 100 M [32P]-Pi across the apical membrane 
by 42.95 ± 1.38 %. The presence of FGF-23 at the basolateral 
membrane inhibited Pi uptake by 13.97 ± 1.18 %, but the presence of 
FGF-23 at the apical membrane did not have a significant effect (2.45 
± 1.19 % of inhibition). The results are expressed as the mean ± SEM 
from 12 rat PTC monolayers derived from 3 individual kidneys. 
Significance was determined using ANOVA and a Dunnett’s post-test. 
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Figure 5.35: The effect of –klotho on the renal handling of 100 M [32P]-Pi 
by rat PTC monolayers.  
The uptake of 100 M [32P]-Pi across the apical membrane of rat PTC 
monolayers was measured in the presence and absence of -klotho. 
A positive control of 1 mM PFA was included. The presence of 1 mM 
PFA inhibited uptake of 100 M [32P]-Pi across the apical membrane 
by 42.95 ± 1.38 %. The presence of -klotho at the basolateral 
membrane inhibited Pi uptake by 20.28 ± 1.64 %, whilst the presence 
of -klotho at the apical membrane did not have a significant effect 
(4.30 ± 1.87 % inhibition). The results are expressed as the mean ± 
SEM from 12 rat PTC monolayers derived from 3 individual kidneys. 
Significance was determined using ANOVA and a Dunnett’s post-test. 
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Figure 5.36: The effect of FGF-23 and –klotho on the renal handling of 
100 M [32P]-Pi by rat PTC monolayers.  
The uptake of 100 M [32P]-Pi across the apical membrane of rat PTC 
monolayers was measured in the presence and absence of FGF-23 
and -klotho. A positive control of 1 mM PFA was included. The 
presence of 1 mM PFA inhibited uptake of 100 M [32P]-Pi across the 
apical membrane by 42.95 ± 1.38 %. The presence of FGF-23 at the 
basolateral membrane inhibited Pi uptake by 15.47 ± 0.85 %. The 
presence of -klotho at the basolateral membrane inhibited Pi uptake 
by 20.28 ± 1.64 %. The presence of both FGF-23 and -klotho at the 
basolateral membrane inhibited Pi uptake significantly more than the 
presence of each alone (38.81 ± 1.23 % inhibition). The results are 
expressed as the mean ± SEM from 12 rat PTC monolayers derived 
from 3 individual kidneys. Significance was determined using ANOVA 
and a Dunnett’s post-test. 
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Figure 5.37: The effect of –klotho on the renal handling of 100 M [32P]-Pi 
by rat PTC monolayers.  
The uptake of 100 M [32P]-Pi across the apical membrane of rat PTC 
monolayers was measured in the presence of a range of 
concentrations of -klotho (0.18 to 0.54 nM). -klotho significantly 
inhibited Pi uptake in a concentration dependent manner. The results 
are expressed as the mean ± SEM from 8 rat PTC monolayers derived 
from 2 individual kidneys. Significance was determined using ANOVA 
and a Dunnett’s post-test. 
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5.3.19. The effect of TFV upon Pi renal handling by rat PTC 
monolayers. 
The effect of TFV on the rate of Pi uptake was studied in rat PTC monolayers. 
Initially the uptake of 100 M [32P]-Pi across the apical membrane of 
monolayers was measured in the presence and absence of 10 µM TFV. As 
shown in Figure 5.38, the presence of 10 µM TFV inhibited uptake of 100 M 
[32P]-Pi across the apical membrane by 25.05 ± 3.27 %. Apical uptake of Pi was 
25.99 ± 1.24 pmol / minute /cm2 in the absence of TFV, but fell to 19.48 ± 0.85 
pmol / minute / cm2 in the presence of 10 M TFV. The kinetics of inhibition 
were determined by measuring uptake in the presence of a range of TFV 
concentrations (1 to 500 µM). TFV inhibited Pi uptake in a concentration 
dependent manner, as shown in Figure 5.39. Non-linear regression analysis of 
the data gave an apparent IC50 value of 68.75 ± 5.24 M TFV. 
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Figure 5.38: The effect of 10 M TFV on the renal handling of 100 M [32P]-
Pi by rat PTC monolayers. 
The uptake of 100 M [32P]-Pi across the apical membrane of rat PTC 
monolayers was measured in the presence and absence of 10 M TFV. 
The presence of TFV inhibited uptake of 100 M [32P]-Pi across the 
apical membrane by 25.05 ± 3.27 %. Apical uptake of Pi was 25.99 ± 
1.24 pmol / minute /cm2 in the absence of TFV, compared to 19.48 ± 
0.85 pmol / minute / cm2 in the presence of 10 M TFV. The results 
are expressed as the mean ± SEM from 12 rat PTC monolayers 
derived from 3 individual kidneys. Significance was determined by a 
Student’s t-test. 
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Figure 5.39: The kinetics of TFV inhibition of apical uptake of 100 M [32P]-
Pi across rat PTC monolayers.  
The uptake of 100 M [32P]-Pi across the apical membrane of rat PTC 
monolayers was measured in the presence of a range of TFV 
concentrations. TFV inhibited Pi uptake in a concentration dependent 
manner. Non-linear regression analysis of the data gave an apparent 
IC50 value of 68.75  5.24 M TFV. The results are expressed as the 
mean ± SEM from 12 rat PTC monolayers derived from 3 individual 
kidneys. 
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5.4. Discussion 
Understanding renal Pi handling has been hampered by the lack of a good 
model of the mammalian proximal tubule. The characteristics of Pi transport 
across the proximal tubule epithelial cells and the influence of hormones have 
been studied using below par models; such as OK cells, and other heterologous 
expression models. However, using a more physiologically relevant in-vitro 
model, like the human and rat PTC monolayers, could reveal more details in the 
mechanism of Pi transport in the kidney. In this chapter, the handling of Pi by 
human and rat PTC monolayers was investigated to validate their use as a 
platform to study renal Pi handling. Alongside this investigation, the impact of 
TFV on renal Pi transport was explored. 
Pi is required for a myriad of cellular functions and skeletal mineralisation. The 
major source of Pi is the diet, where consumed Pi is absorbed in the small 
intestine. The main route by which Pi is lost from the body is excretion in the 
urine. Under regular physiological conditions 80 % of Pi filtered in the kidney is 
reabsorbed in the proximal tubule and returned to circulation. The proportion 
that is reabsorbed can be rapidly altered by hormonal and metabolic factors. 
The prompt response of the Pi transport system in the proximal tubule to 
changes in the need for Pi means that the kidney plays a major role in the 
regulation of serum Pi levels.  
The apical surface of proximal tubular cells contain multiple microvilli that 
increase the surface area of the brush border membrane and aid reabsorption. 
The uptake of Pi across the apical membrane into the proximal tubule cell 
requires movement against an electrochemical gradient. Pi uptake is coupled 
with Na+ uptake to counteract this gradient. The low intracellular Na+ 
concentration and the negative electrical potential difference inside the cell 
create an electrochemical gradient that drives Na+ entry (Kempson, 1988). 
Following uptake, Pi is effluxed from the proximal tubule cell into circulation 
across the basolateral membrane. The molecular identity of the proteins 
mediating the efflux has not yet been characterised but is thought to be a 
passive process that follows the electrochemical gradient for Pi. The Na+-Pi 
cotransport across the apical membrane is thought to be the rate limiting step in 
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Pi reabsorption (Hartmann et al., 1996). Therefore this step has been the focus 
of renal Pi studies.  
Two genetically distinct families of secondary active Na+ coupled co-
transporters mediate the uptake of Pi across the apical membrane of proximal 
tubule cells; SLC34 proteins NaPi-IIa and NaPi-IIc, and the SLC20 protein PiT2. 
SLC34 proteins are specifically expressed in organs important for Pi 
homeostasis, whilst SLC20 proteins are expressed ubiquitously in all tissues 
(Biber et al., 2013; Forster et al., 2013). Any defects in the regulation of these 
transport proteins or the expression of mutated proteins can lead to severe 
pathophysiological conditions. 
As shown in Figure 5.40, NaPi-IIa and NaPi-IIc preferentially transport divalent 
Pi (HPO42-) (Forster et al., 1999; Bacconi et al., 2005), whereas PiT2 prefers 
monovalent Pi (H2PO4-) (Saliba et al., 2006; Ravera et al., 2007). For SLC34 
proteins (NaPi-IIa and NaPi-IIc), transmembrane transport comprises an 
ordered sequence of binding steps. Two Na+ ions bind sequentially, followed by 
divalent Pi, and a third Na+ ion (Biber et al., 2013; Forster et al., 2013; Fenollar-
Ferrer et al., 2015). The carrier protein then re-orientates to release the 
substrates into the cytosol. NaPi-IIa and NaPi-IIc can be distinguished by their 
electrogenicity - NaPi-IIa is electrogenic whereas NaPi-IIc is electroneutral. 
NaPi-IIa has an intrinsic negative charge due to an aspartic acid residue; its 
transporter rate is a function of membrane potential (Bacconi et al., 2005; Virkki 
et al., 2005; Ghezzi et al., 2009). It mediates transport with a 3:1 Na+: HPO42- 
stoichiometry, which results in a net positive charge per transport cycle (Forster 
et al., 1999). In contrast, NaPi-IIc transport kinetics are independent of 
membrane potential. The transporter mediate a 2:1 Na+: HPO42- stoichiometry, 
and a Na+ ion is not translocated, which results in no net charge (Bacconi et al., 
2005; Virkki et al., 2005; Ghezzi et al., 2009). For SLC20 proteins (PiT2) the 
transport sequence begins with the binding of Na+ ion, an interaction with a 
monovalent Pi, and then a second Na+ ion (Saliba et al., 2006; Ravera et al., 
2007). Reorientation of the loaded carrier then results in the release of all the 
substrates into the cytosol.  
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Figure 5.40: Summary of the key renal Pi transporters.  
Serum Pi is freely filtered in the glomerulus. Approximately 800 mg Pi 
per day (80%) is reabsorbed into circulation at the proximal tubule, 
whilst the rest is excreted in the urine. The uptake of Pi across the 
apical membrane into the proximal tubule cell requires movement 
against an electrochemical gradient. Therefore, Pi uptake is coupled 
with Na+ uptake. The transmembrane transport of Pi is predominantly 
mediated by NaPi-IIa and NaPi-IIc, with a minor contribution from 
PiT2. NaPi-IIa and NaPi-IIc preferentially transport divalent Pi (HPO42-
), whereas PiT2 prefers monovalent Pi (H2PO4-). Within the proximal 
tubule cell monovalent and divalent Pi may react with water to change 
their valency. The transport proteins mediating the export of Pi into 
circulation are not known. Diagram taken from Alizadeh Naderi and 
Reilly, 2010 (Alizadeh Naderi and Reilly, 2010).  
 
 
mRNA expression of proximal tubule renal Pi transporters in human PTC 
monolayers grown on 24-well Transwell® inserts and plastic 24-well plates were 
measured by qPCR. Table 5.1 shows the percentage of mRNA expression 
when compared to freshly isolated human PTCs. Human PTC monolayers 
maintained expression of the key renal Pi transporters, NaPi-IIa, NaPi-IIb and 
PiT2, under both culture conditions. However, there was a significant fall in the 
expression of NaPi-IIc, PiT2 and NPT1 when compared with freshly human 
PTCs. No statistical difference in expression levels was observed between the 
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two culture conditions. Other putative Pi transporters NPT1, NPT4, NPT5 were 
identified, but are not thought to be clinically relevant. 
Unidirectional transepithelial fluxes of radiolabelled [32P]-Pi (100 µM) in both the 
secretory and absorptive directions were measured over 1 hr in paired 
monolayers of human and rat PTCs grown on 24-well Transwell® inserts. A net 
absorption of Pi (300.94 ± 5.56 pmol / minute / cm2) across the human PTC 
monolayers was observed, shown in Figure 5.10. The absorptive and secretory 
movement of [32P]-Pi was 301.46 ± 5.56 pmol / minute / cm2 and 0.52 ± 0.02 
pmol / minute / cm2, respectively. Similarly, as shown in Figure 5.27 the rat PTC 
monolayers the absorptive movement of [32P]-Pi (1129.06 ± 25.01 pmol / minute 
/ cm2) was significantly greater than the secretory movement (27.91 ± 1.09 pmol 
/ minute / cm2), resulting in a net reabsorption of 1101.15 ± 24.84 pmol / minute 
/ cm2. Uptake of [32P]-Pi (100 µM) across the basolateral and apical membrane 
of human PTCs over 5 min was compared. As shown in Figure 5.11, Pi uptake 
across the apical membrane (312.36 ± 5.13 pmol / minute / cm2) was 4.72-
times greater than across the basolateral membrane (66.22 ± 1.50 pmol / 
minute / cm2). This information suggests both human and rat PTC monolayers 
exhibit Pi reabsorption in concurrence with the literature. 
In order to ensure the flux and uptake of Pi was measured under initial rate 
conditions the movement of [32P]-Pi (100 µM) across human and rat PTC 
monolayers over time was studied. The findings in Figure 5.9 and Figure 5.26 
suggest Pi transport across human and rat PTC monolayers between 0 and 20 
min is within the linear initial rate of uptake Pi transport. Due to the high-energy 
β emissions from the 32P radionuclide an incubation time of 5 min was selected. 
This would also ensure the reactions had progressed enough to be measured 
within the radiation detection instrument’s sensitivity and minimise skin and eye 
dose exposure. The non-specific binding of [32P]-Pi to the human and rat PTC 
monolayers was found to be 1.62  0.14 pmol / cm2 and 0.19  0.03 pmol / cm2, 
respectively. 
The kinetic parameters, Vmax and Km of Pi uptake across the apical membrane 
of both human and rat PTC monolayers were quantified. Human monolayers 
were incubated with a range of [32P]-Pi concentrations (10 to 500 µM) for 5 min 
and the intracellular accumulation of [32P]-Pi was measured. Non-linear 
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regression analysis of the data in Figure 5.12 gave a Vmax of 562.90  99.18 
pmol / minute / cm2 and an apparent Km value of 106.05  36.40 µM. This Km 
value is within the range of the published values of human Pi transporters, as 
shown in Table 5.2. In a similar manner rat PTC monolayers were incubated 
with 100 to 1000 µM [32P]-Pi and non-linear regression analysis of the data in 
Figure 5.28 gave a Vmax of 433.90  30.42 pmol / minute / cm2 and an apparent 
Km value of 1221.36  133.23 µM. Unfortunately there are no published Km 
values of rat Pi transporters to compare the data against. 
 
Table 5.2: Published Km values of Pi transporters.  
Km values were determined by expressing the transporters in Xenopus 
Laevis oocytes. 
 
The key renal Pi transporters are secondary active Na+-Pi cotransporters. In 
order to confirm the Pi transport across human and rat PTC monolayers was 
Na+ dependent, Pi transport in the presence and absence of Na+ was measured 
over several time periods. In both species the apical uptake of [32P]-Pi (100 µM) 
was significantly attenuated by the absence of Na+. Linear regression analysis 
of the human data in Figure 5.13 gave a slope of 70.18  1.38 pmol / cm2 / 
minute in the presence of 137 mM Na+, but only 0.66  0.11 pmol / cm2 / minute 
in absence of Na+. Similarly, linear regression analysis of the rat data in Figure 
5.29 gave a slope of 2.86  0.12 pmol / cm2 / minute in the presence of 137 mM 
Na+, and only 0.64  0.04 pmol / cm2 / minute in the absence of Na+. 
Furthermore, the kinetics of apical [32P]-Pi (100 µM) uptake in the presence of a 
range of Na+ concentrations (0 to 137 mM) was determined in both human and 
Transporter System Km (M) Reference 
hNaPi-IIa X.Laevis oocytes 140  10 (Bacconi et al., 2005) 
hNaPi-IIc X.Laevis oocytes 70 (Segawa et al., 2002) 
hPiT2 X.Laevis oocytes 160  40 (Bottger et al., 2006) 
hNPT1 X.Laevis oocytes 290  50 (Miyamoto et al., 1995) 
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rat PTC monolayers. A strong correlation between Na+ concentration and Pi 
uptake was observed; Pi uptake increased linearly with Na+ concentration in 
human PTC monolayers. However, uptake plateaued between 120 and 137 mM 
Na+. The maximum rate of Pi uptake in human PTC monolayers was 312.36  
5.13 pmol / minute / cm2 at 137 mM Na+. Non-linear regression analysis of the 
human data, shown in Figure 5.15, gave an estimated Hill coefficient of 1.88  
0.16, and Km value of 38.15  1.89 mM Na+. A Hill coefficient greater than 1 
indicates strong positive cooperative interaction, suggesting the apical Pi 
transporter(s) contain multiple binding sites and once the first Na+ ion has 
bound the receptor, it’s affinity for other ligand molecules increases (Weiss, 
1997). The reported apparent affinities of human NaPi-IIa and NaPi-IIc for Na+ 
is 40 mM and the apparent affinity of PiT2 for Na+ is 50 mM (Biber et al., 2013). 
A similar Hill coefficient of 1.7 ± 0.2 has previously been reported for human 
NaPi-IIc (Ghezzi et al., 2009). Comparatively, rat PTC monolayers also 
exhibited linearity of Pi uptake with Na+ concentration. The maximum rate of Pi 
uptake was 25.99  1.24 pmol / minute / cm2 at 137 mM Na+. Non-linear 
regression analysis of the rat data, shown in Figure 5.30, gave an estimated Hill 
coefficient of 2.80  0.29, and Km value of 58.26  2.61 mM Na+. The reported 
affinity of rat NaPi-II for Na+ is 63 ± 8 mM, with a Hill coefficient of 3 ± 0.9 
(Fucentese et al., 1995).  
The pH of the luminal fluid changes markedly, from 7.4 to 6.9, along the length 
of the proximal tubule. Transport capacity is strongly pH dependent because pH 
defines the valency of Pi - divalent Pi is common in the proximal tubule lumen 
(pKa ≈ 6.8) (Forster et al., 2000). Therefore the influence of pH on the apical 
uptake of Pi was measured in human and rat PTC monolayers. The apical 
uptake of 100 M [32P]-Pi was measured in experimental buffer of pH 6.0, 6.5, 
7.0, 7.5 and 8.0. As shown in Figure 5.16 and Figure 5.31, an increase in pH 
led to an increased in uptake of Pi. In human and rat PTC monolayers 
increasing the pH from 6.0 (154.45  12.64 and 12.27  0.48 pmol / minute / 
cm2, respectively) to 7.5 (317.09  4.43 and 27.86  0.54 pmol / minute / cm2, 
respectively) doubled the rate of Pi uptake. Similar findings in brush border 
membrane vesicles (BBMVs) of rat and porcine kidney have been reported 
(Burckhardt et al., 1981; Quamme, 1990; Forster et al., 2000). An increase in Pi 
uptake with increasing pH suggests a preferential uptake of divalent Pi. This 
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information in agreement with the published literature, and suggests NaPi-II 
transporters predominantly mediated the uptake of Pi across the PTC 
monolayers.  
Phosphonocarboxylic acids, originally developed as antiviral agents, are known 
inhibitors of Na+-Pi cotransport in rat renal BBMVs (Szczepanska-Konkel et al., 
1986). Of this class of molecules, PFA is the most effective inhibitor. This has 
been attributed to the close structural resemblance between the 
phosphonoformate ion (H2PO3COO-) and Pi (Szczepanska-Konkel et al., 1986; 
Kempson, 1988). PFA competitively inhibits NaPi-II transporters (Villa-Bellosta 
and Sorribas, 2008), but is not an inhibitor of PiT2 (Villa-Bellosta et al., 2007). 
Studies investigating the binding of [14C]-PFA to renal BBMVs show inhibition is 
saturable and dependent upon time, temperature and the Na+ concentration 
(Szczepanska-Konkel et al., 1987), and that PFA may compete with Pi for the 
binding site on NaPi-II.  
PFA inhibition of renal Pi transport was evaluated in human and rat PTC 
monolayers. The apical uptake of 100 M [32P]-Pi was measured in the 
presence of a range of PFA concentrations (0 to 1500 M). The results in 
Figure 5.17 and Figure 5.32 show dose-dependent inhibition of Pi uptake by 
PFA. Non-linear regression analysis of the data gave an apparent IC50 value of 
570.35  62.50 M PFA in human PTC monolayers and 1046.08  158.42 M 
PFA in rat PTC monolayers. Using the Cheng-Prusoff equation, inhibition 
constants (Ki) were calculated from these parameters. The calculated Ki values 
of PFA in human and rat PTC monolayers were 293.55  32.17 and 966.91  
146.43 M, respectively. The relationship between PFA concentration and Pi 
uptake exhibited in human PTC monolayers was similar to the published 
literature, which is summarised in Table 5.3. The reported IC50 and Ki values for 
rat PTC monolayers, on the other hand, were higher than expected. From the 
data in Figure 5.32 it is clear that PFA induced saturation of Pi uptake was not 
reached. Therefore, to gain more accurate data the experiment should be 
repeated with higher concentrations of PFA, due to time constraints this was not 
possible.  
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Table 5.3: Published IC50 and Ki values for PFA inhibition of renal Pi 
transport.  
 
In rodents and humans, the binding of PTH to PTHR1 at either the basolateral 
or apical membrane of the proximal tubule initiates a series of intracellular 
changes that include the generation of cAMP, elevation of the free cytosolic 
Ca2+ level, and the inhibition of Pi reabsorption. Inhibition of Pi reabsorption is 
induced by the retrieval of NaPi-IIa and NaPi-IIc from the apical membrane 
(Traebert et al., 2000; Yang et al., 2004; Bacic et al., 2006; Forster et al., 2006). 
In order to ascertain the retention of PTH intracellular signalling pathways in 
cultured human and rat PTC monolayers, the effect of PTH on the apical uptake 
of Pi was investigated. The uptake of 100 M [32P]-Pi across the apical 
membrane of human PTC monolayers was measured in the presence of a 
range of PTH concentrations (0 to 10 nM). The presence of PTH significantly 
inhibited Pi uptake in a concentration dependent manner in both species as can 
be seen in Figure 5.18 and Figure 5.33. These findings confirm the PTH 
intracellular signalling pathways were retained during culture. 
FGF-23 is synthesised by osteocytes and osteoblasts (Mirams et al., 2004; 
Sitara et al., 2004), and released from the bone in response to high dietary Pi 
intake, hyperphosphatemia, or an increase in serum calcitriol levels (Gupta et 
al., 2004; Shimada et al., 2004; Ferrari et al., 2005; Kolek et al., 2005; Liu et al., 
2006). The regulation of renal Pi transport by FGF-23 is mediated by FGFR1 
and 4 (Gattineni et al., 2014). It has been demonstrated that α-klotho and 
FGFR1 co-localisation converts FGFR1 into a high affinity FGF-23 receptor with 
a high affinity for FGF-23 (Urakawa et al., 2006). FGF-23 is dependent upon α-
klotho to induce FGF-receptor signalling (Kuro-o et al., 1997; Urakawa et al., 
System IC50 (μM) Ki (μM) Reference 
OK cell 320 260 (Villa-Bellosta and Sorribas, 2009) 
X.Laevis 
oocytes 
1000 670 (Villa-Bellosta and Sorribas, 2009) 
OK cells _ 6000 
(Loghman-Adham and Dousa, 
1992) 
Mouse BBMV _ 310 (Harvey and Tenenhouse, 1992) 
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2006). FGF-23 binding to the FGF-23 receptor induces phosphaturia and lowers 
serum Pi levels, by activation of the mitogen-activated protein kinase (MAPK) 
cascade and phospho-ERK1/2, which results in the retrieval of NaPi-IIa and 
NaPi-IIc from the apical membrane. (Yamashita et al., 2002; Urakawa et al., 
2006; Weinman et al., 2011; Andrukhova et al., 2012). This in turn reduces the 
amount of Pi reabsorbed from the urine. 
α-Klotho is a transmembrane protein that is also found in a serum soluble form 
after proteolytic cleavage from the membrane. α-Klotho induced phosphaturic 
effects have also been observed in FGF-23 knock out mice, indicating a direct 
effect on NaPi-IIa (Vervloet and Larsson, 2011). Klotho has a β-glucuronidase 
activity (Tohyama et al., 2004). The proposed mechanism of action is that α-
klotho deglycosylates NaPi-IIa and NaPi-IIc or a putative regulatory protein, 
which results in the inhibition of transporter activity and an increased 
susceptibility to resident proteases. Proteolytic degradation of the transporters 
then ensue and consequently a reduced surface expression of those 
transporters (Hu et al., 2010). 
In order to validate the abovementioned pathways, FGF-23 and α-klotho effects 
on Pi uptake rate by human and rat PTC monolayers were studied. As shown in 
Figure 5.19 and Figure 5.34, the presence of 0.9 nM FGF-23 at the basolateral 
membrane inhibited Pi uptake in human and rat PTC monolayers by more than 
20 % and 13 %, respectively. In contrast, the presence of 0.9 nM FGF-23 and 
heparin at the apical membrane did not change Pi absorption in either model 
when compared to the respective controls. These results imply that the FGF 
receptors were located at the basolateral membrane of the PTC monolayers, 
they expressed membrane-bound α-klotho, and that the FGF-23 intracellular 
signalling pathways were retained during culture. Similarly, the presence of 
soluble 0.9 nM -klotho at the basolateral membrane inhibited Pi uptake by 
more than 29 % in human PTC monolayers, and more than 20 % in rat PTC 
monolayers (Figure 5.20 and Figure 5.35). The presence of -klotho at the 
apical membrane did not exhibit significant effects on either models. The data in 
Figure 5.22 and Figure 5.37 show this is also a concentration dependent effect. 
These findings suggest that binding of soluble α-klotho at the basolateral 
membrane of rat PTC monolayers caused a decrease in Pi absorption, and the 
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cells retained the α-klotho intracellular signalling pathways in culture. In Figure 
5.21 and Figure 5.36 human and rat PTC monolayers were exposed to both 0.9 
nM FGF-23 and 0.9 nM soluble -klotho at the basolateral membrane. The 
presence of both inhibited Pi uptake significantly greater than the presence of 
each alone (39.18 ± 1.39 % in human and 38.81 ± 1.23 % in rat PTC 
monolayers), suggesting an additive effect.  
Human and rat PTC monolayers were thus demonstrated as capable of Pi 
transport with sensitivity to PFA, PTH, FGF-23 and -klotho, typical of the 
proximal tubule. The impact of TFV on renal Pi transport was then investigated 
in the human and rat PTC monolayers. Initially the uptake of 100 M [32P]-Pi 
across the apical membrane of human and rat PTC monolayers was measured 
in the presence and absence of 10 µM TFV. As shown in Figure 5.23 and 
Figure 5.38, the presence of 10 µM TFV inhibited uptake by 35.40 ± 1.05 % in 
human and 25.05 ± 3.27 % in rat PTC monolayers. The kinetics of inhibition 
were determined by measuring uptake of 100 M [32P]-Pi in the presence of a 
range of TFV concentrations (1 to 500 µM). TFV inhibited Pi uptake in a 
concentration dependent manner. Non-linear regression analysis of the human 
data in Figure 5.24 gave an apparent IC50 value of 52.25 ± 4.71 M TFV and Ki 
value of 26.89  2.42 M (using the Cheng-Prusoff Equation). Similarly, non-
linear regression analysis of the rat data in Figure 5.39 gave an apparent IC50 
value of 68.75 ± 5.24 M TFV and Ki value of 63.55  4.84 M. From the MTS 
data in Figure 4.20 we know that an hr incubation with 10 µM TFV will not 
induce proximal tubular toxicity. The findings suggest that TFV induced 
hypophosphatemia may not arise from TFV-induced proximal tubular damage 
but from an inhibition of Pi uptake. The reported serum Cmax of TFV in patients is 
0.30  0.09 g / mL (1.04  0.31 M, MW 287.213 g / mol) (Kearney et al., 
2004). Extrapolation of our data suggests that 1 M TFV would cause a small 
inhibition of transporter mediated Pi reabsorption. The consequent increased 
renal loss of Pi (hyperphosphaturia), would generate decreased serum Pi levels 
(hypophosphatemia), and Pi loss from bone. If TFV is inhibiting transporter 
mediated reabsorption of phosphate it may also have an impact upon the 
absorption of dietary Pi in the small intestine. 
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In order to confirm if TFV inhibition of Pi reabsorption is the result of a drug 
substrate interaction a clinical trial has begun under the supervision of Dr David 
Ashley Price and Dr Brendam Payne in the infectious and tropical medicine 
service in the Newcastle upon Tyne Hospitals NHS foundation trust. Newly 
diagnosed HIV patients suitable for TFV combination ART will provide a urine 
sample before treatment. The concentration of Pi in the urine sample will be 
measured, and this reading will be considered as the baseline reading. The 
patients will then take TFV daily and provide a urine sample 24 hrs and 3 
months after the therapy was first taken. If TFV inhibition of Pi reabsorption is 
the result of a drug-substrate interaction, we would expect to see an increase in 
the urinary Pi concentration within 24 hrs of therapy. Due to the wide spread 
occurrence of hypophosphatemia in HIV ART-naïve and non-TFV ART patients, 
it is not believed that TFV alone is the cause of hypophosphatemia but one of 
many contributing factor in a complex adverse effect. 
In addition, this novel finding has led to a new research initiative at Gilead. They 
have begun investigating the mechanism of TFV interaction with Pi transporters 
in collaboration with academics at the University of Zurich and Newcastle 
University. Preliminary radiolabelled [32P]-Pi uptake electrophysiological studies 
in Xenopus laevis oocytes expressing renal NaPi-IIa and intestinal NaPi-IIb 
have shown inhibition of Pi uptake and suggest TFV binds to the transporters.  
The outcomes of this work may have a large translational impact. TFV in 
combination with other antivirals is a first line therapy for both HIV-1 and HBV 
infected patients, as recommended by the World Health Organisation (WHO, 
2014; WHO, 2015a). In 2014, 36.9 million people were living with HIV and 240 
million with HBV globally (WHO, 2015c; WHO, 2015b). Approximately 14.9 
million people living with HIV (40.4%) were receiving HIV ART in 2014 (WHO, 
2015c). The number of people taking this medication is certain to increase in 
the future due to the substantial progress in access to HIV-1 treatment and the 
introduction of ‘pre-exposure prophylaxis’. Furthermore, the validation of human 
and rat PTC monolayers as platforms to study renal Pi handling will hopefully 
encourage others to use primary models. The implementation of this more 
physiologically relevant model may resolve unanswered questions such as the 
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molecular identity of the basolateral proteins mediating the efflux of Pi into 
circulation.  
5.5. Summary 
Understanding renal Pi handling in man has been hampered by the lack of a 
good model of the human proximal tubule. Therefore in this chapter the renal 
handling of Pi by human and rat PTC monolayers were characterised to validate 
their use as platforms to study renal Pi handling. Using qPCR, mRNA 
expression of the key renal Pi transporters (NaPi-IIa, NaPi-IIc and PiT2) in 
human PTC monolayers was confirmed. Measurement of radiolabelled 100 M 
[32P]-Pi uptake revealed a net reabsorption of Pi across human and rat PTC 
monolayers. Uptake of Pi across the apical membrane of human and rat PTC 
monolayers was sodium dependent, saturable and inhibited by PTH, FGF-23 
and -klotho. 
TFV is the first-line antiviral therapy for HIV and HBV. It is generally safe but 
has been associated with hyperphosphaturia, hypophosphatemia and the onset 
of osteomalacia in around 30% of patients. These adverse effects have been 
attributed to the renal toxicity of TFV and decline in proximal tubule cell function 
resulting from cell death. However medically induced renal tubular damage 
leading to Fanconi syndrome occurs in less than 0.1% of patients on TDF and 
thus cannot account for the high prevalence of hypophosphatemia.  
Uptake of Pi across the apical membrane was inhibited by the addition of TFV in 
a saturable manner with an apparent Ki value of 52.25 ± 4.71 M in human PTC 
monolayers and 68.75 ± 5.24 M in rat PTC monolayers. This suggesting that 
the impact of TFV upon renal Pi handling may not arise from TFV-induced 
proximal tubule damage but rather from an inhibition of transporter mediated Pi 
uptake. The consequent increased in renal loss of Pi and decrease in plasma 
levels could then lead to Pi loss from the bones. The data highlight the 
importance of developing holistic cell based models of the human proximal 
tubule. The outcomes of this work have initiated a patient clinical trial. 
   
 240 
 
6. Concluding discussion 
The kidney plays a key role in the systemic clearance of drugs, with around 32% 
of the top 200 prescribed drugs in the USA exhibiting significant (>25%) renal 
elimination (Morrissey et al., 2013). Pre-clinical in-vivo screening of NMEs is 
often poorly predictive of human toxicity (Giacomini et al., 2010). In recognition 
of this problem regulatory authorities requisitioned the development of 
alternative in-vitro cell based screening assays to reduce and replace current 
animal testing. It is estimated that nephrotoxicity accounts for 8 % of safety 
failures in pre-clinical studies and 9 % of safety failures in clinical studies of 
drug development (Cook et al., 2014). The assays currently offered by contract 
research organisations are based on human or animal cells transfected to 
express single or dual human drug transporters on their surfaces. The major 
limitation of these assays is that they do not accurately reflect in-vivo, where 
there may be more than one transporter involved in the drug handling or 
competition with other drug molecules. The focus of my PhD project has been 
the development of rat and human primary proximal tubule cell models as 
predictive in-vitro models of proximal tubule drug handling. 
Primary human and rat primary proximal tubule cells (PTCs) were isolated from 
renal cortex using a combination of enzymatic digestion and density 
centrifugation. A challenge in the use of primary cells is the acquisition of 
tissues from which the cells are derived. It is paramount that an efficient 
isolation protocol is performed to maximise the yield of cells. Therefore the 
enzymatic digestion phase of the isolation procedure in each species was 
optimised and detailed in chapter 3. 
The difference in cell growth and differentiation is also discussed in chapter 3. 
For instance, the changes in transporter mRNA expression levels were 
compared between freshly isolated PTCs with cultured ones. A significant fall in 
the mRNA expression of most transporters in cultured cells were shown. On 
average, at day 7 the human PTCs had expression levels around 40 to 50 % of 
fresh cells and rat PTCs had expression levels around 20 to 30 % of fresh cells. 
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In stark contrast, immortalised primary proximal tubule cells (RPTEC) showed a 
profound loss of transporter expression compared with fresh cells; RPTECs at 
day 7 had expression levels of around 0-5 % of fresh tissue.  
While cultured primary cells retained the full array of transporter expression, we 
also discovered the culture conditions affected expression levels. Human and 
rat PTCs were cultured on Transwell inserts and plastic. Cells on Transwell 
inserts formed confluent monolayers with low paracellular permeability from day 
6 of cell culture. Growth of cells on polycarbonate inserts is reported to improve 
cell polarisation, transporter expression and viability (Fulcher et al., 2005). 
Indeed, at day 7 of culture, mRNA expression of key renal drug transporters in 
human PTCs such as OAT3, OATP4C1, BCRP, MRP1, MRP3 and MRP4, were 
significantly higher following culture on Transwell® inserts when compared to 
cells grown on plastic. This suggests that cells grown on Transwell® inserts 
may be more differentiated than cells grown on plastic. Interestingly, no 
significance in expression levels was observed between the two culture 
conditions with rat PTCs. 
It is thought that this loss of differentiation in culture is due to the lack of 
microenvironmental cues that promote kidney histodifferentiation in-vivo (Jang 
et al., 2013). The apical surface of the epithelium is continuously exposed to 
shear stress due to the constant flow of the glomerular filtrate. Several research 
groups have recently developed microfluidic cell culture devices to mimic the in-
vivo environment. Exposure of mouse proximal tubule cells to shear stress has 
been shown to alter expression of apical and basolateral transporters. The 
presence of shear stress led to an increase in protein expression and 
translocation of Na+/H+ antiporter 3 to the apical membrane and Na+/K+-ATPase 
to the basolateral membrane (Duan et al., 2010). It has also been shown to 
improve albumin transport and glucose reabsorption within human primary 
proximal tubule cells (Jang et al., 2013). Limitations of these models are that the 
microfluidic devices are very expensive to produce and the number of cells 
generated is very low, with some only managing approximately 32 000 cells in 
total. This makes the detection of toxicity biomarkers and substrate 
concentrations difficult to determine. Within our laboratory we are developing an 
alternative platform. We have created a prototype of a chain of 3 polycarbonate 
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inserts with circulating basolateral and apical medium driven by a peristaltic 
pump. Initial characterisation studies have shown increased mRNA expression 
and functionality of several ABC and SLC transporters. Advantages of this 
model are cheaper production costs and higher cell numbers. We have recently 
recieved proof-of-concept funding to develop this model further into a 24-well 
plate format in collaboration with the Medical Physics department. A further 
advantage of these tehnologies is that you could can also link cells from 
different organs. For example a chip or well containing intesinal (Caco-2) cells 
could be linked fluidically to hepatocyte (HepG2) cells then renal (primary 
proximal tubule) cells to mimic the physiological interactions between different 
organs or to study drug distribution in-vitro.  
Unlike metabolic enzymes, selective inhibitors or antibodies for most drug 
transporters have not been identified (Giacomini et al., 2010). Although gene 
expression data can indicate the presence of different transporters in tissues, 
this data cannot be used in PKPB modelling because of the poor correlation 
between mRNA and protein levels (Prasad and Unadkat, 2014). Therefore 
quantitative information on protein expression of drug transporters, mediating 
the uptake and efflux of drugs and their metabolites, is crucial for in-vitro/in-vivo 
prediction of drug distribution and clearance. The University of Washington 
Research Affiliate Program on Transporters (UWRAPT), established by Prof. 
Jashvant Undakat, have developed a novel muliple reaction monitoring 
approach to quanitfy transporter expression which links mass spectrometry with 
liquid chromatography (Prasad and Unadkat, 2014). This technique, which is 
reliant upon selective quantification of surrogate peptides in a digested protein 
sample, has shown greater selectivity, speed, and sensitivity than the current 
semi-quantitative western blotting technique. In order to better understand drug 
transporter expression in human proximal tubular cells at the protein level, we 
have been regularly sending samples of human kidney UWRAPT for analysis. 
Knowledge of transporter expression at the protein level in fresh tissue and 
models of the proximal tubule will allow creation PK/PB models of drug 
clearance, using scaling factors. 
In chapter 4, the utility of human and rat PTC monolayers as predictive in-vitro 
models of proximal tubular drug handling were demonstrated using radiolabeled 
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[3H]-TFV. TFV is the first line antiviral therapy given to HIV-1 and HBV patients. 
Following on from marketing approval, a low rate of nephrotoxicity has been 
reported with long-term therapy. Retrospective histological and ultrastructural 
studies conducted in renal biopsies have reported accumulation of TFV within 
proximal tubular cells results in drug induced-mitochondrial toxicity (Cote et al., 
2006; Kohler et al., 2009; Herlitz et al., 2010; Perazella, 2010; Fernandez-
Fernandez et al., 2011; Kohler et al., 2011). The renal handling of TFV was 
therefore characterised using the human and rat PTC models to elucidate the 
mechanism of drug accumulation. 
Human and rat PTC monolayers exhibited a cell-to-media ratio greater than 1, 
which indicated uptake and accumulation of TFV across the basolateral 
membrane. The transporters mediating the renal transport of TFV were 
identified using a cocktail of transporter inhibitors. The basolateral uptake of 
TFV was mediated by OATP4C1 and OAT1. TFV was found to have low 
affinities for the apical efflux transporters MRP2, MRP4, MDR1 and BCRP. This 
could result in poor effux of TFV from the proximal tubular cells and 
accumulation. Furthermore, from in-vivo studies it is known that TFV is cleared 
by a combination of glomerular filtration and tubular secretion. Thus TFV may 
also enter the proximal tubule across the apical membrane through OATP1A 
isoforms and/or Pi transporters. Thereby inhibiting Pi reabsorption from 
ultrafiltrate and causing hypophosphatemia. A summary of these findings is 
shown in Figure 6.1.  
The novel identification of OATP4C1 as a TFV transporter has led Gilead to 
develop assays for investigating OATP4C1-mediated DDI, and the FDA to 
recognise OATP4C1 as a key renal transporter. The life expectancy of HIV-1 
and HBV infected patients is now comparable to the general population. 
Therefore, it is important to be aware of any potential DDIs that may occur with 
co-medication. Known substrates of OATP4C1 include cardiac glycosides (DX 
and ouabain), thyroid hormones (T3 and T4), cAMP and methotrexate. These 
findings also validate the use of human and rat PTC monolayers as a platform 
for drug transporter and DDI studies. 
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Figure 6.1: An overview of the renal handling of TFV based upon my PhD 
findings.  
The transporters mediating the renal transport of TFV were identified 
using a cocktail of transporter inhibitors. The basolateral uptake of 
TFV was mediated by OATP4C1 and OAT1. TFV was found to have 
low affinities for the apical efflux transporters MRP2, MRP4, MDR1 
and BCRP. This could result in poor efflux of TFV from the proximal 
tubular cells and accumulation. Furthermore, from in-vivo studies it is 
known that TFV is cleared by a combination of glomerular filtration 
and tubular secretion. Thus TFV may also enter the proximal tubule 
across the apical membrane through OATP1A isoforms and/or Pi 
transporters. 
Understanding renal Pi handling has been hampered by the lack of a good 
model of the mammalian proximal tubule. In chapter 5 the renal handling of 
[32P]-Pi by human and rat PTC monolayers was characterised to validate their 
use as platforms to study renal Pi handling. mRNA expression of the key renal 
Pi transporters (NaPi-IIa, NaPi-IIc and PiT2) in human PTC monolayers was 
confirmed by qPCR. Measurement of radiolabelled 100 M [32P]-Pi uptake 
revealed a net reabsorption of Pi across human and rat PTC monolayers. 
Uptake of Pi across the apical membrane of human and rat PTC monolayers 
was found to be sodium dependent, saturable and inhibited by PTH, FGF-23 
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and -klotho. The validation of human and rat PTC monolayers as platforms to 
study renal Pi handling will hopefully encourage others to use primary models. 
The implementation of this holistic model may resolve unanswered questions 
such as the molecular identity of the basolateral protein mediating the efflux of 
Pi into circulation. 
TFV has been associated with hyperphosphaturia, hypophosphatemia and the 
onset of osteomalacia in around 30 % of patients (Badiou et al., 2006; Buchacz 
et al., 2006). These adverse effects have been attributed to the renal toxicity of 
TFV and decline in proximal tubule cell function resulting from cell death (Martin 
et al., 1994; Birkus et al., 2002; Cote et al., 2006; Kohler et al., 2009; Herlitz et 
al., 2010; Perazella, 2010; Fernandez-Fernandez et al., 2011; Kohler et al., 
2011). However, medically induced renal tubular damage leading to Fanconi 
syndrome occurs in less than 0.1 % of patients on TVF and thus cannot account 
for the high prevalence of hypophosphatemia (Nelson et al., 2007; Herlitz et al., 
2010; Fernandez-Fernandez et al., 2011). In order to determine if there was an 
alternative explanation, Pi transport in the presence of TFV was investigated 
using the human and rat PTC models. Uptake of Pi across the apical membrane 
was inhibited by the addition of TFV in a saturable manner with an apparent Ki 
value of 26.89 ± 2.42 M in human PTC monolayers and 63.55 ± 4.84 M in rat 
PTC monolayers. This suggests that the impact of TFV upon renal Pi handling 
may not arise from TFV-induced proximal tubule damage but rather from an 
inhibition of transporter mediated Pi reabsorption at the apical membrane of 
proximal tubular cells. The consequent increase in renal loss of phosphate 
(hyperphosphaturia) due to inhibition of phosphate reabsorption causes 
decreased plasma levels of phosphate (hypophosphatemia) and phosphate loss 
from bone (osteomalacia). The data highlight the importance of developing 
holistic cell based models of the human proximal tubule. If TFV is inhibiting 
transporter mediated reabsorption of phosphate it may also have an impact 
upon the absorption of dietary Pi in the small intestine. The outcomes of this 
work have initiated a patient clinical trial to investigate this hypothesis. The 
results could have a large translational impact, as over 14.9 million HIV and 
HBV pateints are pescribed TFV.  
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Rat and human PTC are not limited to only drug transporter and drug interaction 
studies. Several studies have confirmed the suitability of rat and human primary 
proximal tubular cells cultures as an in-vitro model to study nephrotoxicity 
(Cummings and Lash, 2000; Cummings et al., 2000; Lash et al., 2001; Lash et 
al., 2003; Lash et al., 2005; Lash et al., 2006). However, a limitation to their use 
in nephrotoxicity studies is the finite lifespan of the human and rat PTCs.  
The model can be improved further by identification of biomarkers of proximal 
tubule damage. Identification of NME induced nephrotoxicity within humans at 
the pre-clinical in-vitro screening stage would decrease drug attrition. Segment 
specifc biomarkers have been identified to detect and quantify nephrotoxicity 
better than existing biomarkers. Proximal tubular specific biomarkers include 
kidney injury molecule 1,  - glutathione-S-transferase, N-acetyl--
glucosaminidase, Netrin-1, Retinol binding protein, interleukin-18, exosomal 
feutin A, and L-fatty acid binding protein (Vaidya et al., 2008; Bonventre et al., 
2010). As part of my PhD studies I was able to confirm protein expression of 
kidney injury molecule 1 using an ELISA assay. Further characterisation to 
idenifty a panel of proximal tubular biomarkers is required. This is because a 
biomarker of injury might not detect a functional defect or reliably indicate 
delayed repair. Similarly a biomarker of inflammation may not be sensitive in 
detecting early toxicity in the absence of inflaamation.   
Barriers in the use of tissue for primary cell cultures research studies can be 
grouped in to the following categories: regulatory, supply, and practical barriers. 
Regulatory barriers include ethical approval, licenses and regulatory 
acceptance of data. Supply barriers are the short supply of human tissue, the 
cost of obtaining human material and inter-individual variability. Practical 
barriers include the short lifespan of cells, the requirement of specialist 
equipment, and the shortage of trained technical staff. 
Some of the barriers can be addressed. For instance, to provide a reliable 
source of human cells and limit inter-individual variability, protocols for the 
differentiation of human embryonic stem cells into renal epithelial cells are 
currently under development. Indeed, a protocol for the differentiation of human 
embryonic stem cells into functional proximal tubular cells has been published 
(Narayanan et al., 2013). The resulting culture of a heterogeneous cell 
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population expressed characteristic markers of proximal tubular cells, which are 
comparable to the primary human proximal tubule cells, and generated tubular 
structures in-vitro and in-vivo. However, they still showed signs of 
dedifferentiation, and require further investigation. 
Likewise, further investigation is also required in the human and rat PTCs to 
verify its utility in other aspects of drug development. In this thesis, human and 
rat PTCs have been validated as physiological relevant models of the proximal 
tubule in the kidney, and they have been demonstrated as predictive tools of 
renal drug handling. The robustness of their use is thus presented, and with 
further validation, for instance in their use in nephrotoxicity prediction, would 
greatly impact on drug development.  
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